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Biomaterials 
Biomaterials have been investigated and used in many areas of medicine [1]. Biomaterials 
are defined by the American National Institute of Health as “‘any substance or combination 
of substances, other than drugs, synthetic or natural in origin, which can be used for any 
period of time, which augments or replaces partially or totally any tissue, organ or function 
of the body, in order to maintain or improve the quality of life of the individual” [2]. 
Biomaterials are commonly used in tissue engineering and regenerative medicine [3]. The 
general aim of tissue engineering and regenerative medicine is to regenerate damaged 
organs or tissues by using suitable biomaterials and combination of biomaterials with cells 
and therapeutics [4]. The field of tissue engineering/regenerative medicine is growing and 
there are numerous applications in cartilage, bone, kidney, pancreas, skin, heart, muscle, 
tendon [5, 6]. 
Biomaterials are designed as scaffolds and as drug delivery systems in tissue engineering. 
These scaffolds and drug carriers can be in a form of hydrogel, particle, membrane, 
nanofiber, 3-D printed material or a porous scaffold mimicking the architecture of the 
organs [3, 7, 8]. The common properties to characterize a biomaterial are biocompatibility, 
biodegradability, mechanical property and scaffold architecture [9]. There is a variety of 
biomaterials exploited in the field of regenerative medicine. Depending on the type or origin 
of the material, biomaterials can be grouped as: inorganic materials, synthetic polymers and 
natural polymers [10]. Ceramics or hydroxyapatite as a bone substitute are examples of 
inorganic materials [11]. Most commonly used synthetic polymers are biodegradable 
polyester family members, which includes polycaprolactone (PCL), polyglycolides, 
polylactides such as poly(lactic acid) (PLA), poly(lactic-co-glycolic acid) (PLGA) [12]. These 
synthetic polymers are degraded in the body; however, some of the acidic monomers can 
decrease the pH of the surrounding tissue [13, 14]. Synthetic polymers are sometimes 
functionalized to mimic native tissue more closely [15]. On the other hand, natural polymers 
such as alginate, hyaluronic acid, chitosan are derived from biological organisms therefore 
resemble more to natural tissue in terms of composition and degradation time [16]. 
Hyaluronic acid and other sulphated or non-sulfated glycosaminoglycans (GAGs) are 
commonly used because they are the components of human extracellular matrix (ECM). 
Besides GAGs, protein derived materials are widely explored. Collagen as the main 
component of the ECM as well as other components such as elastins and fibrins are mainly 
investigated [17]. They are not only biocompatible and biodegradable but also resemble the 
native ECM. 
 Smart materials 
The above mentioned materials are engineered for practical handling and application or to 
better mimic the ECM and increase the regenerative capacity of the materials. Among them 
several smart materials have been developed. For example, materials that change 
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properties via an external stimulus such as temperature, pH or stress [18]. In situ gelling 
hydrogels are well known examples of smart materials. These materials are injectable and 
form a hydrogel network structure controlled by an external stimulus For example poly(N-
isopropylacrylamide) (PNIPAM) modified hyaluronic acid [19] forms a hydrogel above 32 °C. 
Alginate forming a network in the presence of calcium ions is another example of an in-situ 
gelling hydrogel [20]. There are also examples of shear thinning materials that disassemble 
their network under shear stress and reassemble (recover) when stress is removed [21]. 
Hydrogels based on poly (lactic-co-glycolic acid) (PLGA) [22], sugar and oxaborole [23], 
hyaluronic acid [24]  and alginate [25] were engineered to have such shear thinning 
behaviour.  
Role of delivery systems in tissue engineering and regenerative medicine  
Delivery systems are designed to deliver a certain drug or therapeutic agent (e.g. protein, 
small drug, interfering RNA) to the site of action [26]. The functionality and the structure of 
the delivery system are designed for a specific application. For example, in cancer 
treatment, the aim of the delivery system is to target only cancer cells to increase the 
effectiveness of drug and to reduce adverse events on healthy cells [27, 28].  
In tissue engineering and regenerative medicine, delivery systems are generally used to 
deliver soluble factors to promote tissue regeneration, anti-inflammatory drugs to suppress 
inflammation or anti-microbial drugs to prevent implant infections [29, 30]. For 
protein/peptide based drugs such as growth factors, the challenge is to maintain stability of 
the protein and provide a sustained release of the protein over certain period of time that is 
required for the regeneration of the tissue [31]. 
The choice of a delivery system depends on the application. Since the release profile of a 
protein is very important for the protein to be effective over long time, the choice of a 
delivery system is important [32]. Different ways to deliver drugs using biomaterials are 
illustrated in Figure 1. A drug can be encapsulated in a scaffold or a sphere, or it can be 
adsorbed to a delivery system or covalently linked. 
Bone tissue engineering and bone healing 
In trauma or disease related bone defects, bone grafts are used when the natural bone 
formation process is insufficient (due to age or disease or size of the trauma). It is estimated 
that more than 2.2 million bone grafting procedures are annually performed to repair bone 
defects in orthopaedics, neurosurgery and dentistry worldwide  [34]. The common practice 
is using autograft which is collected from the patient. 
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Figure 1. “Schematic representation of the most common strategies to deliver drugs from 
three-dimensional scaffolds in bone TE. Drugs may be adsorbed onto the pore surface of 
the scaffolds in either their unprotected (a) or their protected (microsphere/matrix) (b) 
forms. Alternatively, drugs may be entrapped in the scaffold structure in either their 
unprotected (c) or their protected (microsphere/matrix) (d) forms.” (Reproduced with 
permission from Mourino et al. [33]) 
Bone tissue engineering aims to replace the use of autografts where possible. It is a 
developing field aiming to regenerate bone by the use of biomaterials, drugs and cells [35]. 
The biomaterial should serve as a scaffold for the regenerating bone and as a delivery 
system for the loaded drugs and cells. Bone tissue engineering can in principle be applied to 
any bone defect for orthotopic bone formation, and can be used in maxillofacial surgery, 
spinal fusion and even any soft tissue for de novo bone formation. 
Bone extracellular matrix is composed of both inorganic matrix mainly hydroxyapatite, and 
organic matrix mainly collagen I. Hydroxyapatite crystals are deposited on the collagen 
fibers [36]. This extracellular matrix plays a role in the repair of the tissue by maintaining the 
soluble factors, hosting cells and allowing the nutrition transport. The biomaterial used for 
the regeneration therefore should support the regenerating extracellular matrix to maintain 
these roles.  
Fracture healing represents a good example to understand the natural healing process 
(Figure 2). In fracture healing, four main bone repair processes occur: (i) inflammation 
(haematoma formation), (ii) soft callus formation, (iii) hard callus formation and (iv) bone 
remodelling [37] (Figure 2). Each stage is characterized by a specific set of cellular and 
molecular events. At cellular level, inflammatory cells, vascular cells, osteochondral 
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progenitors and osteoclasts act as key regulators in wound healing, whereas at molecular 
level, repair is driven by pro-inflammatory cytokines and pro-osteogenic and angiogenic 
factors [37, 38]. 
The initial stage is inflammation and inflammatory cytokines secreted in this stage are 
critical for the inflammatory response that triggers osteogenesis [39]. Directly after trauma, 
a haematoma is formed from blood, bone marrow and immune cells. Platelets, 
macrophages and other inflammatory cells infiltrate the haematoma and form a fibrin 
network (clot) that facilitates cellular migration. Within the clot, platelets degranulate, 
thereby releasing chemotactic signalling molecules that stimulate undifferentiated MSCs 
and enhance proliferation of MSCs, chondrocytes and osteoblasts. Progenitor cells of 
chondrocytes and osteoblasts arise from MSCs mainly in the bone marrow [40]. Over the 
course of time, the clot remodels into granulation tissue [41]. The next stage is cartilage 
formation that is driven by chondrocytes and fibroblasts, which are stimulated by cytokines 
and growth factors. These specific cells produce a soft (fibrocartilaginous) callus, that 
provides mechanical support and serves as a template [42]. In the generation of hard callus, 
soft callus is gradually removed and revascularization occurs. This phase is dominated by 
osteoblasts and characterized by active periods of osteogenesis. During the final stage, bone 
is remodelled, by the osteoclasts and osteoblasts and involves two main steps; bone 
resorption of primary bone and production of new (secondary) bone [43]. All of these steps 
are important for bone to regenerate and heal completely. If this regeneration fails due to a 
disease or a size of the defect, grafting is necessary. 
Bone tissue engineering materials 
Autologous bone grafting is the gold standard in clinics. However, limited source of 
autograft and donor site morbidity [45] has diverted the field to seek for alternatives. 
Several bone substitutes have been approved by the Food and Drug Administration (FDA) 
for clinical use. The majority of clinically used products are based on inorganic materials 
such as calcium phosphate ceramics, calcium phosphate cements and bioglass [46, 47]. 
Synthetic polymers such as methylmethacrylate polymer and porous polyethylene polymer 
are less commonly used as bone substitutes [48]. A limited number of natural polymers are 
used as bone substitutes. Collagen is the most commonly used one; it is used as a composite 
or as a carrier for growth factors. Hyaluronic acid is used as a carrier for demineralised bone 
matrix  [49]. These FDA approved bone substitutes are in many cases not as effective as 
autologous bone. Therefore autologous bone grafting remains the gold standard. This shows 
that there is still room for improvement by means of bone tissue engineering and by 
improving biomaterials to better mimic the bone tissue. Besides, using implants such as 
titanium can lead to resorption of the healthy bone as it is in the case of femoral implants 
[50]. This means that implants should be designed to interact and integrate better with the 
native bone tissue along with providing mechanical strength. There are several potential 
pre-clinical biomaterials that can perform better than clinical products. Natural biopolymers 
Chapter 1 
12 
 
such as alginate, chitosan and other ECM materials such as proteoglycans, hyaluronic acid, 
proteins such as collagen, fibrin and the composites of these materials are examples of 
materials in pre-clinical development [51].  
 
 
Figure 2. Bone fracture repair process. The primary cell types that are found at each stage 
are demonstrated (PMN: polymorphonuclear leukocyte). Time span is representative for 
mouse femur fracture healing. (Reproduced with permission from Einhorn et al. [44]) 
Bone morphogenetic protein-2 and its use in bone regeneration  
One successful therapeutic approach in bone tissue engineering is combining a suitable 
material with a growth factor to regenerate the bone. Bone morphogenetic proteins BMP-2 
and BMP-7 delivered with collagen are FDA approved growth factor based bone therapies. 
(Medtronic; Stryker). Bone morphogenetic protein-2 was discovered by Dr. Marshall Urist 
[52]. He showed the potential of BMP-2 to induce bone formation. BMP-2 is a growth factor 
of the TGF-beta family and it is involved in bone organogenesis. However, its function is not 
only inducing bone formation, but it is also involved in many developmental and 
physiological events. Among many examples, it is known that BMP-2 is required for early 
heart development [53]. BMPs have been shown to regulate the action of follicle stimulating 
hormone in the ovaries [54]. At a molecular level, different modes of cross-talk exists 
between TGF-β/BMP and the signalling pathways of Mitogen-activated protein kinase, 
phosphatidylinositol-3 kinase/Akt, Wnt, Hedgehog, Notch, and the interleukin/interferon-
gamma/tumor necrosis factor-alpha cytokines pathways [55]. Some of these pathways have 
been shown to regulate the effects of BMP-induced signalling in bone dynamics [56]. Such a 
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potent growth factor therefore should be spatio-temporally controlled. In body, TGF-
β/smad pathway is controlled by complex expression of intracellular and extracellular 
inhibitors and activators.  
BMP-2 soaked collagen sponge was first introduced in the United States in 2002 as 
approved by Food and Drug Administration (FDA) for anterior lumbar interbody fusion in a 
titanium cage[57]. In 2004 it was also approved for tibial nonunions as an alternative to 
autograft, and in 2007 for oral maxillofacial reconstructions [58, 59]. However, independent 
reviews stated a reporting bias in the industry-sponsored publications [60, 61]. In addition 
several adverse events associated with BMP-2 were reported and some of them were life-
threatening, especially in anterior cervical spine fusions [61]. These were cervical and soft 
tissue swelling, airway compromise, and need for reoperation [62]. As a result, FDA issued a 
Public Health Notification about BMP-2 use in 2008 [63]. Later, these adverse events have 
been associated to the poor release profile of BMP-2 with a high initial burst release and 
supraphysiological doses of BMP-2 [64]. Due to the fast release of BMP-2 (around 50% in 
the first two days) a high loading concentration of the protein was necessary to achieve 
effective dose in the following days [65]. It is many times postulated that with a good carrier 
for BMP-2, protein release can be modulated to be more effective [64, 66]. In this way, the 
initial loaded dose can be decreased thereby adverse effects are expected to decrease.   
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Aim and outline of this thesis 
In this thesis, we aim to design and compare different biomaterials in terms of growth factor 
(BMP-2) release profile and bone regenerative capacity with a final goal to develop 
biomaterials that can induce or augment bone healing. My research question is: Which 
design of slow release system with which release profile will induce bone healing? 
Chapter 2 reviews the current osteogenic growth factor delivery systems with special 
attention to bone morphogenetic protein-2 (BMP-2). In this chapter we review the gene and 
protein delivery strategies mentioning advantages and drawbacks of each system and new 
technologies allowing protein delivery with specific coupling to the scaffolds. 
In chapter 3a, the development of a slow release system for an osteogenic protein, such as 
BMP-2, is demonstrated. Using recombinant collagen I based recombinant peptide (protein) 
(RCP) microspheres and varying the characteristic of these microspheres we modulate the 
release profile of BMP-2. Furthermore, we study the molecular interaction between BMP-2 
and RCP directly by means of surface plasmon resonance experiments. In Chapter 3b, 
microspheres carrying different concentrations of BMP-2 are tested in rats in an ectopic 
model to study bone formation. 
For chapter 4, we develop different in situ gelling hydrogels to deliver BMP-2 carrying 
microspheres. The purpose of the hydrogel is to keep the microspheres in situ, fill a defect 
and create a scaffold for the infiltrated cells to deposit their own matrix. We compare the 
performance of various hydrogel-microsphere composites with respect to physical chemical 
characteristics, BMP-2 in vivo release, bone formation, cell infiltration and inflammatory 
characteristics. The alginate microsphere formulation appears to be the best hydrogel for 
bone formation and this formulation is selected for the study in chapter 5. 
In chapter 5, we hypothesize that the dose of BMP-2 delivered with RCP microspheres in an 
alginate gel has an effect on bone formation in terms of bone volume. This hypothesis is first 
tested using four doses of BMP-2 in an ectopic bone model in rats. Later two doses of BMP-
2 are tested in calvarial defect model in rats. 
In chapter 6, the parameters that can be further improved in a biomaterial are discussed. 
Degradation rate, interaction with the matrix and drug release profile of our material are 
compared to those described in literature. As a future perspective, application areas are 
proposed and feasibility of clinical translation is discussed. 
Finally, in chapter 7 I summarize the findings of the research performed for this thesis. 
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INTRODUCTION 
Healing of bone fractures describes a remarkable process in that the injured tissue heals 
without scar formation, thus typically resulting in a complete regeneration of the bone´s 
anatomy and function [67]. Long bone fractures are reported to occur in the western world 
at an incidence rate of 300 - 400 cases per 100,000 individuals per year [68, 69] and heal in 
most cases without surgical intervention within 20 weeks [70]. The needs for a progressive 
union of bone fractures have been identified and defined as a so-called diamond shaped 
concept comprising the parameters: adequate cellular environment, sufficient growth 
factors, bone matrix and mechanical stability. Patients lacking one of these parameters 
might develop complications during the healing process, which subsequently can result in a 
delayed or even non-union of the fracture [71]. The incidence of non-union fractures has 
been reported to range from 4 - 10 % [70, 72]. Non-union fractures are associated to 
reductions in the patient´s general life quality but also to concomitant inconveniences and 
costs due to prolonged hospitalization and secondary interventions. It is therefore of great 
interest to develop new therapeutic concepts that positively affect bone healing. 
In the past, the main focus for a regenerative stimulation of non-union fractures was laid on 
the use of autograft, allograft, and xenograft bone. Of these, autografts were considered as 
golden standard as these are osteogenic, osteoconductive, and osteoinductive [73-75]. 
However, the use of autografts is limited due to the given volume quantities and due to 
donor site morbidities which are frequently observed and typically accompanied by chronic 
pain [76]. Other major complications which occurred upon extraction of autograft bone are 
vascular injuries, deep infections, or neurologic injuries at the donor site [77]. 
Another regenerative approach which recently gained attention as alternative to autograft 
bone in clinical settings is the use of platelet-rich plasma (PRP). This method in principle 
utilizes intrinsic growth factors of platelet concentrates in order to stimulate and accelerate 
a healing response [78]. However, despite the efficacy of PRP in in vitro and in vivo 
scenarios, its use and delivery in terms of bone regeneration have yet not been optimized. A 
significant drawback of such preparations is that optimal doses for administration as well as 
the identity of the active substances within the concentrates are largely unknown [79]. 
Extensive studies focusing on the underlying molecular mechanisms of fracture repair 
identified some specific factors to be involved in the healing process like parathyroid 
hormone (PTH), hypoxia-inducible factor 1a (HIF-1a), factors modulating the Wnt signaling 
pathway, and bone morphogenetic proteins (BMPs) [80]. The use of defined compounds like 
such growth factors allows more precise treatment of bone fractures and are financially 
advantageous since high amounts of these factors can be prepared in appropriate 
recombinant expression systems [81]. Here, the most promising growth factor candidates 
are bone morphogenetic proteins (BMPs), which were originally identified by their 
capabilities to induce the formation of bone when implanted at ectopic sites [52, 82].  
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BMPs belong to the large TGF-beta superfamily of secreted growth factors which play an 
important role in early embryonal development but are also crucial for the maintenance and 
regeneration of tissues and organs in the adult organism [83-85]. The existence of BMPs in 
all vertebrates as well as non-vertebrate animals highlights the importance of these factors 
for a multitude of biological processes, which recently gave rise to the suggestion to rename 
the term "bone morphogenetic protein" into "body morphogenetic protein" [86]. This 
renaming would also eliminate the misinterpretation that all BMPs are truly osteogenic. 
BMPs which indeed induce bone formation can be, based on sequence homology and 
receptor usage, divided into three subgroups, the BMP-2, -4; the BMP-5, -6, -7; and the 
BMP-9, -10 subgroup, respectively [87, 88]. Other proteins which are, based on a historical 
context, also called BMPs are either not osteogenic or their precise function has yet not 
been fully elucidated. For instance, BMP-1 (also known as Mammalian tolloid protein 
(mTLD) or Procollagen C-proteinase (PCP)) represents a metalloprotease and does not share 
structural similarities with other TGF-β superfamily members [89]. Further examples are 
provided by BMP-3, BMP-13 (also known as GDF-6) and BMP-14 (also known as GDF-5) 
which function, at least partially, as BMP antagonists/inhibitors rather than being agonistic 
on their own [90-92]. 
Signal transduction by TGF-β superfamily members is typically initiated by binding to two 
types of serine/threonine kinase receptor chains termed type I and type II [93-95]. Upon 
complex formation, the constitutively active type II receptor activates the type I receptor 
which subsequently leads to an activation of the so-called canonical SMAD signalling 
pathway [96, 97]. Disregarding cross-talks with other connected signalling cascades (like e.g. 
the MAP-Kinase signalling pathway) only two different SMAD pathways, the so-called 
SMAD-2/-3 or the SMAD-1/-5/-8 pathway, are established. Which of the two canonical 
pathways finally gets activated solely depends on the individual type I receptor (the 
particular signalling receptor) being present in the signalling active ligand-receptor complex. 
Thus, within this superfamily a strong signal convergence starting from a manifold of ligands 
and ending principally in the activation of only two different SMAD signalling pathways is 
established which appears even more limited as far as osteogenic BMPs are concerned [98]. 
Despite differences in the preferential receptor usage observed for the particular osteogenic 
ligands, signalling occurs in all cases via the SMAD-1/-5/-8 pathway. For BMP-2 and -4 -10, 
signalling is mediated by the type I receptors (BMPR-IA or IB) whereas the BMP-5/-6/-7 
subgroup utilizes ActR-I (Alk2) for signalling (for review, see Katagiri et al. [99]). For BMP-9 
high affinity binding to ALK1 has been reported but signalling can also occur via ActR-I [100]. 
The obvious discrepancy between the number of ligands (more than 20 BMP members have 
been identified in mammals to date) and the limited amount of receptors raises important 
questions especially how these proteins can share so many different cellular functions and 
furthermore how those can act as morphogens during embryogenesis. Different temporal 
and/or spatial expression patterns might best explain this issue but since double knock-outs 
of ligand genes often lead to more severe phenotypes than observed for the individual 
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single knock-outs the existence of at least partial compensation must be taken into 
consideration. It therefore seems plausible that cellular signalling is modulated massively at 
several cellular levels (for review see Nickel et al. [98]). Extracellularly so-called modulator 
proteins (e.g. Noggin, Chordin, etc.) can bind to the ligand thereby preventing its interaction 
with the receptors as shown for Noggin [101] or Follistatin [102]. Thus, ablation of the 
interaction of the osteogenic factors to Noggin also indirectly increases the osteogenic 
potential of the particular ligand [103]. 
Aside from these modulators, the biological activity of BMP-2 or -7 is also regulated by their 
capability to bind to components of the extracellular matrix (ECM) such as heparin or 
heparan sulfates [104, 105]. In vivo, the ECM seems to function as reservoir by adsorbing 
the ligands from the three-dimensionality of the interstitial liquid thereby increasing the 
ligands concentration on the cell surface. The matrix serves as a store allowing a slow 
release of the ligand over prolonged periods of time. Hence modulating the binding strength 
of the growth factors to the ECM could result in altered bioactivities which indeed has 
already been observed in vitro and in vivo [106]. 
Taken together, the different aforementioned parameters which concertedly define the 
particular ligand´s osteogenic potential have been addressed in several pre-clinical and 
clinical trials. They generally aimed to produce osteogenic formulations allowing the 
application of the growth factor to defect sites. For that purpose, they use systems which 
concomitantly control the factor´s release to achieve sufficient high local concentrations 
over the period of time needed to heal the defect. 
This review sheds light into the design of the different systems to deliver BMP-2 for in vivo 
applications. As outlined above, the control over the growth factor´s bioactivity and spatial-
temporal presence is obviously crucial for bone healing but seems extremely difficult to 
achieve. 
Growth factors like BMP-2 can principally be brought to injured site in two different ways. 
At first, DNA that encodes for the particular growth factor can be delivered either in form of 
a suitable expression plasmid or integrated into a viral particle or the genetic information is 
already introduced into an acceptor cell´s genome in order to express the particular growth 
factor at the site of action. As second method, the gene product, i.e. the recombinant 
expressed growth factor itself or peptide mimicking its specific bioactivity, is applied 
ectopically to the injured site. For an overview, see Figure 1. 
Gene therapy offers a multitude of different applications ranging from cancer to various 
infectious diseases, cardiovascular or other monogenic disorders. Due to its generic 
potential, over 1800 clinical trials involving gene therapy were conducted by 2012 [107]. 
Also in bone regeneration the potential of gene delivery is still under investigation. 
Principally, as mentioned before the genetic information can be delivered by a vector to the 
injured site where cells will take it up and start protein expression, or by the delivery of cells 
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that are already transfected with an appropriate vector ex vivo which, after implantation, 
will express the protein at the site of injury.  
 
Figure 1. Main principles for growth factor delivery. (A) cDNA encoding for the desired 
growth factor is introduced into the cells e.g. via plasmids or viral vectors and is translated 
and secreted at the site of injury. (B) The protein is deposited at the site of injury in a form 
of depot e.g. in form of functionalized scaffolds. 
 
In the following, both techniques are discussed in detail comparing the feasibility and 
drawbacks of each technique in scope of bone regeneration by application of the best 
investigated osteogenic factor, BMP-2, as well as potential ways to further improve each 
technique. 
BMP-2 DELIVERY USING BMP-2 ENCODING cDNAs 
General aspects of various DNA delivery methods 
The choice of the growth factor to be expressed is very important since the single gene to 
be delivered, here that of BMP-2, must initiate an apparently high complex process resulting 
finally in the full restoration of the bone defect. For more complicated cases (e.g. where a 
large defect area needs to be repaired) gene delivery of a combinations of BMP-2 along with 
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factors of other growth factor families (e.g. VEGF) [108] or combinations of BMP-2 and 
transcription factors (e.g. BMP-2 and Runx2) seems advantageous [109]. Co-expression of 
BMP-2 and transcriptional factors being specific for bone tissue such as Runx2 might provide 
more efficient bone regeneration since it regulates expression of other osteogenic factors 
that drive e.g. the osteogenic differentiation of mesenchymal stem cells [110]. However, the 
osteogenic gene to be delivered is not the only parameter to be considered. Also the choice 
of the vector or the matrix that will determine the transfection efficiency of the gene and 
the residence time is equally important. A major concern of gene therapy is the stable and 
controllable overexpression of the delivered gene. In order to prevent extreme expression 
levels, which in terms of BMP-2 delivery might result in unwanted off-target effects, 
constructs with inducible promoters - such as tetracycline-sensitive promoters (TetON) - 
might be favorable [111]. 
In general, the vectors that are used for gene therapy can be subdivided into two classes: 
viral and non-viral vectors. The use of viral and non-viral vectors for tissue engineering has 
been reviewed elsewhere [112-114] but advantages and disadvantages of the particular 
expression systems are important to note. Viral vectors - as the name suggests - are derived 
from viruses (i.e. adenovirus; lentivirus) and have higher transfection efficiencies than non-
viral vectors. However, due to safety concerns, the use of viral vectors in clinics is still under 
debate. Safety concerns address immunogenicity of particular viruses which indeed differ 
amongst different virus types. The adenovirus, which was one of the first used vector 
systems for gene delivery, may induce inflammatory or antigenic responses due to 
expressed viral hull proteins [115], whereas adeno-associated viruses (AAV) are considered 
to be safer since viral proteins are not expressed in the receiver cell (for review, see Buning 
et al. [116]). On the other hand, retroviruses or lentiviruses might induce insertional 
mutagenesis which limits their general potential for gene therapy. The use of adenovirus or 
AAV in bone regeneration at this stage seems more feasible since it poses less risks and it 
provides transient expression for several weeks matching the time frame for bone defect to 
heal [112].  
Due to the mentioned safety concerns, a promising alternative relies on the use of 
liposomes that act as a vehicle for non-viral vectors (plasmids) and might reach adequate 
efficacy with coincident lower risks compared to viral vectors. Besides safety, liposomes are 
easy to prepare and their use is not constrained by the size of the used DNA [117]. Both, 
viral or non-viral vectors can be applied to the injury site either directly or embedded within 
a matrix/scaffold. 
Delivery of BMP-2 encoding genes by direct injection of viral or non-viral vectors or by 
application of DNA-functionalized matrices 
Different DNA delivery methods have been investigated in vivo using different animal 
models. In rodents, the injection of adenovirus carrying the BMP-2 gene resulted in 
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successful delivery and as a result of BMP-2 over-expression improved osteogenesis in the 
defect area could be observed [118]. However, in other animal studies the same adenoviral 
system failed [119]. In these cases, a high level of BMP-2 expression was observed within 
the first week after implantation which strongly decreased in the following weeks. 
Inflammatory cells were found in the defect area which showed an immune response 
against BMP-2 and/or the adenoviral vehicle which might explain the observed retardation 
of osteogenesis [119]. This study revealed the importance of larger animal studies before 
conducting clinical trials which is also recommended by FDA guidelines [120]. 
In order to improve the efficacy of the applied vehicles, they might be shielded from the 
recipient´s immune system using so-called stealth (PEGylated) liposomes. Another method 
to increase the transfection efficiency of the vehicle relies on the use of cell penetrating 
peptides (CPPs) [121]. Also targeted delivery of the vehicles specifically to bone tissue would 
result in a homing of the transgene to the defect site. A very interesting new idea for 
efficient gene delivery is based on "designer" histones serving as targeting molecules thus 
aiming to improve the osteogenic capacity of growth factors [122]. Taken together, more 
sophisticated designs of vectors (e.g. with stealth liposomes, CPPs, inducible systems or 
targeting molecules) hold more potential if used in direct gene delivery approaches. But, the 
development of suitable delivery systems is not easy since the individual design strongly 
depends on the application itself and the clinical outcome of such a complex design is hard 
to predict. Different ways to improve gene delivery systems in general are detailed 
elsewhere [123] but one important improvement to be noted relies on the encapsulation of 
the vector within a biomaterial or functionalizing the material´s surface with DNA encoding 
for the desired protein [123]. Those matrices are called "gene-activated" matrices (GAMs) 
and their applications have been extensively tested either in a form of hydrogels [124] or 
implant coatings [125]. In one example, BMP-2 encoding cDNA was embedded within 
alginate hydrogels which serves as a potent transfection agent and as a good scaffold 
material at the same time [126]. Advantages of such matrices are the long shelf-life of the 
material (possibility of freeze-drying), and ability to function as a defect filler [114]. 
For the regeneration of more complex tissue structures like the bone-cartilage interface, 
scaffolds comprising two layers were designed, one of which consisted of a "chondrogenic 
plasmid" (TGF-β1)- functionalized chitosan-gelatin and the other an "osteogenic plasmid" 
(BMP-2)-functionalized hydroxyapatite/chitosan-gelatin [127]. Mesenchymal stem cells 
were also seeded in each layer of the gene activated matrix. Detailed analyses of this system 
revealed that the used stem cells differentiate towards chondrocytic or osteoblastic lineages 
depending on the layer they were positioned. Furthermore, a successful regeneration of an 
osteochondral defect could be achieved using this construct in a rabbit knee model. 
The different natural or synthetic scaffold materials being used for bone regeneration are 
not in scope of this review article. However, since the scaffold also actively takes part in the 
regeneration process, the characteristics of each biomaterial should be considered, 
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compared and selected for a specific application. Among different natural polymers, 
insoluble collagen-based bone matrices (ICBM) have been widely used which is based on the 
fact that that bone organic matrix principally consists of collagen (90%) [128]. The drawback 
of this matrix relies on remnants of immunogenic molecules that might challenge the host´s 
immune system. Other natural matrices which are represented by in situ gelling systems like 
alginates or peptide nanofibers are injectable, thus allowing easy filling of the defect area. 
Although a matrix is important to fill the defect area and localize cells and growth factors at 
the site, it does not always result in better healing process which depends strongly on the 
chosen scaffold. For instance, in a study where either untreated or adenoviral transduced 
cells expressing BMP-2 were injected either directly or embedded within alginates into a 
bone defect in nude rats, the alginate scaffold clearly impeded BMP-2 induced bone 
formation [129]. This study nicely demonstrates that parameters like the choice of the cells 
to be introduced or the selected scaffold material only seem to fine-tune the outcome of 
the individual experiment but the initial trigger of this complex process is provided by the 
applied osteogenic growth factor. 
Gene delivery by cells ex vivo transfected with BMP-2 encoding cDNAs. 
Cell mediated gene therapy is another approach in which cells are transfected ex vivo with 
the cDNA encoding for the desired growth factor and are subsequently administered to the 
injury site for tissue regeneration. The disadvantages of cell based gene therapy compared 
to acellular approaches are related to costs and also the necessity to obtain sufficient 
amounts of suitable autologous cell material. Furthermore, the procedure is more difficult 
to perform than the before mentioned acellular approaches, it is more time-consuming due 
to the necessity to expand the autologous cells. Additionally, the work has to be done 
according to the guidelines of Good Manufacturing Practice (GMP). However, there are also 
noteworthy advantages, since the delivered cells themselves might actively participate in 
the regeneration process. Due to complications associated with allogenic cell sources, the 
use of autologous cells is the gold standard in the clinics so far [130]. But, there is also a 
drawback of this technique. An additional treatment or surgery is required in order to 
obtain these cells being often accompanied by a significant tissue morbidity at the site of 
explantation [131]. The current practices and studies in bone and cartilage regeneration 
generally involve mesenchymal stem cells (MSCs) derived either from bone marrow or other 
sources. Owen and co-workers already showed in the late 1980s that bone marrow derived 
stem cells (BMDSCs) can be differentiated towards different cell types including bone [132]. 
More recently, an alternative, powerful method was established to re-program non-stem 
cells to so-called "induced pluripotent stem cells" (IPSCs). Here, somatic cells (e.g. 
adipocytes which can be obtained easily by liposuction) are dedifferentiated to so-called 
induced pluripotent stem cells (iPSCs) which subsequently are again differentiated to MSCs 
[133]. This new method is not yet in clinical use, but first clinical trials using IPSCs for 
macular degeneration have been initiated in Japan [134]. In one of the early clinical studies 
addressing the treatment of bone disorders, the transplantation of allogenic MSCs has been 
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investigated in children with osteogenesis imperfecta. In this study, the allogenic BDMSCs 
were shown to improve the velocity of bone growth in five of the six patients [135] which 
led to several follow-ups in the field of bone regeneration. Recently, a clinical trial has 
investigated the effect of BMDSCs for craniofacial bone regeneration. Here, accelerated 
alveolar bone regeneration could be observed in a jawbone defect thereby eliminating the 
need for secondary bone grafting [136]. While usage of BDMSCs progresses in clinical trials 
aiming for bone regeneration, pre-clinical studies already involve MSC-based gene delivery. 
In one of these pre-clinical studies, bone marrow derived cells were co-transfected with 
cDNAs encoding for BMP-2 and vascular endothelial growth factor-165 (VEGF-165) in order 
to induce bone regeneration by means of BMP-2 mediated osteogenesis and VEGF 
mediated angiogenesis [137]. The cohort expressing both growth factors simultaneously 
was found to be better in terms of the formation and deposition of newly formed bone 
compared to the cohorts expressing only one of the two growth factors in rabbit orbital 
defect model [137]. The delivery of VEGF in combination with the osteogenic BMP-2 induces 
neo- vascularization of the newly formed bone tissue thus enabling superior supply of 
nutrients [138]. 
Harvesting bone marrow is not an easy procedure since it often causes post-operational 
pain. Therefore, alternative stem-cell sources, such as adipose tissue, have been intensively 
investigated. In a study employing BMP-2 transfected adipose stem cells, their potential for 
bone regeneration was clearly demonstrated. When rats were treated with the transfected 
stem cells being embedded into alginate gels, complete bone healing was observed in a 
cranial defect model [139]. Thus, due to the easy of collection adipose tissue derived stem 
cells are preferred over BMDSCs at least for this application. 
However, most of the clinical trials utilizing MSCs for bone regeneration were not 
successful. Meijer et al. [130] stated possible reasons and identified important parameters 
as the number of cells with osteogenic capacity, the bio-compatibility of the used scaffolds, 
the presence of osteogenic factors, and vascular supply. Furthermore, it was also reported 
that results of pre-clinical trials in most cases could not serve as layout for the clinical 
studies since differences in e.g. the regeneration time of rodents and humans produced 
different experimental outcomes [130]. 
In MSC mediated gene delivery, one of the critical issues is the localization of the modified 
cells, and consequently the localization of the expressed protein. However, when MSCs 
were injected, it was observed that the injected cells do not easily home to bone and 98% of 
the injected MSCs are lost through liver and spleen [140]. To overcome this problem, the 
cells might be transfected to co-express an osteogenic growth factor like BMP-2 along with 
bone-homing proteins e.g. CD49d [141]. 
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DELIVERY OF RECOMBINANT BMP-2 
General aspects 
Growth factors which can be delivered to the site of injury might recruit endogenous stem 
cells to the site of action which upon exposure to the ligand undergo differentiation, thus 
inducing bone healing in situ. An FDA approved product, INFUSE® Bone Graft, which 
contains BMP-2 being adsorbed to a collagen sponge has been clinically used in spinal cord 
injuries. However, some adverse events such as infections, severe swelling, heterotopic 
ossification or urogenital problems have been observed after surgery [62, 142, 143] which 
are discussed to be related to the supraphysiological amounts of the growth factor being 
administered. This leads to the hypothesis that these adverse events might be eliminated by 
reducing the delivered growth factor amount to a suitable yet clinically relevant dose. 
Therefore, the development of a delivery system that provides a sustained release of the 
protein at sufficient concentrations is a challenge of high priority. An overview on the 
various BMP-2 delivery strategies is depicted in Figure 2. These strategies will be discussed 
in more detail in the next sections. 
 
Figure 2. Delivery strategies for recombinant expressed BMP-2 or BMP-2 variants 
The cartoons illustrate the different immobilization strategies as indicated (A) BMP-2 can be 
adsorbed to solid surfaces or encapsulated into e.g. hydrogels (B). Higher coupling 
specificities can be achieved by affinity interactions e.g. using biotinylated BMP-2 being 
coupled to streptavidin coated matrices (C). Covalent coupling can be achieved non site-
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directed to structures being activated e.g. by NHS esters (D) or site-directed via click 
chemistry (E). 
Non-covalent binding strategies 
Delivery of encapsulated or adsorbed BMP-2 
In vivo, growth factors interact with receptors present on the cell surface in a non-covalent 
manner. The signalling molecule, such as BMP-2, is in most cases soluble (i.e. not membrane 
bound) and thus can diffuse or be actively transported to responsive cells. Therefore, many 
research laboratories emphasized on non-covalent binding strategies which utilized growth 
factors being adsorbed to or encapsulated in a broad variety of suitable scaffold materials. 
Natural polymers such as collagen have several advantages. For example, they have 
endogenous enzyme cleavage sites and the degradation time of the material follows the 
endogenous remodelling time of collagenous tissues. Collagen sponges represent the 
earliest and best studied materials used for BMP-2 delivery. A disadvantage of this material 
relies on so-called early burst effects which are often observed upon administration [144]. In 
order to obtain a sustained release of the protein and decreasing this initial burst release 
phenomenon, genipin-crosslinked gelatin microparticles have been designed. Gelatin 
microparticles showed lower burst releases compared to poly(lactic-co-glycolic acid) (PLGA) 
microparticles in vitro. A composite scaffold of these gelatin microparticles embedded in 
poly(propylene fumarate) (PPF) showed a sustained release of BMP-2 in vivo in a 
subcutaneous mouse model. This study also demonstrated that microspheres encapsulated 
within a scaffold provide a better control of growth factor release compared to the scaffold 
alone [145]. In order to produce fully synthetic biodegradable materials, mimics of natural 
polymers such as collagen have been designed. In one of these studies, matrix 
metalloproteinase (MMP) cleavage sites and RGD (Arg-Gly-Asp) moieties were introduced 
into polyethylene glycol (PEG) polymers. Here, the release of BMP-2 was shown to be 
induced by MMP-2 mediated degradation in vitro. The effect of these hydrogels containing 5 
µg of BMP-2 on bone healing was studied using critical-sized calvarial defect model in rats. 
The MMP-sensitive, BMP-2-loaded hydrogel induced formation of new bone comparable to 
BMP-2 loaded collagen sponges (Helistat®) [146]. Another more complex material which 
was also studied in the context of bone regeneration, is a MMP cleavable PEG hydrogel 
functionalized with an α2β1 integrin-specific peptide (GFOGER; single letter amino acid 
code, O = hydroxyprolin). This material was shown to be effective for bone-healing in a 
mouse critical size defect model even in the absence of BMP-2 but doping the hydrogel with 
low BMP-2 doses (0.03 μg) resulted in higher bone formation capabilities and complete 
bridging of bone gaps after 8 weeks [147]. Hybrid nanofiber mesh/alginate delivery systems 
containing RGD (Arg-Gly-Asp) have been compared to collagen sponges for BMP-2 release 
[148]. Bone formation at 8 weeks post-surgery was significantly increased in the nanofiber 
mesh/alginate group compared to the collagen sponges at the same dose (1.0 μg rhBMP-2). 
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In order to obtain 3D scaffolds with defined and reconstructable structures, Lee et al. [149] 
created polymeric 3D scaffolds by solid free-form fabrication (SFF) technology, computer-
aided design (CAD) and computer-aided manufacturing (CAM) techniques. BMP-2 loaded 
microspheres were encapsulated within these microstereolithography-produced scaffolds 
and after 7 days BMP-2 started to be released linearly. When the performance of the 
construct was studied in a rat cranial bone defect model, around 75% bone formation was 
observed after 11 weeks  [149]. 
The detailed description of the results, using different combinations of BMP-2 and materials 
as mentioned before, led to the assumption that the material type has a major impact on 
the success of bone regenerative approaches. These material related effects become 
obvious by comparing e.g. brushite and PLGA controlled release systems loaded with the 
same doses of BMP-2. PLGA appeared significantly more osteogenic than brushite which is 
attributed to the slow resorption rate of brushite [150]. As a consequence, BMP-2 is not 
released in sufficiently high concentrations which might indicate the requirement of an at 
least minimal burst release. On the other hand, the hard brushite material might also 
impede the migration of invading cells which are essential for the process of bone 
regeneration. 
Delivery of BMP-2 utilizing affinity interactions 
One of the strategies for protein immobilization relies on affinity interactions of specifically 
tagged proteins with appropriately functionalized surfaces. Unlike covalent coupling, affinity 
interactions are weaker, with the strength depending on the particular interaction partners. 
In most cases, the interaction can be affected e.g. by changing pH values, the temperature 
of the solution, or by using a competitive ligand. In vivo, these parameters can certainly only 
be altered to a limited extent. However, there are profound advantages of such approaches 
relying on a high specificity of the interaction, a mainly uniform orientation of both 
interacting partners, mild coupling conditions and a broad availability of various 
commercially available affinity tag systems. Reversibility of affinity interactions may be 
advantageous when the controlled release of the growth factor is crucial, for instance if the 
ligand has to be internalized from the effector cell to gain full signaling capabilities. 
Nevertheless, there are also some limitations that one needs to consider when choosing the 
affinity-tag coupling strategy, such as laborious protein engineering, overall cost of affinity 
ligands, the possibility of changing the proteins properties, an unpredictable release of the 
immobilized growth factor or limited possibilities for tag positioning. Usually affinity tags are 
placed on either N- or C-terminus of a protein to minimize changes in its biological activity. 
Though, positioning of an affinity tag at either the N- or C-terminus of the protein sequence 
may be in some cases detrimental for its trafficking and folding. 
Common affinity immobilization approaches can be performed via a vast number of 
different molecular fusion tags, such as small charge-based (poly-arginine or poly-histidine-) 
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affinity tags, epitope tags based on the interaction with antibodies (hemaglutinin (HA), Myc, 
FLAG™, V5 epitope), protein fusion tags (Protein A, Small Ubiquitin-related MOdifier 
(SUMO), glutathione S-transferase (GST), maltose binding protein (MBP), calmodulin binding 
protein (CBP), certain protein domains (cellulose binding domain, chitin binding domain), 
biotinylation (based on strong biotin-avidin affinity), and many others [151-154]. 
As already mentioned, BMP immobilization has been broadly exploited in terms of physical 
adsorption, encapsulation and non-specific covalent immobilization. Nevertheless, addition 
of fusion tags was in context of BMPs employed mostly for protein purification (histag [155], 
maltose binding protein [156]), or detection and enrichment purposes [157, 158], and only 
in a few cases designed to enable a more permanent immobilization on scaffolds. Insertion 
of any kind of tag within the mature part of thr BMP sequence is strongly restricted to the 
N-terminus, which is caused by the buried architecture of its C-terminal end. Because of the 
specific domain arrangement of BMP proteins comprising a pro- and a mature-domain, 
insertion of any tag used in an eukaryotic heterologous expression system is thus strongly 
restricted to the N-terminal end of the mature part as well which might impose hindrance in 
the intracellular protein trafficking and proper processing of the mature peptide. 
BMP-2 immobilization via His-tags 
One of the best explored affinity tags used in protein science is a strain of 6 histidines, 
demonstrating a high affinity towards bivalent metal ions. An application for BMP-2 
immobilization via an introduced his-tag was reported by Zhao et al. [159]. BMP-2 was 
expressed as fusion protein with 6 histidines (his6-tag) fused to the N-terminal end of the 
mature part of human BMP-2. 10 µg of the tagged BMP-2 protein was loaded onto a 
demineralized bone matrix (DBM) which was covalently decorated with pentahistidin 
antibodies (so-called MAbs-DBM). The antibodies were used to enhance the loading 
capacity of the demineralized scaffold. These scaffolds were subsequently tested in cell 
based assays for osteogenic differentiation using C2C12 cells and also in vivo for inducing 
ectopic bone formation in male Sprague–Dawley rats. The results clearly showed that his-
tag immobilized BMP-2 was able to induce alkaline phophatase (ALP) activity in C2C12 cells 
in a dose dependent manner independent of whether it was adsorbed to the undecorated 
demineralized scaffold or bound to the pentahistidin antibody decorated scaffold. However, 
his-tag-BMP-2 bound to MAbs-DBM induced higher ALP signals at the same BMP-2 dose. In 
vivo, after two weeks of implantation his-tag-BMP-2/DBM and His-BMP-2/MAbs-DBM both 
induced formation of ectopic bone in proximity to the scaffolds which could not be 
observed in case of unloaded scaffolds. Moreover his-tag-BMP-2/MAbs-DBM revealed 
thicker layers of bone tissue and higher levels of calcification [159]. 
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BMP-2 immobilization via bi-functional peptide linkers 
Hamilton and co-workers have recently established a phage display procedure for the 
isolation of short bi-functional collagen and BMP-2 binding peptides [160]. For this purpose, 
they employed a biotinylated BMP-2 (linked by conventional N-Hydroxysuccinimide(NHS)-
coupling techniques), which was then immobilized to a streptavidin-coated 96-well 
microplate. Ten different phage display libraries, designed with a central specific amino acid 
core motif were screened for peptides that bind to BMP-2. The identified BMP-2-binding 
peptides were then individually combined with a collagen-binding peptide sequence 
(generated in previous work [161]) by a flexible linker. Such bifunctional peptides were 
mixed with BMP-2 supplied with an injectable collagen gel. The osteogenic properties of the 
construct (200 µl of collagen gel containing 2 mg of BMP-2) were investigated in vivo. Two 
weeks after surgery approximately 25% of the implant was covered with new bone in the 
peptide-containing group, whereas no bone formation was observed in the control group 
(without the bi-functional peptide). Further analyses revealed that binding of the BMP-2-
binding peptides to BMP-2 was not affected by the presence of human plasma since plasma 
components theoretically could interact and thus compete for the binding of the peptide to 
BMP-2 [160]. 
BMP-2 immobilization via interaction with heparin/chitosan 
Heparin, also known as a heparan sulphate is a highly sulfated glycosaminoglycan, carrying a 
strong negative surface charge. It is stored mainly in mast cells of the immune system and 
appears in the extracellular matrix of eukaryotic cells where it interacts with multiple 
growth factors and serves as an antibacterial and hydrating factor for the cellular matrix 
[162]. Owing to its strong affinity towards BMP-2, a number of BMP immobilization 
approaches using heparin/heparin-binding-site interaction emerged in the recent years. 
In a paper by Kim et al. [163] titanium dental implants were covalently covered with heparin 
by using classical EDC/NHS-mediated coupling chemistry. The work focused on the 
development of a dental implant with antibacterial properties and enhanced osteogenic 
function. The BMP-2 binding to the heparin-grafted titanium discs was accomplished by 
immersing it in a BMP-2 solution (10 or 50 ng/mL) for 24 h at ambient temperature. In vitro 
tests showed reduced inflammatory potential as analyzed in a murine macrophage cell line, 
a sustained release of BMP-2 from the heparin-titanium discs and stimulated osteoblast 
function which was further proven by significantly higher ALP activities and calcium contents 
in cells grown on BMP-2 (50 ng)-immobilized titanium surfaces. Similar approaches to 
functionalize titanium surfaces were performed by Lee et al. and reported in 2012 [164]. 
Also recently, a similar approach for BMP-2 immobilization on polycaprolactone fibers was 
published in which their potential to induce osteogenic differentiation of periodontal 
ligament cells was studied [165]. The polycaprolactone fiber surface was functionalized with 
heparin-dopamine and further coated with BMP-2. The publication reports sustained BMP-2 
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release profiles over 28 days with no evident cytotoxicity against periodontal ligament cells 
(PDLCs). Fibers with immobilized BMP-2 significantly induced osteogenic differentiation with 
a significant increase in ALP activity, calcium deposition and mRNA expression levels of 
osteocalcin and osteopontin compared to the unmodified PCL fibers [165]. A subsequent in 
vivo study demonstrated that the implanted BMP-2/Hep–DOPA/PCL/PLGA scaffolds 
implanted into rat femur defects induced more bone formation compared to that of BMP-
2/Hep/PCL/PLGA- and PCL/PLGA scaffolds [166]. Similarly, BMP-2 has also been immobilized 
onto calcium coated chitosan scaffolds [167]. These in vivo studies were performed in New 
Zealand male rabbits. Defects of 4 mm in diameter were drilled into tibiae maesetae of both 
legs and the scaffolds were implanted into the deficient area. The osteogenic potential of 
the scaffold was analysed 3 weeks after implantation. The results showed that BMP-2 
remained active in the chitosan scaffolds and its release kinetic was dependent on the 
presence of calcium phosphate salts. Chitosan scaffolds containing both calcium phosphate 
salts (CPS) and BMP-2 were more osteoinductive than their counterparts alone [167]. 
BMP-2 immobilization via biotin-streptavidin interactions 
A complex of biotin bound to streptavidin is the strongest known non-covalent biological 
interaction, with a dissociation constant (KD) of 10-13 M [168]. The complex formation is 
robust and binding may only be disrupted by harsh, denaturing conditions. For this reason 
biotin and streptavidin are a very convenient choice for protein immobilization. In context of 
BMP-2 immobilization, biotin-streptavidin interaction has been used to study the biological 
activity of bound BMP-2 [169], as well as for quantifying small amounts of immobilized 
BMP-2 on various materials [170]. Recently, a continuous surface BMP-2 gradient was 
constructed using biotin-streptavidin interaction, to enable cell screening studies [171]. 
However, since the production of streptavidin is cost-intensive, such approaches were in the 
past mainly addressed in basic research for e.g. protein purification or protein 
quantification. 
BMP-2 immobilization via synthetic oligonucleotides 
In an in vitro study conducted by Schliephake and co-workers [172] a set of complementary 
DNA strands was used for BMP-2 immobilization. The aim of the study was to investigate 
whether oligonucleotides could be suitable to immobilize and slowly release osteogenic 
growth factors, and thereby enhance the osteogenic potential of titanium implants. 60-mer 
non-coding DNA oligonucleotides were fixed to titanium surfaces by anodic polarization. 
Conjugation of BMP-2 with complementary sequences was achieved by chemical 
crosslinking using disuccinimidyl suberate (DS) as linker molecule. The functionalized BMP-2 
was then hybridized to the titanium-anchored oligonucleotides at room temperature (the 
coupling scheme is similar to that of biotinylated BMP-2 interacting with strepatavidin, see 
figure 2C). In vitro experiments were performed using human bone marrow stromal cells 
(hMSCs). Release studies over 28-days showed a continuous release of BMP-2 from the 
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titanium surface. Also proliferation of cells was significantly increased and the osteogenic 
markers, osteopontin and alkaline phosphatase, were upregulated. Additionally, BMP-2-
conjugated scaffolds revealed significantly higher number of focal adhesion points. Released 
BMP-2 was tested for its biological activity which was shown to be comparable to non-
conjugated BMP-2, proving that the conjugation process did not affect its biological activity. 
As many affinity binding approaches clearly showed that an increase of the affinity of BMP-2 
to particular scaffolds enhances the osteogenic potential of the construct, several research 
groups have focused on covalent binding of the growth factor onto various materials. 
Delivery strategies using covalently coupled recombinant BMP-2 
Most of the injectable BMP carriers are unable to retain BMP at the site of injection. As a 
consequence, most carriers lose 50% or more of pre-loaded BMP after a few days in vivo. 
The delivery of a covalently immobilized growth factor would therefore offer the advantage 
of a controlled and sustained influence on cell behavior in comparison with soluble or slowly 
released proteins. 
Implanting constructs being functionalized with covalently bound BMP-2 [173] 
demonstrated the easy delivery of this growth factor with a homogeneous distribution on 
the implant surface, primarily circumferential bone induction, rapid gap filling by trabecular 
bone within 4 weeks and an easy control and avoidance of ectopic bone formation. Covalent 
immobilization of BMP-2 and epidermal growth factor (EGF) has also been achieved on 
titanium dioxide (TiO2) nanotube surfaces by N,N-carbonyldiimidazole (CDI) coupling either 
via direct binding to amine groups of the growth factor or via spacers such as 11-hydroxy-
undecylphosphonic acid (PhoA) [174]. Coupling proteins via N,N-carbonyldiimidazole is non-
site directed and may result at least partially in deactivation or denaturation of the coupled 
proteins. BMP-2 coating did not contribute to cell proliferation, attachment, adhesion or 
proliferation as shown for EGF if exposed to bone marrow derived MSCs. These findings 
indicate that these cellular activities are not triggered by BMP-2 or that the cells in general 
might be BMP-2 insensitive. 
Since naturally occurring growth factors only contain a limited subset of reactive groups 
(NH2-, OH- COOH-, and SH-groups) being present in sidechains of particular amino acids, the 
chemical coupling reactions have to address the individual demands of these functional 
groups for coupling. In order to extend the spectrum to a broader variety of potential 
coupling chemistries, bi-functional linkers have been designed for coupling of growth factors 
to scaffolds. Several coupling methods have recently been developed to further control the 
orientation of the growth factors to be immobilized including usage of cysteine-containing 
tags, peptide aptamers and fibrin or collagen substrates [175]. However, these methods 
entail protein modifications thus can also affect the outcome of individual cellular 
responses. Recently, Tabisz et al. [176] published a strategy for site-directed coupling of 
BMP-2 to scaffolds by click-chemistry utilizing an artificial amino acid, which had been 
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introduced during bacterial expression by amber codon suppression [177]. The constructed 
BMP-2 variant showed the same bioactivity compared to wildtype BMP-2 and could be 
coupled site-directed and biologically active coupled to solid surfaces. This technique allows 
an interesting alternative since the linker used for coupling already gets introduced into the 
protein upon protein expression thus avoiding secondary modifications. Another hallmark of 
this technique is that the position of the artificial amino acid is not restricted to the N-
terminus of BMP-2 thus allowing a positioning which certainly will not impede the binding of 
BMP-2 to its cognate receptors. 
Engineered surfaces decorated with site-directed and covalently bound BMP-2 being 
immobilized via optimized linkers might represent an excellent alternative in order to 
maintain the growth factor´s biological activity. Other surfaces, for instance gold surfaces 
have been first decorated with a hetero-bifunctional linker which subsequently were 
exposed to BMP-2. For tracking purpose, BMP-2 has been iodinated with Na125I prior to 
coupling. The activated surfaces were used in cell based assays using C2C12 cells [178]. Also 
here, the covalently immobilized BMP-2 activated BMP-dependent signal transduction, thus 
resulting in the expected cellular responses like suppression of myotube formation and 
upregulated ALP expression. Specific BMP-2 binding peptides have been screened and used 
as part of an engineered hetero-bifunctional spacer enabling the simultaneous binding to 
BMP-2 and collagen [160]. In cell based assays, the bifunctional linker increased the 
retention of BMP-2 within a collagen matrix and led to increased osteogenic activities. But, 
it is not clear if BMP-2 can bind its cognate cellular receptors while still bound to the peptide 
or if BMP-2 has to be first released for interaction with these receptors. However, in vivo 
results demonstrate that the presence of the linker significantly increased osteogenic 
activity [160]. 
Delivery strategies using covalently coupled BMP-2 derived peptides 
The use of peptides mimicking BMP-2 specific bioactivities might represent an attractive 
alternative for the costly recombinant growth factors [179]. Synthetic BMP-2 peptides might 
circumvent the use of native proteins that may undergo degradation and denaturation in 
vivo. But, due to the dimeric nature of the BMPs, the binding epitopes for the type I- (wrist 
epitope) and the type II receptor (knuckle epitope) exist twice. So, to achieve full receptor 
activation, the native ligand has to bind to two type I- and two type II-receptor chains 
forming a heterohexameric ligand-receptor assembly [180]. Thus, mimicking these 
capabilities with a simple peptide seems not feasible. However, coupling of a synthetic 
peptide corresponding to amino acids located within the knuckle epitope by EDC/NHS 
chemistry to alginate gels induced prolonged ectopic calcification for up to 7 weeks in rat 
calf muscle whereas BMP-2-doped collagen gel showed maximum ectopic calcification 
already after 3 weeks but the formed calcified ossicles disappeared after 5 weeks [181]. The 
peptide-functionalized alginate scaffold also induced ALP activity (ALP) in a murine 
osteoblast cell line. Furthermore, it could be demonstrated that upon exposure to this 
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construct SMAD signaling is initiated resulting e.g. in the upregulation of osteopontin 
expression and an increased mineral deposition in murine mesenchymal stem cells [182]. 
Compromised bone growth often occurs in the immediate vicinity of metallic implants, 
leading to weakened bone quality and implant failure. BMP-2 peptides covalently bound to 
glass, titanium, cobalt chromium (CoCr) and gold substrate have been shown to enhance 
and accelerate the growth and differentiation of osteoblasts and other cell lines. Chemical 
immobilization of synthetic peptides onto titanium implants was conducted to evaluate the 
in vitro and in vivo osteointegration capacity [183]. A peptide mimicking both, the wrist and 
the knuckle epitope was chemically synthesized using a so-called F-moc chemistry with an 
additional N-terminal modification by a cysteine-containing spacer which eases chemical 
conjugation onto implant surfaces. This peptide covalently coupled to titanium discs showed 
in MC3T3-E1 cells higher proliferation and upregulated expression of osteogenic markers 
such as ALP compared to the control disc. Importantly, the peptide modified implant 
material introduced into canine mandibles showed a significant increase of bone growth, 
thereby confirming that biochemical modifications of Ti surfaces can indeed increase the 
rate of bone healing compared to untreated Ti surfaces. Potentially useful findings have also 
been reported for CoCr alloy implants, where the presence of a BMP mimicking peptide 
(coupled via a cysteine amino acid at the N-terminus) showed twofold increase in ALP 
activity after 2 weeks of incubation and a fourfold increase in calcium content after 3 weeks 
of incubation compared to controls [184]. Peptides mimicking the knuckle epitope of BMP-2 
have also been immobilized on anodized nanotubular titanium [185]. Results showed 
increased osteoblast adhesion compared to non-functionalized anodized titanium. This in 
vitro study adds anodized materials that hold nanometer surface textures to the growing list 
of materials that promote osteogenesis. 
Several reports found in the more recent literature have demonstrated that surface textures 
in the nanometer-scale topography can influence proliferation and differentiation of 
embryonic and mesenchymal stem cells. Therefore, nanoscale topographies in combination 
with growth factors may promote proliferation or lineage differentiation of stem cells. To 
develop these substrates, the factors have to be immobilized directly on the surface of the 
substrate. One study showed that nanopatterned polyurethane acrylate (PUA) substrates 
uniformly coated with poly(glycidyl methacrylate) (pGMA) by initiated chemical vapor 
deposition (iCVD) followed by covalent immobilization of BMP-2 peptides results in a much 
more efficient BMP-2 peptide immobilization than e.g. physical adsorption. Results of 
Alizarin Red S staining, immunostaining, and quantitative real-time polymerase chain 
reaction (qRT-PCR) revealed that hMSCs cultured on such nanopatterned surfaces enhanced 
osteogenic differentiation [186]. However, despite the studies demonstrating the influence 
of peptide-modified surfaces on cellular behavior in vitro, there is relatively little evidence 
reporting their effects on osteogenesis and osteoclastogenesis (remodeling) in vivo. 
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COMPARISON OF GENE AND PROTEIN/PEPTIDE DELIVERY STRATEGIES 
In an in vitro study, gene delivery of BMP-2 and ectopic delivery of the recombinant BMP-2 
protein were directly compared. Interestingly, both approaches showed comparable 
mineralization results. A difference was observed in osteogenic protein expression levels 
where BMP-2 transfected cells expressed more osteopontin compared to the cells treated 
with same amount of recombinant BMP-2 protein in the cell culture medium [187]. Both, 
gene and protein delivery have advantages and drawbacks. Gene delivery provides supply of 
proteins for a relatively long time and the expression period can be controlled by inducible 
expression vectors. But a safety concern remains about the use of viral vectors in clinics. 
When non-viral vectors are considered, transfection of long DNA fragments appears difficult 
to perform and the efficiency may not be enough to realize complete bone restauration. In 
gene delivery, the protein is continuously produced by the cells and therefore stability is not 
an issue. However, in the development of protein delivery systems, the stability of the 
protein in the period of at least several weeks should always be considered and assured. 
Besides, the required dose and release kinetic should be assigned correctly for successful 
clinical outcomes.  
As suggested, both systems need further improvements, more characterization of the 
improved systems and solid pre-clinical data to pursue with clinical trials. 
FUTURE PERSPECTIVES 
The complexity of tissue engineering in the field of bone regeneration inspired numerous 
investigators to date and as more investigations are conducted more complexity arises 
[188]. For the generation of innovative products more advanced engineering strategies of 
biomaterials probably including cells as well as growth factors are required. Controllable and 
reproducible production techniques of innovative materials have to be elaborated on 
products acting osteogenic on their own. Ideally, these materials are applied together with 
cells, either actively taking part in the regeneration of the bone defect and/or secreting the 
signalling molecules which act as initial trigger of a whole cell-cell communication cascade 
resulting finally in the recruitment of osteoprogenitor cells from the surrounding tissue. This 
initiating signal is most-likely provided by BMP-2 as described in this manuscript since 
application of this protein (or another osteogenic BMP) at ectopic sites (e.g. in muscular 
tissue) results in the formation of an ossicle by mechanisms being similar to those occurring 
in natural bone growth and repair. Ideally, the provided signal is sufficiently active for the 
period of time the bone defect needs to heal. In principal, this can be achieved best by 
genetically manipulated cells but due to immunological concerns, autologous cells are 
required. Alternatively, the signal can be provided by the application of recombinant BMPs. 
Here, numerous trials have been conducted within the last decades all of which faced the 
same problem relying on the general (bio-) chemical properties of this class of growth 
factors. As these proteins can induce the formation of ectopic bone, it has to be assured 
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that responsive tissues (e.g. muscular tissue) are not exposed to these proteins even in 
situations of bone fractures. For that purpose, the osteogenic BMPs are evolutionary 
"designed" as badly soluble proteins which additionally bind strongly to components of the 
extracellular matrix. Local administration of huge amounts must consequently result in a 
kind of precipitate rendering the majority of the protein biologically inactive. This inactive 
clot is typically eliminated by several environmental mechanisms. The design of 2nd 
generation BMPs should, therefore, focus on protein variants which in general provide 
higher bioactivities over longer periods of time. This can be achieved by enhancing the 
individual binding affinities of the ligand to the cell surface receptors by rational structure 
based design. Due to enhanced binding affinities, the applied dose of the BMPs being 
required can be significantly reduced but the protein modification bears the risk to induce 
immunological responses. Another way to keep the growth factor´s signalling capacities 
biologically active and locally in place might be provided by tight binding of the factor to 
suitable scaffold structures. As discussed in this review this might be realized addressing the 
material side (with scaffolds being optimized for BMP binding) and/or addressing the 
growth factor side (by a covalently bound BMP which ideally is coupled to the matrix side 
directly), thus enabling a robust and reproducible decoration of the chosen matrix. If initial 
steps of the regeneration process involve the migration of stem cells being recruited by a 
growth factor gradient, the coupling of this factor should - at least partially - occur via 
linkers which are cleavable by e.g. matrix-metalloproteinases. 
In conclusion, by addressing the key problems which have been identified to date it seems 
feasible to create either cell-based or cell-free delivery systems for BMP-2 which in the near 
future can routinely be used in clinics in case of complex traumas and other cases requiring 
medical intervention. 
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Abstract 
Bone morphogenetic protein-2 (BMP-2) is a powerful osteoinductive protein; however, 
there is a need for the development of a safe and efficient BMP-2 release system for bone 
regeneration therapies. Recombinant extracellular matrix proteins are promising next 
generation biomaterials since the proteins are well-defined, reproducible and can be 
tailored for specific applications. In this study, we have developed a novel and versatile 
BMP-2 delivery system using microspheres from a recombinant peptide based on human 
collagen I (RCP). In general, a two-phase release pattern was observed while the majority of 
BMP-2 was retained in the microspheres for at least two weeks. Among different 
parameters studied, the crosslinking and the size of the RCP microspheres changed the in 
vitro BMP-2 release kinetics significantly. Increasing the chemical crosslinking 
(hexamethylene diisocyanide) degree decreased the amount of initial burst release (24 h) 
from 23% to 17%. Crosslinking by dehydrothermal treatment further decreased the burst 
release to 11%. Interestingly, the 50 and 72 µm-sized spheres showed a significant decrease 
in the burst release compared to 207-µm sized spheres. Very importantly, using a reporter 
cell line, the released BMP-2 was shown to be bioactive. SPR data showed that N-terminal 
sequence of BMP-2 was important for the binding and retention of BMP-2 and suggested 
the presence of a specific binding epitope on RCP (KD: 1.2 nM). This study demonstrated 
that the presented RCP microspheres are promising versatile BMP-2 delivery vehicles.  
Keywords: bone morphogenetic protein-2, microspheres, protein delivery, bone 
regeneration 
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INTRODUCTION 
Bone has a high self-regeneration capacity and most of the fractures can heal without any 
scar formation [36]. However, in critical-size bone defects, a surgical procedure with use of 
bone grafts is required [189, 190]. To replace the use of natural bone in clinics, there has 
been a tremendous effort to develop biomaterial based synthetic bone substitutes [191]. 
The biomaterials have been used in combination with growth factors to create an 
osteoinductive environment and to induce substantial amount of bone formation. These 
osteoinductive growth factors are known to recruit osteoprogenitor cells and guide their 
differentiation during the regeneration of the bone [192]. Bone morphogenetic protein-2 
(BMP-2) and bone morphogenetic protein-7 (BMP-7) are growth factors that are already 
clinically used in bone regeneration [193]. BMP-2 adsorbed onto a collagen sponge matrix 
has been approved by the FDA for spinal applications [194]. However, off-label use [195] of 
BMP-2 especially in the cervical spine fusion resulted in adverse events such as hematoma, 
swallowing/breathing difficulties or swelling without hematoma [196]. Therefore, to obtain 
better clinical outcomes utilizing BMP-2, it is crucial to reduce the applied dose and/or to 
regulate its spatio-temporal delivery using appropriate delivery systems [148].  
Several materials, especially natural biopolymers, have been investigated as controlled 
release systems for BMP-2 [150, 197-199]. Natural biopolymers are often chosen as a 
delivery system in tissue engineering not only due to their biocompatibility and 
biodegradability, but also due to their intrinsic features mimicking the extracellular matrix. 
As such, collagen was widely studied since it is a major component of the organic bone 
matrix [200]. However, in case of collagen sponge, one of the first natural scaffolds used for 
BMP-2 delivery, an early burst release of BMP-2 is typically observed[144]. More 
sophisticated BMP-2 release systems based on collagen’s degradation product, gelatin have 
been developed [201]. For example, genipin-crosslinked gelatin microspheres have been 
shown to provide a slower release compared to PLGA microspheres [145].  However, 
animal-derived collagen or gelatin-based materials bear the risk of antigenic response, and 
batch-to-batch variability which complicates their clinical translation [202].  
We have previously developed a human collagen type I-derived recombinant peptide (RCP) 
as designer biomaterial, which is produced by a fermentation process using genetically 
modified yeast Pichia pastoris [203].The major advantage of RCP over animal-derived 
proteins is that genetically engineered RCP offers a versatile and powerful platform to 
create functional (collagen-based) peptides with a low immunogenic response. The specific 
RCP variant used in this study is enriched with several RGD units. RCP-based microspheres 
have been shown to support cell attachment and cell proliferation [204]. Furthermore, RCP 
is advantageous over animal-derived collagen/gelatin not only for enhanced cell binding, 
but also for its well-defined protein sequence, the reproducibility of the production process, 
and low immunogenicity [205]. Previous in vivo studies have shown that RCP-based 
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microspheres do not elicit a strong immune response or foreign body reaction when 
injected subcutaneously [206].  
In this study, we developed novel RCP microspheres for a defined release of recombinant 
BMP-2. The aim of this research was to identify the parameters that control BMP-2 release 
kinetics. Detailed understanding of different parameters affecting these release kinetics is 
required for the final design of a controlled release system. Based on literature, we selected 
crosslinking [201], particle size [207] and pore size [208] as potential parameters to 
modulate release. Hence, we used different crosslinking techniques and different 
preparation methods to create a small library of microspheres. In brief, the effect of 
crosslinking was studied by using high and low amounts of chemical crosslinker 
(hexamethylene diisocyanide); and long and short dehydrothermal treatment. The effect of 
size was studied creating three different sizes of spheres: 50 and 72 and 207 µm; and pore 
size studied by creating pore sizes of 1 µm, 10 µm and macropores (>10µm). These 
microspheres were subsequently loaded with BMP-2 by adsorption and their release 
profiles were investigated by ELISA. Furthermore, the bioactivity of the released protein was 
confirmed by cellular assays using a reporter C2C12 cell line. To gain better understanding 
of the interaction between BMP-2 and RCP on a molecular level a Surface Plasmon 
Resonance (SPR) study was performed using multiple BMP-2 variants.  
MATERIALS AND METHODS 
Materials 
Recombinant peptide (RCP) based on human collagen I, commercially available from Fujifilm 
as Cellnest™, was produced by a fermentation process using genetically modified yeast 
Pichia pastoris as described previously [203, 206]. RCP comprises 571 amino acids, has an 
isoelectric point (pI) of 10.02 and a molecular weight of 51.2 kDa. The mature part of 
rhBMP-2 (amino acids 283 to 396 plus an N-terminal Met-Ala) was expressed in E. coli, 
isolated from inclusion bodies, renatured and purified as previously described [209]. In the 
variant EHBMP-2 the N-terminal segment of the mature part of BMP-2, which contains two 
triplets of basic amino acid residues (QA KHK Q RKR …), was replaced by a non- basic dummy 
sequence of identical length [104]. In T4BMP-2 the N-terminal sequence motif harboring 
two basic triplets (shown above) was doubled (QA KHK Q RKR A KHK Q RKR…) [210]. Both 
protein variants were expressed and purified identical to wildtype BMP-2 [209]. For use in 
SPR, the extracellular domain of the BMP type I receptor BMPR-IA (BMPRIAec) was 
expressed in E.coli and purified as described [209]. 
Hexamethylene diisocyanide (HMDIC), corn oil, calcium carbonate (CaCO3), picrylsulfonic 
acid (TNBS,5% w/v solution in H2O), bovine serum albumin (BSA) and collagenase from 
Clostridium histolyticum were purchased from Sigma-Aldrich (St. Louis, MO, USA). Ethanol, 
acetone and hydrochloric acid were purchased from Millipore (Billerica, MA, USA). ELISA 
development kit and reagents were ordered from Peprotech (Rocky Hill, NJ, USA). Gibco 
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products: Dulbecco’s Modified Eagle’s Medium (DMEM) and penicillin-streptomycin were 
ordered from Thermofisher Scientific (Waltham, MA, USA). SteadyLite Plus was ordered 
from Perkin Elmer (Waltham, MA, USA).  MilliQ water was used in the experiments.   
Preparation of RCP microspheres  
RCP microspheres were produced by emulsification using calcium carbonate (CaCO3) 
crystals as pore-forming agent. Briefly, a 20% (w/v) aqueous RCP solution was mixed with 
CaCO3 powder (fine powder with particle size of <1 µm or 10 µm) in a 1:1 weight ratio of 
RCP to CaCO3. The suspension was added dropwise to preheated corn oil at 50°C while 
stirring the emulsion at 800 rpm for 20min. Then, the emulsion was cooled using an ice bath 
and the emulsified microspheres were washed three times with acetone. After overnight 
drying at 60°C, microspheres were sieved to the desired size (Sieves Retsch GmbH, Haan, 
Germany). In the experiments 32-50 µm, 50-72 µm or 200-300 µm sieve fractions of 
microspheres were used. Subsequently, the microspheres were crosslinked. DHT 
(dehydrothermal) crosslinking was conducted at 160°C in vacuum (~5x10-3 mbar) for 1 day 
or 4 days. Hexamethylene diisocyanide (HMDIC) crosslinking was conducted by suspending 
1 g of spheres, and 1mL of HMDIC (high) or 30 µL of HMDIC (low) in 100 mL ethanol for 1 
day. (High HMDIC corresponds to an excess amount of chemical crosslinker, while low 
HMDIC corresponds to less than the amount required to crosslink all amino groups present 
in the RCP). After crosslinking, the CaCO3 porogen was removed by suspending the 
microspheres in 0.23 M HCl for 30 min until the formation of carbon dioxide stopped. The 
microspheres were washed repeatedly with water until a neutral pH was achieved. 
Complete removal of CaCO3 was confirmed by Energy-dispersive X-ray spectroscopy (EDX) 
mapping of calcium on spheres (Jeol JSM-6335F Field Emission Scanning Electron 
Microscope). In order to produce 200-300 µm microspheres, the viscosity of corn oil was 
decreased during emulsification by adding n-heptane. Macroporous microspheres with 
pores larger than 10 µm were produced by a double emulsification method as described 
elsewhere [211]. No CaCO3 porogen was used in the preparation of these macroporous 
microspheres. 
Characterization of microspheres 
The microsphere size was measured by a particle size analyzer (Mastersizer 2000, Malvern 
instruments, Malvern, United Kingdom). Dry microspheres were resuspended and measured 
in ethanol. The swollen sphere size was determined after overnight incubation in pure 
water. All measurements were performed in triplicate. The average microsphere size was 
calculated based on volume weighted mean. The size distribution of spheres is indicated as 
10% (D0.1), which means 10% of spheres are below this size; and 90% (D0.9), which means 
90% of spheres are below this size. The swelling ratio for each type of microsphere was 
calculated using the ratio of swollen diameter in water (dt) to dry diameter (do) and 
subsequently converted to volume (dt/do)3. 
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Carboxyl and amine groups of RCP are crosslinked by DHT; whereas, only amines are 
crosslinked by HMDIC. Therefore, the degree of crosslinking was determined by measuring 
the residual free amines of the microspheres using a colorimetric assay, based on 2,4,6-
trinitrobenzenesulfonic acid (TNBS). TNBS reacts with primary amines including both 
terminal α-amino groups and side chain ε-amino groups [212]. The absorbance was 
measured at 345 nm using a CARY 50 UV-Vis spectrophotometer (Agilent Technologies, 
Santa Clara, CA, USA). The experiment was done in triplicate and non-crosslinked RCP was 
used as a reference to calculate the reduction of amino groups upon crosslinking. The 
morphology and distribution of microspheres were visualized by a Jeol JSM-6335F Field 
Emission Scanning Electron Microscope with an accelerating electron voltage of 2.5-5.0 kV. 
Samples were coated with 10 nm Pt. 
BMP-2 loading, release and bioactivity 
The experimental setup for BMP-2 release measurements was adapted from Poldervaart et 
al. [213]. BMP-2 loading was performed in 1.5 mL Eppendorf LoBind tubes, where 75 µL of 
rhBMP-2 solution with a concentration of 12 µg/mL was added on top of 15 mg dry 
microspheres and incubated overnight at 4 °C to allow adsorption of BMP-2 during the 
swelling of microspheres. During this incubation, all liquid is absorbed by the microspheres. 
The above loading ratio corresponds to 60 ng BMP-2 per mg microspheres. In the “loading 
dose experiment” the concentration of the BMP-2 solution was varied to obtain 6, 60 and 
600 ng BMP-2 per mg microspheres. For the experiment comparing microspheres with 
different pore size, the same number of microspheres instead of same weight was used to 
correct for differences in microsphere density. The number of spheres per mg was 
calculated by counting the spheres under the microscope. For the mentioned experiment, 
900 ng of BMP-2 was loaded onto 15 mg 1 µm porous spheres, 15 mg 10 µm porous 
spheres, and 7.7 mg macroporous spheres. 
To initiate the release assay next day, 925 µL release medium containing DMEM, 1% BSA 
and 1% penicillin-streptomycin was added on top of the swollen microspheres. BSA was 
used to prevent adsorption of BMP-2 to the tubes and penicillin-streptomycin was used to 
prevent bacterial growth potentially resulting in degradation of RCP. The tubes were placed 
on a tube rotator at 37°C and the release was followed for 2 weeks by refreshing medium at 
regular time intervals. For the refreshment, the complete release medium (900µL) was 
collected after centrifugation at 3000 rpm for 5 min and replaced with fresh medium 
(900µL). Released rhBMP-2 was quantified by ELISA using the rhBMP-2 ELISA development 
kit (Peprotech) according to the supplier´s protocol. Released BMP-2 was calculated using a 
standard calibration curve. The percentage of released BMP-2 was calculated relative to the 
positive control, which is BMP-2 solution at the same concentration (900ng/mL) without 
microspheres kept at the same conditions as the release samples. After 2 weeks the release 
assay was finalized by degradation of the microspheres to liberate the remainder of BMP-2 
inside the microspheres. Hereto, 900 µL of a collagenase solution (2mg/mL DMEM) was 
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added to the microspheres. After overnight incubation the BMP-2 concentration was 
analyzed again by ELISA. The positive control at the same concentration was also treated 
with collagenase to calculate the percentage of BMP-2 released.  
The bioactivity of the released BMP-2 was determined employing a cell assay using C2C12-
BreLUC cells. The cell line is genetically modified with a reporter gene construct harboring a 
BMP-responsive element to control luciferase expression in a dose-dependent response to 
BMP-2 stimulation. This type of construct has previously been used as a reporter for 
different bone morphogenetic proteins in different cell lines [214, 215]. Cells were 
maintained in DMEM with 10% fetal calf serum, 1% penicillin-streptomycin and 0.5% G418. 
For the assay, 5x103 cells per well were seeded in 96 well plates and after 30 min the release 
medium was added to cells. A standard calibration curve with BMP-2 was made. After 24 
hours of incubation, SteadyLite Plus kit components were added according to the 
manufacturer’s protocol and 15 min after cell lysis, the luminescence signal was measured 
for 6 s using a Wallac VICTOR Multilabel reader (Perkin Elmer, Waltham, MA, USA). Sample 
BMP-2 concentrations were calculated based on BMP-2 standard calibration curve. 
Surface plasmon resonance (SPR) spectrometry 
A ProteOn XPR36 biosensor system (Bio-Rad, Hercules, CA, USA) was used for all surface 
plasmon resonance interaction experiments. Measurements were performed at 25°C using 
10mM HEPES pH 7.4, 3.4mM EDTA, 0.005% (v/v) Tween-20 supplied with different NaCl 
concentrations (150 mM and 500 mM) as running buffer, the flow rate for interaction data 
acquisition was set to 50µL min-1. For interaction analyses BMPRIAec protein was 
biotinylated in a 1:2 stoichiometric ratio using Sulfo-NHS-LC-biotin (Pierce, Thermo Fisher 
Scientific, Rockford, IL, USA) following the manufacturer’s protocol. For immobilization, a 
GLC sensor chip was first activated using EDC/Sulfo-NHS (Bio-Rad, Hercules, CA, USA) 
according to manufacturer’s recommendation, then streptavidin (Sigma-Aldrich, St. Louis, 
MO, USA) was perfused over the activated sensor surface at a concentration of 40ug mL-1 
until resonance unit (RU) levels reached 2000 to 2200 RU. The biotinylated receptor 
ectodomain was subsequently immobilized onto this streptavidin sensor surface at a density 
of approximately 500 RU. RCP (100 µg/mL) was coupled directly to the EDC/NHS activated 
chip matrix at a density of 1300 RU.  For a single kinetics measurement six different analyte 
(BMP-2) concentrations starting at 50nM (log2 dilution series) were used. The association 
time was set to 180s; dissociation data were obtained from perfusion with running buffer 
for 120s. Interaction data were acquired employing the so-called single-shot kinetic setup 
specific to the ProteOn XPR36 SPR system, which allows measuring all six analyte 
concentrations simultaneously. After each BMP-2/BMP-2 variant perfusion, the sensor chip 
was regenerated with three subsequent 120s pulses injecting 100mM glycine pH 2.5, 10mM 
glycine pH 1.5 and 4M MgCl2 at a flowrate of 50µL min-1. Bulk phase effects (buffer jumps, 
etc.), non-specific binding of the analyte to the chip matrix, the interaction of the analyte to 
a streptavidin surface on a control flow channel and the interaction at the, so-called, non-
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modified interspots were subtracted from all binding data. Equilibrium binding constants 
(Kd) were calculated by fitting the association and dissociation phase of the sensograms 
using a grouped regression analysis of the rate constants (kon, koff) and employing a simple 
1:1 Langmuir-type interaction model. Fitting analyses were considered successful when Chi2 
values were less than 10% of the maximal signal amplitude. Standard deviation of the 
kinetic rate and equilibrium binding constants were derived from three independent 
experiments using five-six different analyte concentrations. For clarity, only the SPR curves 
at 25 nM BMP-2 protein (wildtype or variants thereof) are shown in the results. 
Study design 
Eight different types of microspheres were produced by changing the preparation or 
crosslinking method, or the material. First, 50-72 µm microspheres were crosslinked by 4 
different methods: HMDIC high (MS#1), HMDIC low (MS#2), DHT 4 day (MS#3) and DHT 1 
day (MS#4). Effects of sphere size and pore size were investigated using HMDIC-high 
crosslinked spheres only. To investigate the effect of sphere size three different sizes of 
microspheres were produced: 32-50 µm (MS#5), 50-72 µm (MS#1) and 200-300 µm (MS#6). 
The effect of porosity and pore size was investigated using the large 200-300 µm-sized 
microspheres because producing macroporous spheres was only possible at this size. 
Microspheres with different porosity were produced by 1 µm CaCO3 (MS#6), 10 µm CaCO3 
(MS#7) pore leaching or by the double emulsification method (MS#8). We have used this 
library of different microspheres to study the influence of physicochemical characteristics of 
spheres on BMP-2 release (as summarized in Table 1).  
Statistical analyses 
Differences in release for each time point were analyzed by one-way ANOVA. Linear 
regression analysis was done after plotting cumulative release (%) vs. log2 (time) and 
corresponding r2, slope values were calculated. Two-phase decay model in Graphpad Prism 
was used to analyze the rate of release kinetics. Experiments were run in triplicate, 
statistical significance between means is shown with asterisks corresponding to * = p < 0.05, 
** = p < 0.01, *** = p < 0.001. 
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RESULTS  
Preparation and characterization of the microspheres 
In order to investigate the effect of several parameters on BMP-2 release, a small library of 
RCP microspheres was created, comprising spheres differing in size, pore size or the 
crosslinking technique used. These microspheres were extensively characterized in terms of 
their morphology, size distribution and the number of residual amino groups (Table 1). The 
size uniformity was confirmed by laser diffraction. The smallest spheres prepared in this 
study had an average ‘dry’ diameter of 50 µm (MS#5) and the largest spheres of 269 µm 
(MS#8). This wide variation in sphere size allowed us to investigate the effect of size on 
BMP-2 release over a broad size range. The degree of crosslinking was investigated by 
analyzing the residual or non-reacted amines using the colorimetric TNBS assay. In this 
assay, the non-crosslinked RCP was used as a reference. Theoretically, non-crosslinked RCP 
contains 65 mmol/100 g primary amines in the form of lysine. HMDIC-high crosslinking 
conditions using a large excess of reactive isocyanate groups led in general to a reduction of 
more than 80% of these RCP primary amines (MS#1, MS#5-7). As expected, a lower amount 
of HMDIC increased the number of unreacted primary amine groups significantly (MS#2 vs 
MS#1). Crosslinking by heat (DHT) resulted in a smaller reduction of primary amine groups 
than HMDIC crosslinking. The MS#4 sample with a shorter DHT crosslinking time in 
comparison with MS#3 contained more residual amines. The swelling ratio of different 
crosslinked spheres at the same size (MS#1-4) showed a clear relation with crosslinking; less 
crosslinking resulted in more swelling. 
Influence of the loading dose on BMP-2 release 
To investigate the effect of the loading dose on protein binding and release, 50-75 µm 
HMDIC high 1 µm porous microspheres (MS#1) were loaded with three doses of BMP-2: 6 
ng BMP-2 per mg microspheres, 60 ng BMP-2 per mg microspheres and 600 ng BMP-2 per 
mg microspheres. As shown in Figure 1, the percentage of released BMP-2 during the first 
two days was independent of the loading dose and fits a one-phase exponential decay 
exhibiting an r2 value >0.91. Irrespective of the 100-fold difference in loading dose the 
dissociation rate K was similar for the three conditions, between 10-5 and 10-6 s-1.  In the 
following experiments we employed 60 ng BMP-2 per mg microspheres unless specified 
otherwise. 
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Figure 1. Loading amount had no effect on fraction of BMP-2 released. HMDIC-high 
crosslinked microspheres (50-75 µm, MS#1) were loaded with different amounts of BMP-2 
and cumulative release was normalized to the positive control of each concentration. 
Corresponding statistical table shows the results of the nonlinear regression of one phase 
exponential decay.  Experiment was run in triplicate, mean and SD are shown for each point. 
Influence of crosslinking on BMP-2 release 
To study the effect of the type and intensity of crosslinking on BMP-2 release, 50-75 μm 
microspheres with 1 μm pores were crosslinked either chemically or thermally, employing 
hexamethylene diisocyanate (HMDIC) or dehydrothermal (DHT) crosslinking, respectively. As 
evidenced by SEM images, the spheres were spherical and their size distribution was 
uniform (Figure 2a). As shown in Figure 2c, the release of BMP-2 was indeed influenced by 
the crosslinking method. HMDIC crosslinking resulted in an increased release when 
compared to DHT crosslinking. In case of HMDIC, stronger crosslinking resulted in a reduced 
release rate and approximately 10% less BMP-2 release. For DHT, the degree of crosslinking 
did not significantly affect the BMP-2 release. HMDIC-high crosslinking was chosen as 
crosslinking method for the following experiments. 
Regardless of the crosslinking method, the release of BMP-2 was rapid in the first 24 hours 
(Figure 2c); whereas after 1-2 days, the release rate strongly decreased (Figure 2b). The 
release data were extensively examined using several well-known drug release models 
[216]. However, none of the models such as zero-order, first order, Higuchi or Hixson 
models fit to data. The n exponent of the Korsmeyer-Peppas model [217] was calculated to 
be 0.11 which indicates that the release is not simply diffusion controlled. Interestingly, the 
data of the first two days of release fitted well to a single exponential decay model, whereas 
release curves over the full two weeks fitted better to a two-phase exponential decay 
(r2>0.98), in which the initial fast release (rate 8x10-5-1.2x10-4 (1/s)) is followed by an 
Chapter 3a 
46 
 
attenuated release (rate: 1.3x10-6-2.1x10-6 (1/s)). Although the exponential model is not a 
common drug release model, several studies employed it to describe the release [148, 218]. 
As can be seen from Figure 2, the majority of the BMP-2 protein was not yet released within 
two weeks. After two weeks, the BMP-2 loaded microspheres were degraded with 
collagenase and the residual amount of BMP-2 adhered to the microspheres was 
determined showing that more than 50% of BMP-2 initially loaded could be still be released 
from these spheres (Figure 2b).  
 
Figure 2. Crosslinking influenced BMP-2 release. (a) SEM images of microspheres 
crosslinked by HMDIC or DHT (MS#1-4) do not reveal sign of morphological difference. (b) 
BMP-2 is released from HMDIC- and DHT-crosslinked spheres for two weeks after which 
remaining BMP-2 was liberated by upon collagenase degradation of microspheres. (c) In first 
24 hours, a significant difference between DHT- crosslinked spheres and HMDIC-crosslinked 
spheres, and difference between HMDIC high and HMDIC low was observed. (d) 
Corresponding statistical table shows nonlinear regression, two-phase decay analysis for the 
two weeks data. Concentration was normalized to the positive control to calculate %-
release. Experiments were performed in triplicate, data are shown as mean and SD, 
statistical significance between means is indicated by asterisks corresponding to * = p < 
0.05, ** = p < 0.01, *** = p < 0.001. 
Influence of the microsphere size on BMP-2 release 
To study the effect of microsphere size on BMP-2 release, microspheres of different sizes 
were produced (MS#1, MS#5 and MS#6). SEM analyses confirmed their comparable 
morphology and distinct sizes (Figure 3a). As shown in Figure 3b, the release of BMP-2 was 
found to be very similar for the two small-sized microsphere samples; whereas, large 
microspheres resulted in significantly higher release. Interestingly, large spheres exhibit 50% 
of burst release in the first day. The similar release rates observed for the two small sphere 
samples might be partially due to an overlapping sphere size of MS#1 (50.5-96.3 µm) and 
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MS#5 (35.0-57.7 µm); whereas the large sphere sample clearly exhibit a discrete size range 
(MS#6: 114.8-276.7 µm).  
 
Figure 3. Microsphere size on influenced BMP-2 release. (a) SEM images of microspheres 
with average sizes of 50 μm, 72 μm and 207 μm (MS#1, MS#5 and MS#6). (b) A significant 
difference in the cumulative release of BMP-2 from large sized-spheres (207 average size) to 
that from small-sized spheres (50 μm and 72 μm average size) was observed. Concentration 
was normalized to the positive control to calculate percentage release. Experiment was run 
in triplicate; data are shown in mean and SD; statistical significance between means is 
shown with asterisks corresponding to * = p < 0.05, ** = p < 0.01, *** = p < 0.001. 
Influence of the microsphere pore size on BMP-2 release and bioactivity of released BMP-
2 
To study the effect of pore size, three types of different spheres with different pore sizes 
were used: 1 μm porous microspheres, 10 μm porous microspheres, and macroporous 
spheres characterized by fully interconnected pores larger than 10 μm (Figure 4a). These 
spheres were produced to have large sizes between 200-270 μm (MS#6, MS#7 and MS#8), 
since it is not possible to produce smaller spheres with large pores (macroporous). As shown 
by the SEM pictures in Figure 4a, the different porous spheres provided distinct surface 
morphologies with varying surface roughness and completely different surface pore size. 
Due to the difference in porosity, the density of the spheres was different. To use the same 
number of spheres instead of same weight, the number of spheres per mg was determined 
in this experiment. The release of BMP-2 from microspheres with different pore sizes was 
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found to be very similar within the first 24 h (Figure 4b). Thus no effect of pore size on BMP-
2 release was observed for the loading concentration used.  
 
Figure 4. Pore size of spheres had no influence on BMP-2 release. (a) Porosity difference of 
microspheres having pore sizes of 1 µm, 10 µm and macropores (MS#6, MS#7 and MS#8) 
can be seen by SEM images. The upper images are at 500X magnification showing one 
microsphere, lower images are 2000X or 5000X magnification showing the surface of the 
spheres. (b) No significant difference in cumulative release of BMP-2 from different porous 
spheres was observed.  Concentration was normalized to the positive control to calculate 
percent release. Experiment was run in triplicate, data are shown in mean and SD. 
In order to investigate the bioactivity of the released BMP-2, a modified C2C12 cell line, 
stably transformed with a firefly luciferase gene, which is controlled by a BMP-responsive 
element (BRE) was used. This cell line represents a well-established read-out system for the 
bioactivity of various BMPs since the receptors and downstream mediators are 
endogenously expressed. Released protein detected by C2C12 cells shows a similar trend 
and same order as observed in the ELISA analysis (Supplementary Figure). Time dependent 
bioactivity showed that the bioactivity was in the range of 20% to 95% which was calculated 
by the ratio of BMP-2 detected by C2C12 cells to BMP-2 detected by ELISA for each time 
point (Supplementary Figure). BMP-2 released from macroporous spheres (45-71%) and 1 
µm porous spheres (76%-93%) retained its bioactivity more than that from 10µm porous 
spheres (21-54%). Cumulative bioactive BMP-2 at Day 19 was in the range of 40-60% (Figure 
5). The difference in bioactivity at Day 19 was not significant between different sphere 
types. 
RCP microspheres as novel delivery vehicles for BMP-2 
49 
 
 
Figure 5. Released BMP-2 was found to be bioactive in the range of 40-60% depending on 
the sphere type. The bioactivity of released BMP-2 from the RCP spheres with various pore 
size ((MS#6, MS#7 and MS#8), was confirmed using a reporter cell line. BMP-2 released 
from the spheres was analyzed by BRE-Luc C2C12 cells by incubating supernatant with the 
cells and measuring the bioluminescence signal. Cumulative bioactivity in percentage at Day 
19 was calculated by the ratio of the BMP-2 detected by C2C12 cells (ng) to BMP-2 detected 
by ELISA (ng). For each assay, the amount of BMP-2 (ng) was calculated based on serial 
dilutions of fresh BMP-2 solution. Experiment was run in triplicate, data are shown in mean 
and SD. 
Binding of various BMP-2 variants to RCP using Surface plasma resonance (SPR) 
Since the release experiments revealed an unexpectedly strong, long-term adsorption of 
BMP-2 to the RCP microspheres, we anticipated a specific interaction between BMP-2 and 
RCP. This interaction was further studied using SPR. It is known that the N-terminal segment 
of the mature part of BMP-2 contains an arrangement of two triplets of basic amino acid 
residues, which facilitate binding to negatively charged components of the extracellular 
matrix (ECM) such as heparin or heparan sulphates [104]. Therefore, we investigated 
whether the same motifs are involved in the strong interaction of BMP-2 with the RCP by 
comparing the binding capacity of wildtype BMP-2 (wtBMP-2) to RCP with two variants, 
which either lack (EHBMP-2) or contain a duplication of the heparin binding motif (T4BMP-
2). Thus, these variants could either show an attenuated or an enhanced binding to RCP, 
respectively. To assess the specificity of this motif in the interaction between BMP-2 and 
RCP, we compared binding of these variants to RCP to the interaction of BMP-2 with the 
type I receptor BMPR-IA, which was shown not to be significantly affected by the presence 
or absence heparin binding motifs [219, 220].  
As shown in Figure 6a, measurements at physiological conditions revealed strong binding of 
the wtBMP-2 and T4BMP-2 to both RCP and the BMPR-IA receptor (curves not shown). The 
wt BMP-2 binding to RCP is even faster than that of T4BMP-2. The curves were, however, 
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often not linear and could not be interpreted by a simple Langmuir type 1:1 interaction 
model. Detailed inspection of the sensograms shows that the association of the BMP-2 
analyte was probably biased by so-called mass transfer limitation, which is possibly due to 
complementary charged segments in the BMP-2 analyte and immobilized ligand RCP. To 
reduce the charge interaction, measurements were also performed at higher salt 
concentration (500 mM, Figure 6b). Indeed at this higher salt concentration simple Langmuir 
type adsorption isotherms were obtained. At this high salt concentration, the binding 
affinity of wtBMP2 to RCP was in the same nanomolar range as its binding affinity to the 
BMPR-IA receptor which was in turn similar to that reported in literature [221]. Consistent 
with the literature [219, 220], all three BMP-2 variants bound to the extracellular domain of 
BMPR-IA with similar affinity (wtBMP-2: KD=0.3 nM; EHBMP-2: KD=0.2 nM; T4BMP-2: KD=0.3 
nM) indicating that the N-terminal segment is not involved in BMPR-IA binding (Table 2). 
This is in sharp contrast to the binding of the three BMP-2 variants to RCP, which was 
strongly affected by changes in the N-terminal segment. At 150 mM chloride, binding 
affinity of EHBMP-2 to RCP (KD=63 nM) was about a ten-fold lower than binding of wtBMP-2 
(KD=6.8 nM). While at low ionic strength all 3 variants were still binding (although with a 
clearly different binding strength), at high ionic strength the EHBMP-2, in which the 
positively charged N-terminus is exchanged for a polar but less charged sequence, did no 
longer bind to RCP. This implies that the N-terminal region of BMP-2 containing the two 
basic triplet motifs is essential for the interaction with RCP. Since wildtype BMP-2 and the 
T4BMP-2, which harbors a doubled basic triplet motif, exhibit identical binding affinities to 
RCP (wtBMP-2 KD=1.2nM vs T4BMP-2 KD=1.9nM) and have similar binding kinetics (Table 2) 
it can be ruled out that the interaction between BMP-2 and RCP is based on a (non-specific) 
electrostatic interaction but very likely involves specific RCP binding epitopes.  
 
Figure 6. SPR interaction analysis of the binding of BMP-2 and variants to RCP. Binding of 
BMP-2 variants (wildtype BMP-2, EHBMP-2 and T4BMP-2) to RCP immobilized on the sensor 
surface. Five analyte concentrations ranging from 25 to 1.6nM were used, for 
representation only the interaction at 25nM analyte concentration is shown. (a) Due to the 
highly charged nature of BMP-2 and RCP, at low ionic strength the SPR data is affected by 
mass transfer limitation, i.e. not enough analyte is transported to the immobilized ligand on 
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the biosensor. This leads to an almost linear association phase (time point 0s to 200s) and 
results in underestimated association rate constants. (b) To overcome the mass transfer 
limitation, SPR measurements were performed at and 500mM sodium chloride 
concentration.  
Table 2. Equilibrium binding constants and kinetic rate constants derived from the SPR 
measurements of the interaction of BMP-2 and variants with RCP 
analyte 
ionic strength 
(expr. in mM 
NaCl) 
association rate 
constant kon 
x 105 [M-1s-1] 
dissociation rate 
constant koff 
x 10-3 [s-1] 
equilibrium 
binding 
constant KD 
[nM] 
wt BMP-2 
150 
2.4 1.6 6.8 
EHBMP-2 3.9 25 63 
T4BMP-2 n.d. n.d. n.d. 
wt BMP-2 
500 
14 1.7 1.2 
EHBMP-2 n.b. n.b. n.b. 
T4BMP-2 13 2.4 1.9 
     
(ligand BMPR-IA)  
kon 
x 105 [M-1s-1] 
koff 
x 10-5 [s-1] 
KD 
[nM] 
wt BMP-2 
500 
3.3 8.8 0.3 
EHBMP-2 4.5 8.9 0.2 
T4BMP-2 3.2 8.8 0.3 
n.d.: not-determined; n.b.: no binding 
 
DISCUSSION 
In this study, we investigated novel microspheres of collagen I-based recombinant peptide 
(RCP) as an injectable BMP-2 delivery system. At first, we have shown that the initial stage 
of the release is not affected by the loading dose in a wide range of BMP-2 loading 
concentrations, between 6 and 600 ng BMP-2 per mg of microspheres, implying that in this 
wide range of concentrations the microspheres are not saturated with BMP-2. Important 
factors that affect the release kinetics of BMP-2 were shown to be sphere size and 
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crosslinking intensity. Both the total release and the initial burst release decrease with the 
degree of crosslinking and increase with sphere size. Very importantly, the BMP-2 protein 
released from the microspheres was found to be bioactive. SPR interaction analysis 
suggested that a specific interaction plays a role in binding of BMP-2 to RCP (KD: 1.2 nM). 
Overall, this study provided important information about the influence of the RCP sphere 
characteristics on BMP-2 release kinetics. 
In general, we observed a two-phase exponential release from the RCP microspheres. A fast 
release in the first few days was followed by a very slow release that continued to decrease. 
After two weeks, the majority of the BMP-2 was still inside the microspheres and could be 
released upon enzymatic degradation of the RCP-microspheres. This surprisingly strong 
binding is not observed for natural gelatin particles for which a burst release followed by a 
linear release was reported [145]. To understand more of the unexpected strong binding of 
BMP-2 to RCP, an SPR study was conducted. This SPR study revealed that the basic N-
terminal BMP-2 site is of major importance for the interaction with RCP. Although ionic 
interactions are the assumed to be the main interaction mechanism of the N-terminal basic 
segment found in various BMP proteins and components of the extracellular matrix, such as 
heparan sulfates [219], BMP-2-RCP binding is not just accomplished by simple electrostatic 
interaction only. This hypothesis is based on the observation that the BMP-2 variant T4 
binds to RCP with similar affinity as wildtype BMP-2, although the N-terminal charged 
interaction epitope is present twice in this T4-BMP variant. Hence the involved binding 
interface appears geometrically defined and thus repetition of the motif does not provide 
additional surface area. Speculating on the underlying mechanism of two phase exponential 
release and considering the SPR data, we think there are at least two main factors involved 
in the binding of BMP-2 to RCP. The release kinetics suggests that there is a strongly and 
weakly bound fraction of BMP-2. The weakly bound part is released in the first fast phase 
and strongly bound part is released in the second slow phase. Also SPR data suggest there 
are two different kinds of interactions at physiological conditions i.e. specific and non-
specific interactions. These two types of interactions can be combinations of multiple non-
covalent forces such as Van der Waals, hydrophobic, electrostatic interaction that are 
generally involved in protein-protein binding. These results suggest there is a correlation 
between the molecular phenomena observed by SPR and physical phenomena observed by 
the release kinetics. On the other hand, the release kinetics can be affected by many other 
factors such as multilayer binding. As a result of the observed complex interaction it is not 
possible to model the release by employing simple non-interacting drug release 
mathematical models (see also [222]). We have studied the release of BMP-2 variants from 
the RCP microspheres to compare the order of binding of the variants found in the SPR 
experiment to the order of release from spheres (Figure 7). In contrast to the SPR data we 
have seen that the release of both EHBMP-2 and T4BMP-2 is faster than wtBMP-2. A 
possible explanation for the difference is that the molecular conformation of RCP 
immobilized on the SPR chip surface is different than that of the microsphere surface. 
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Crosslinking the microspheres might have prevented binding of T4 variant by steric 
hindrance. Taken together, the results show that BMP-2 binding to RCP is also affected by 
the structure or treatment method of RCP. 
 
Figure 7. The release of BMP-2 variants from RCP microspheres (MS#1). Concentration was 
normalized to the positive control to calculate percent release. Experiment was run in 
triplicate, data are shown in mean and SD. 
The strong binding of BMP-2 to RCP did not impair its bioactivity upon release. Using a BMP-
2 responsive cell-based bioactivity assay the released BMP-2 was found to be bioactive 
almost to the same level as measured by ELISA. These data suggest that adsorption of BMP-
2 to the scaffold does not abolish its bioactivity due to unfolding or facilitated degradation. 
Unfortunately, it was not possible to confirm the bioactivity of the strongly bound fraction 
since the enzymatic treatment required to destroy the RCP microspheres was not 
compatible with the cell-assay. 
Important factors that affect the release kinetics of BMP-2 from the RCP microspheres were 
shown to be sphere size and crosslinking intensity. Both the total release and the initial 
burst release decrease with the degree of crosslinking and increase with sphere size. In 
agreement with data published for gelatine microspheres [201], we observed the influence 
of the crosslinking degree on BMP-2 release. For example, a higher crosslinking degree as 
induced by HMDIC resulted in less burst and a slower release. The ratio between 
hydrophobicity and charge can change as a result of crosslinking of charged groups and thus 
it may influence the binding of BMP-2. As shown above, there is also an effect of sphere size 
on release. Small spheres with a mean diameter of 50 μm and 72 μm had a similar release 
pattern, whereas much larger microspheres with a mean size of 207 μm released 
significantly more BMP-2 compared to the smaller spheres mainly due to an enhanced initial 
burst release. For pure diffusion controlled release, a faster release from smaller spheres is 
expected as a result of the shorter diffusion distances and larger total surface area [223]. 
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However, as mentioned above, the current release system is not diffusion controlled due to 
the complex interaction between BMP-2 and RCP. The reason why, in our case, large 
spheres release more BMP-2 is rather speculative. For instance, different crosslinking 
density of the spheres can play a role. Although the spheres were crosslinked with the same 
amount of crosslinker, the crosslinking might be denser at the surface of large spheres than 
that of inside. This difference would also change the swelling characteristics and swelling 
time of the spheres. These factors might have influenced the ratio of strong/weak binding of 
BMP-2 to the microspheres, and thus the release profile. Similar to this study, it has been 
shown that increasing the chitosan sphere size increased the release of bovine serum 
albumin (BSA) [224].  
In literature, optimal release profile for BMP-2 is generally described as a small initial burst 
release followed by sustained release over a couple of weeks, especially for ectopic bone 
formation [225]. Although the initial burst release of BMP-2 can be considered as a 
drawback, it may be necessary to trigger the initial healing process promoting migration of 
stem cells towards the site of implantation [226]. Absence of a burst release might impair 
the bone formation ability of BMP-2 loaded material [227]. A small burst release in the 
nanogram range followed by a sustained release has been shown to be more effective in 
bone formation for implants loaded with 2 µg BMP-2 [227]. On the other hand, burst 
release delivering high doses in the high microgram to milligram range could cause 
undesired side effects such as the formation of ectopic bone in the surrounding soft tissue, 
as it is the case for absorbable collagen sponge [62]. Thus, when considering burst release, it 
is important to distinguish between nanogram and microgram/miligram amounts of release. 
Here, we present that HMDIC crosslinked small spheres release 15-20% of BMP-2 loaded in 
the first day; DHT-spheres release 10% of BMP-2 showing that burst release can be 
modulated by crosslinking degree and 10% burst release is minimal compared to the BMP-2 
release from collagen sponge which is more than 50% in the first day [228, 229]. Therefore, 
small sized spheres are expected to function better in vivo due to a small initial burst release 
and more sustained release profile. The design of the different RCP microspheres presented 
in this manuscript provides important information about the influence of the sphere 
characteristic on BMP-2 release and allows the generation of tuneable BMP-2 delivery 
systems for a broad variety of therapeutic applications for bone regeneration. We have also 
laid the groundwork for future in vivo studies by narrowing down potential system design 
parameters. In these in vivo studies also the degradation of the RCP microspheres can be 
further examined. 
CONCLUSION 
We have developed a novel BMP-2 delivery system based on tuneable RCP microspheres. 
This in vitro study provided important information about the influence of the RCP 
microsphere characteristics on BMP-2 release kinetics and demonstrated the potential of 
RCP microspheres as BMP-2 delivery material. BMP-2 was found to bind to RCP with high 
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affinity (KD: 1.2 nM) suggesting a specific interaction between two proteins. Among 
different spheres studied, small sized RCP spheres crosslinked by HMDIC or DHT are most 
promising delivery materials for BMP-2 showing a small burst release (10%-20%) in the first 
day succeeded by a sustained release.  
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SUPPLEMENTARY INFORMATION 
 
Supplementary Figure 1. Bioactivity of released BMP-2 over 19 days. BRE-Luc C2C12 cells 
incubated with BMP-2 released from porous microspheres (MS#6, MS#7 and MS#8), and 
cumulative released bioactive BMP-2 was calculated based on BMP-2 standard calibration 
curve. Corresponding table shows the bioactivity in percentage at each time point 
calculated by the ratio of the BMP-2 detected by C2C12 cells (ng) to BMP-2 detected by 
ELISA (ng). For each assay, the amount of BMP-2 (ng) was calculated based on serial 
dilutions of fresh BMP-2 solution. 
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Supplementary Figure 2. BMP-2 release from spheres comprised of RGD and DGR 
containing RCP.  RGD microspheres correspond to HMDIC-high crosslinked microspheres 
(50-75 µm, MS#1). Arginine-glycine-aspartic acid (RGD) sequence in RCP was replaced with 
aspartic acid-glycine-arginine (DGR) and DGR spheres were produced using the same 
method of RGD particles.  BMP-2 is released from these spheres for two weeks after which 
remaining BMP-2 was liberated by upon collagenase degradation of microspheres. The 
percentage of released BMP-2 was calculated relative to the positive control, which is BMP-
2 solution at the same concentration (900 ng/mL) without microspheres. Experiment was 
performed in triplicate, data are shown as mean and SD. 
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ABSTRACT 
There is a need for development of an effective delivery system for BMP-2. In this report, 
we aimed to control the release of BMP-2 by using RCP microspheres for which a strong 
binding of BMP-2 was observed previously. Microspheres loaded with 83 µg/mL, 8.3 µg/mL 
and 0.83 µg/mL BMP-2 were injected subcutaneously in rats to compare the ectopic bone 
formation capacity of these concentrations. Bone formation was imaged by micro-CT for 12 
weeks and finally confirmed by histology. Only microspheres comprising 83 µg/mL BMP-2 
induced ectopic bone formation, as confirmed by micro-CT and histological examination, 
and we have observed microspheres in these samples at the end of the experiment. On the 
other hand, 8.3 µg/mL, 0.83 µg/mL and the negative control did not form any bone and 
could not be retrieved at the end of the experiment, as a result of degradation of 
microspheres. Time course analysis of bone formation revealed that bone volume increased 
between 2 – 6 weeks after injection. Bone density continued to increase from week 2 until 
the end of the experiment. Overall, this study showed that a BMP-2 concentration of 83 
µg/mL is necessary to induce ectopic bone formation with the RCP microsphere paste, and 
even with this concentration bone formation was minimal showing that the RCP 
microsphere delivery system can be further developed for a better control of BMP-2 release 
over time and to induce higher ectopic bone volume.  
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INTRODUCTION 
There is a need for the development of an effective biomaterial for bone regeneration 
therapies [230]. This biomaterial should be osteoinductive and osteoconductive [231]. Often 
use of growth factors such as bone morphogenetic protein rendered osteoinductivity of the 
biomaterial. Among other growth factors, bone morphogenetic protein-2 (BMP-2) has been 
widely used in this field and FDA approved for spinal fusion, tibial non-unions and oral 
maxillofacial reconstructions [57, 58, 232].  However, use of BMP-2 has been associated 
with many adverse events as reported previously [66, 142, 195]. These adverse events are 
related to the burst release of BMP-2 from the collagen sponge and to the high loading dose 
[66, 233]. This high dose (1.5 mg/mL), often described as supraphysiological dose, was 
necessary to achieve effective bone formation when delivered on a collagen sponge. To 
overcome this limitation, an effective delivery system that will change the release profile of 
BMP-2 should be designed [64]. Other biomaterials tested in ectopic models used varying 
doses [234]. Some of the successful low-dose examples are with β-tricalcium phosphate (9 
mm3) containing 5 µg BMP-2 induced 32.5% bone formation [235]. A type of collagen 
sponge (6 mm diameter) with 5 µg BMP-2 induced max. 5 mm3 bone [236], and silk-fibroin 
particles (10 mg) with 5 µg BMP-2 induced 2 mm3 bone [237]. In another study, a low dose 
BMP-2 (<1 µg per specimen) delivered on a collagen sponge or with brushite calcium-
phosphate particles did not form bone at all [238]. A fibrous glass membrane with 8.7 µg 
BMP-2 was effective in controlling BMP-2 release but resulted in slow bone regeneration 
[239]. Collagen and hydroxyapatite scaffold with 10 µg BMP-2 formed ectopic bone in rats 
[240]. Hydroxyapatite/collagen/alginate composite with 4 µg, 20 µg and 100 µg BMP-2 was 
tested and only the highest dose yielded bone, calcifying half of the volume of the implant 
[241].  
We have previously shown in vitro that RCP microspheres are potential slow-release 
systems for BMP-2 (Chapter 3a). In the current study, we have investigated the potential 
use of these BMP-2 loaded RCP microspheres in ectopic bone formation in vivo. For that 
purpose, we have injected BMP-2 containing microspheres in form of a paste, 
subcutaneously into rats and followed bone formation by microCT. We used a BMP-2 
concentration of 83 µg/mL (8.3 µg per implant) that we expect to induce bone formation 
based on literature and we selected two lower doses (8.3 µg/mL and 0.83 µg/mL) with a 
goal to reduce the dose of BMP-2. 
MATERIALS AND METHODS 
Preparation of microspheres 
Microspheres were prepared by emulsification as described elsewhere (Chapter 3a). Small-
sized (50-75 µm) dehydrothermal treatment (DHT) crosslinked spheres were chosen in this 
study because this type of spheres resulted in only 10 % initial burst release of BMP-2. 
Dehydrothermal treatment (DHT) to crosslink the particles was performed for 4 days at 160 
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°C in vacuum (~5x10-3 mbar). After crosslinking, the CaCO3 porogen was removed by 
suspending the microspheres in 0.23 N HCl for 30 min until the formation of carbon dioxide 
stopped. The microspheres were washed repeatedly with water until a neutral pH was 
achieved. Size, morphology and crosslinking density of the spheres were characterized as 
previously described. 
Adsorbed BMP-2 
Wild-type rhBMP-2 was produced as described elsewhere [209]. BMP-2 was adsorbed to the 
microspheres by incubation of 5 µL of 0.2 µg/µL BMP-2 solution per mg of spheres overnight 
at 4 °C.  
Preparation of the paste 
To obtain the high dose (83 µg/mL final concentration of BMP-2), 100 mg BMP-2 loaded 
microspheres were mixed with 230 mg of empty microspheres. 10 mg loaded microspheres 
were mixed with 320 mg empty microspheres to obtain the middle dose (8.3 µg/mL final 
concentration of BMP-2) and 1 mg loaded microspheres were mixed with 329 mg empty 
microspheres to obtain the low dose (0.83 µg/mL). Empty microspheres of 330 mg were 
used as a control. The microsphere mixtures were subsequently mixed with 1.2 mL saline 
(0.9 % NaCl) for at least 10 min with a spoon. Then, freshly prepared paste was loaded to 1 
mL syringes and 100 µL of paste was injected subcutaneously in the animals using a 19 G 
needle.  
Study design and ethics 
All animal experiments were performed with prior approval of the ethics committee for 
laboratory animal use (protocol number EMC 15-114-05). 9 weeks old Male Sprague Dawley 
(SD) rats (Charles River) were used in this study to evaluate ectopic bone formation. The 
animals were randomly assigned and housed in pairs in specific pathogen free (SPF) 
environment and allowed to adapt to the conditions 7 days before implantation. The 
animals were maintained at 22 ± 5°C on a 12 h dark/light cycle with ad libitum access to 
standard rat chow and water. At 12 weeks after implantation, animals were euthanized with 
CO2 and the specimens were harvested for micro-CT analysis and histology.  
Subcutaneous injection of paste to study ectopic bone formation 
To evaluate the effect of different doses of BMP-2 on ectopic bone formation, BMP-2 was 
delivered with microspheres in the form of a paste and subcutaneously injected (total 
volume 100 µl per injection) in the dorsum of the animals. Each animal received 4 or 5 
randomly assigned injections. All injections were performed on animals under isoflurane 
inhalation. To study BMP-2-dose effect on bone formation, three different BMP-2 
concentration were used (83 µg/mL, 8.3 µg/mL, 0.83 µg/mL BMP-2) (n=7 per group).  As a 
control, microspheres without BMP-2 were injected (n=7).   
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Micro-CT imaging 
Micro CT (Quantum FX, Perkin Elmer, Waltham, MA, USA) was used to image animals 
biweekly until the end of the experiment and also to image the implants retrieved at 12 
weeks. To image the ectopic bone in vivo the following parameters were used: Field of view: 
73 mm, Voltage: 90 kV, Current: 160 µA, Scan Time: 120 sec. To image the implants a field of 
view of 20 mm was used. Trabecular and cortical bone mineral density (BMD) was measured 
on the basis of calibration scanning, using two phantoms with known density (0.25 g/cm3 
and 0.75 g/cm3 ; Bruker MicroCT) under identical conditions. For image processing, Analyze 
software was used (Mayoclinic, Rochester, MN, USA), threshold levels were set to 0.1 g/cm3. 
Histology 
For histological examination, specimens were fixed in 4% formalin solution and decalcified 
with 10 % EDTA for 2-4 weeks. Implants were dehydrated and embedded in paraffin. 
Sections of 6 µm thickness were prepared using a microtome (Leica Biosystems, Nussloch, 
Germany) and mounted on subbed glass slides (Thermofisher Scientific, Waltham, MA, 
USA). One of each five consecutive sections was de-paraffinized and rinsed with distilled 
water to be stained with hematoxylin and eosin (H&E) as described elsewhere [242]. The 
sections were imaged by Keyence BZ-9000 BIOREVO (KEYENCE Deutschland GmbH, Neu-
Isenburg, Germany).  
RESULTS  
To compare the bone forming ability, 100 µL paste of microspheres containing 83 µg/mL, 
8.3 µg/mL, or 0.83 µg/mL of adsorbed BMP-2 was injected subcutaneously to rats and 
samples were retrieved at 12 weeks. However, only 83 µg/mL BMP-2 induced bone 
formation whereas 8.3 µg/mL or 0.83 µg/mL failed to form bone, as shown by the 
representative micro-CT image in Figure 1. In these two low dose groups and in the negative 
control group, the paste was disappeared and implants could not be retrieved. In the 83 
µg/mL BMP-2 group, 4 out of 7 injections resulted in bone with a minimum bone volume of 
2.2 mm3 and maximum of 7.3 mm3 (Figure 1a). Strikingly, the bone volume was much lower 
than the injected paste volume of 100 µL (100 mm3). The density of the ectopic bone for the 
four bone-positive implants (formed by 83 µg/mL BMP-2) was between 0.54 and 0.61 g/cm3 
(Figure 1b.).  
Histology confirmed the presence of ectopic bone in 4 out of 7 samples in the 83 µg/mL 
BMP-2 group. In the other groups, for which the implants could not be retrieved histological 
examination was not performed. Figure 1d shows the histology of a 83 µg/mL BMP-2 sample 
and confirms the ectopic bone formation.  
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Figure 1. a. Bone volume (mm3) at 12 weeks. b. Bone density (g/cm3) at 12 weeks. A 
threshold of 0.1 g/cm3 was used for density calculation. Data is shown as dots representing 
each implant and mean ± SD, n=7 for each group. c. Representative CT-image of bone 
formation induced by 83 µg/mL BMP-2 at 12 weeks. d. Histology of an implant retrieved at 
week 12, showing the microspheres (MS), bone (B), bone marrow-like structure (BM). 
The time-dependent bone formation was studied by microCT. Representative microCT 
images are shown in Figure 2a. The bone volume over time for the implanted materials 
giving bone (4 out of 7 for the 83 µg/mL BMP-2 group) is shown in Figure 2b. The bone 
volume increased between 2 and 6 weeks (Figure 2b). Between week 6 and week 8 there is 
a slight decrease in volume and after 8 weeks bone volume remained constant until the end 
of the experiment. It is important to note that, probably as a result of imaging in vivo with 
BMP-2 loaded RCP microspheres induced ectopic bone formation 
65 
 
less resolution, there is a slight difference between ex vivo and in vivo bone volumes. Bone 
densities (Figure 2c) increased from 2 weeks until the end of the experiment at 12 weeks.  
 
Figure 2. a. Representative images of ectopic bone formation in vivo induced by an RCP 
paste comprising 83 µg/mL BMP-2 followed over a time course of 12 weeks. b. Bone 
volume of 83 µg/mL BMP-2 over time course of 12 weeks. c. Bone density of 83 µg/mL BMP-
2 over time course of 12 weeks. Threshold of 0.1 g/cm3 was used for density calculation. 
Data is shown as lines representing each implant, n=4 implants showed bone. 
DISCUSSION 
We have studied the potential use of a paste of BMP-2 loaded RCP microspheres in bone 
formation using an ectopic in vivo model. Our results showed that 4 out of 7 injections of 
the highest dose used of 83 µg/mL BMP-2 induced bone formation, while the lower doses, 
8.3 µg/mL or 0.83 µg/mL BMP-2, did not result in any ectopic bone. The highly variable 
outcome for the high dose stresses the need for a better design of the delivery system.  
The high dose of 83 µg/mL BMP-2 (8.3 µg per implant) used in our study was expected to 
induce ectopic bone formation based on previous findings. β-tricalcium phosphate [235], a 
type of collagen sponge [236] and silk-fibroin particles [237] all loaded with 5 µg BMP-2 
yielded ectopic bone with a bone volume in the range of 2 mm3 - 5 mm3. Indeed, the paste 
loaded with 83 µg/mL BMP-2 did give ectopic bone but the results were highly variable: 3 
out of 7 injections failed to induce bone formation. In addition, large variations in bone 
volume indicate that bone formation is not uniform. This might be explained by the rapid 
degradation of the DHT crosslinked microspheres, resulting in premature release of BMP-2. 
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Although the degradation rate of RCP microspheres in vivo was not investigated in this 
study, the same type of RCP microsphere injected subcutaneously was shown to be mostly 
degraded at week 4 [243]. Interestingly, microspheres were still detected at the 12 weeks 
histological end point examination of the bone-positive 83 µg/mL BMP-2 samples, whereas 
at lower BMP-2 concentration samples could not even be retrieved, most probably due to 
degradation of microspheres. This could indicate that bone formation partially prevented 
microsphere degradation. This phenomenon can be explained by the bone forming cells 
depositing matrix. This matrix deposition and calcification, might have prevented infiltration 
of other cells such as macrophages to degrade the microspheres.  
Our results indicate that the BMP-loaded RCP microsphere slow release system might be 
further improved by several strategies focussed to decrease the degradation rate of the RCP 
microspheres. For example, the effect of crosslinking can be studied. It has been shown 
earlier that hexamethylene diisocyanate (HMDIC) crosslinked RCP particles are slightly more 
persistent against degradation than dehydrothermal (DHT) crosslinked particles in vivo 
[243].  Secondly, a composite material can be used to protect the microspheres and increase 
their degradation time. A hydrogel, for example, with a higher degradation time can 
increase the effectiveness of this system by increasing the degradation time and by 
protecting the RCP material from cell infiltration. In addition, the release of BMP-2 should 
also be studied in vivo to be able to assess its retention time and its relation to crosslinking 
and degradation rate of the carrier material.  
In conclusion, BMP-2 loaded RCP microspheres were able to partially form bone at a 
concentration of 83 µg/mL. As a future prospect, the BMP-2 concentration can be further 
increased to achieve reproducible bone formation. Another alternative is to change the 
design of system for a better temporal control of the BMP-2 delivery resulting in successful 
bone formation with a lower dose of BMP-2. 
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ABSTRACT 
There is still the need for optimized in-situ gelling BMP-2 releasing formulations to fill and 
repair bone defects. Collagen-I based Recombinant Peptide (RCP) microspheres (MS) were 
used as a carrier for BMP-2. The MS were dispersed in hydrogels obtained from high 
mannuronate (SLM) alginate, high guluronate (SLG) alginate and thermoresponsive 
hyaluronan derivative (HApN). SLM+MS, SLG+MS and HApN+MS formulations showed 
sustained release of BMP-2. These formulations were injected subcutaneously in immune 
competent rats. SLM+MS, SLG+MS loaded with BMP-2 induced ectopic bone formation in 
the rats as revealed by X-ray tomography and histology at 4 and 10 weeks, whereas 
HApN+MS did not. Vascularization occurred within all the formulations studied and was 
significantly higher in SLG+MS and HApN+MS than in SLM+MS. CD68, iNOS and CD206 
markers were used to assess the presence of inflammatory cells at 1, 4 and 10 weeks after 
implantation. Inflammation decreased over time in alginate groups, but increased in the 
HApN+MS groups suggesting that a chronic inflammatory milieu to be detrimental to bone 
induction. This study highlights the interplay of the BMP-2 and the delivery matrix material 
on the local induction of bone. 
KEYWORDS: Injectable, alginate, hyaluronan, microspheres, BMP-2 (bone morphogenetic 
protein-2), bone regeneration 
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INTRODUCTION 
Bone is a tissue with high self-regeneration capacity. However, in cases of trauma or certain 
diseases bone does not heal properly and therefore surgical intervention using autografts or 
allografts is necessary. Currently, autografts are the gold standard; however, they are 
associated with donor site morbidity, increased pain, high cost and long patient recovery 
time. The alternative is to use allografts, but they carry the risk of immunogenicity, 
infectious agents and lack the osteoinductive capacity of autografts [231]. To overcome 
these limitations there has been a vast effort to develop new biomaterials to aid large bone 
defect repair. Among these materials, natural biomaterials have been widely studied due to 
their advantages such as biodegradability, biocompatibility and the ability to interact with 
the extracellular matrix and cells [244]. Injectable formulations are preferred over implants 
for the treatment of defects that do not require operational fixation since the application is 
easier and the patient will not suffer from surgery and consequently, achieve a faster 
recovery. Moreover, in the case of irregular bone defects, injectable scaffolds might be 
advantageous because they can adapt to the defect shape better [245]. Alginate, hyaluronic 
acid (HA) and collagen derived materials have been investigated as scaffolds, particles and in 
situ gelling hydrogels [246].  
Materials can be combined with bone forming proteins such as bone morphogenetic protein 
2 (BMP-2) to stimulate bone formation. BMP-2 is considered to be one of the most powerful 
osteoinductive factors and is the only bone morphogenetic protein (loaded in a collagen 
sponge) approved and currently used as a bone graft substitute [194, 247]. However, large 
doses of BMP-2 are needed to produce a significant osteogenic effect [248]. The major 
reason for this is the burst-release of the protein from the collagen sponge. Half of the BMP-
2 was released in the first two days in vivo in a rabbit ulna osteotomy model [65]. This often 
results in undesired ectopic bone formation, soft tissue swelling and bone resorption [249]. 
Therefore, a biomaterial that can provide a slower protein release may perform better in 
clinics, eliminating adverse effects. There are several challenges for developing a suitable 
protein carrier material [234]. It should promote the recruitment of skeletal and endothelial 
progenitor cells and trigger their differentiation to mature osteoblasts and endothelial cells 
with a minimum amount of loaded protein.  
In this study, we aim to develop in situ gelling alginate and HA formulations to retain BMP-2 
releasing microspheres, resulting in slow localized growth factor release. We have 
previously reported the use of recombinant collagen-like peptide microspheres for slow 
release of BMP-2 [250] (Chapter 3). The recombinant collagen-like peptide does not only 
facilitate the cell attachment by its arginylglycylaspartic acid (RGD) rich peptide sequence 
[204] but also can be expected to decrease the risk of immune reaction due to its animal 
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free origin. This cell attachment stimulation is very important when in combination with 
materials such as alginates and HA cell attachment is suboptimal. 
Alginate is a polysaccharide composed of β-D-mannuronic acid (M-block) and α-L-guluronic 
acid (G-block) monomers. Several studies have demonstrated the potential of this hydrogel 
for bone tissue engineering [251]. Alginate in situ gelling formulations have been developed 
in combination with particles and in vitro experiments showed the potential of the 
formulations for drug delivery [252]. Previously, alginate hydrogel with gelatin microspheres 
loaded with BMP-2 was used to study osteogenesis in vivo. However, the formulations could 
not induce bone formation probably due to fast degradation of material; and only after 
addition of biphasic calcium phosphate granules, was the bone formation achieved [213]. 
There are various types of alginate where the ratio of monomer units and molecular weight 
of the polymer chains change. These parameters affect the degradation behavior of the 
hydrogels [253]; therefore, in this study we chose to use two different types of alginates, 
sterile lyophilized high mannuronate (SLM) alginate and sterile lyophilized high guluronate 
(SLG) alginate. In situ gelling formulations of alginates were developed via calcium 
complexation. Hyaluronic acid (HA) is another linear polysaccharide consisting of repeating 
units of D-glucuronic acid and N-acetyl-D-glucosamine and is an abundant 
glycosaminoglycan in extracellular matrices. Therefore, injectable HA hydrogels have been 
used for bone regeneration with BMP-2 [254]. However, to induce subcutaneous bone 
formation with HA, a very high dose of BMP-2 (150 µg/mL) was used [255]. HA gels are 
often functionalized to engineer better delivery systems. Investigators have recently shown 
that HA gels functionalized with fibronectin formed more ectopic bone than its non-
functionalized counterpart [256]. However, functionalizing HA did not always induce more 
bone formation. For example, heparin functionalization of HA led to less ectopic bone 
formation than its non-functionalized counterpart formation when implanted 
intramuscularly [225]. In another study, HA failed to induce bone formation either in the 
presence or absence of BMP-2 [257]. These studies showed that HA and alginates have 
potential for use in bone regeneration. However, choosing the right formulations of 
engineered materials with a right dose of BMP-2 is challenging. Additionally, a huge demand 
in bone regeneration field is the development of in situ gelling materials that enable slow 
protein release, support cell attachment, vascularization and thus induction of bone 
formation. In this study, we have used Poly(N-isopropylacrylamide) functionalized 
hyaluronic acid (HApN) that shows thermoresponsive behavior.  
We aimed to develop in situ gelling formulations with natural polymers for the RCP 
microspheres that can provide slow BMP-2 release and increase cell attachment. We also 
wanted to assess how the hydrogel matrices influence the in vitro release of BMP-2 from 
the microspheres and the bone induction in vivo. For that purpose, we have developed 
three different hydrogel-microsphere systems: two different thixotropic alginate 
formulations and a thermoresponsive (gelling above 32˚C) HApN. The function of these gels 
is to be injectable, in situ gelling, supportive of cell attachment, provide a sustained release 
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of BMP-2 and ultimately induce de novo bone formation. The mechanical properties of 
these gels and BMP-2 release characteristics in vitro were evaluated. The bone formation 
ability of these materials was studied in an ectopic bone formation model in vivo. The 
volume and morphology of the ectopic bone, vascularization, cellular infiltration and 
inflammation were evaluated.  
MATERIALS AND METHODS 
Materials  
Human collagen type I based recombinant peptide (RCP) is a product of Fujifilm 
commercially available as Cellnest™. It is produced in a fermentation process by genetically 
modified yeast Pichia pastoris as described elsewhere [203, 204]. RCP is composed of 571 
amino acids; it has an isoelectric point (pI) of 10.02 and a molecular weight of 51.2 kDa. 
BMP-2 was produced as described previously [209] and it was kindly provided by Dr. 
Joachim Nickel (Fraunhofer IGB, Germany). Pronova SLM20 (sterile alginate where over 50% 
of the monomer units are mannuronate) and Pronova SLG20 (sterile alginate where over 
60% of the monomer units are guluronate) were ordered from Novamatrix (Sandvika, 
Norway). Thermoresponsive HApN consisting of HA grafted with poly (N-
isopropylacrylamide) (PNIPAM) was prepared as described in D’Este et al [258]. 
Hexamethylene diisocyanide (HMDIC), corn oil, sodium chloride, calcium carbonate (CaCO3) 
and glucono delta-lactone (GDL) were purchased from Sigma-Aldrich (St. Louis, MO, USA). 
Ethanol, acetone and hydrochloric acid were purchased from Millipore (Billerica, MA, USA). 
ELISA development kit and reagents for BMP-2 determination were ordered from Peprotech 
(Rocky Hill, NJ, USA). Dulbecco’s Modified Eagle’s Medium (DMEM), fetal bovine serum 
(FBS), phosphate-buffered saline (PBS) and penicillin-streptomycin (P/S) were ordered from 
Thermofisher Scientific (Waltham, MA, USA). 
RCP microsphere preparation 
RCP microspheres were produced by emulsification using calcium carbonate (CaCO3). 
Briefly, a 20% aqueous RCP solution was prepared and mixed with CaCO3 fine powder (with 
a size of <1 µm) in a 1:1 (w/w) ratio of RCP to CaCO3. This suspension was emulsified in corn 
oil at 50 °C. After cooling, the emulsified microspheres were precipitated and washed three 
times with acetone, and subsequently dried overnight at 60 °C. The microspheres were 
sieved to 50-72 µm size (Retsch GmbH, Germany). Particles were then crosslinked by HMDIC 
by mixing 1 g of spheres and 1mL of HMDIC in 100 mL ethanol for 1 day while stirring. 
Excess crosslinker was removed by washing several times with ethanol after which the 
particles were dried at 60 °C. The particles used for the alginate and HApN formulations 
were prepared in identical way except that, for the HApN formulation, CaCO3 was removed 
after the crosslinking step. For the alginate formulations the CaCO3 was left in as the Ca2+ 
also serves to crosslink the alginate into a hydrogel. For the HApN formulation CaCO3 was 
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removed by suspension of MS in 0.23 M hydrochloric acid for 30 min, followed by repeated 
washing with water until a neutral pH was achieved, and the MS were dried at 60 °C. 
Complete removal of the calcium was confirmed by EDX mapping (Supplementary Figure 
S2). The morphology of CaCO3 containing and CaCO3 free microspheres was analyzed by 
scanning electron microscope (SEM) (Supplementary Figure S1). CaCO3 crystals clearly can 
be observed on the surface of the CaCO3 comprising microspheres (Supplementary Figure 
S1). Particles were gamma sterilized at 25 kGray (Synergy Health, The Netherlands) prior to 
use in vitro and in vivo. 
Preparation of the hydrogel formulations 
Preliminary tests with different ratio of alginate/microspheres revealed a narrow range of 
ratio to obtain thixotropic behavior of the hydrogel. To prepare the formulations with 
SLM20 and SLG20 alginates, alginates were dissolved in 0.9 % sterile sodium chloride to 
create 2% w/v solution. 68 mg of calcium comprising microspheres were incubated 
overnight at 4 °C with 170 µL of 122.5 µg/mL BMP-2. The following day, the swollen 
particles were mixed with 1014 µL of SLM or SLG solution. To the SLG formulation, 106 µL of 
0.06 M freshly-prepared GDL solution was added and mixed immediately. GDL was used to 
dissolve minute amounts of CaCO3 so that alginate can be crosslinked and increase the 
mechanical properties of the formulation. In parallel, 106 µL of 0.9 % sodium chloride was 
added to the SLM formulation for which it was not necessary to add GDL as shown by 
rheology. The formulations were thoroughly mixed passing through a 19 G needle 
immediately and incubated overnight at 4 °C to equilibrate. One day later, prepared 
formulations were mixed again prior to injection in vivo or to use for in vitro experiments. 
For both in vivo and in vitro experiments 200 µL of the prepared formulations were used. 
The final amount of BMP-2 was 3.3 µg in each 200 µL hydrogel+MS formulation (Table 1). 
Solubilized Ca2+ ion as shown in µM and % in Table 1 was detected by calcium colorimetric 
assay following the manufacturer’s instructions (Sigma-Aldrich). 
The ratio of HApN/MS was selected based on their mechanical properties and injectability, 
and the following formulations were used for in vitro and in vivo experiments. First, a 15 % 
w/w solution of HApN was prepared in PBS. On the same day, 170 µL BMP-2 at 122.5 µg/mL 
concentration was added to 34 mg of MS (without CaCO3) and particles were incubated at 4 
°C overnight. Next day, 850 µL HApN (15% w/w) and 270 µL PBS were added to the swollen 
particles and the formulation was mixed with a 1 mL syringe and 19 G needle. The 
composition of the final formulations is shown in Table 1. In order to keep the amount of 
RCP the same in all different formulations, half of the microspheres were used in HApN 
condition compared to SLM+MS or SLG+MS formulations that contained 50 % CaCO3 and 
50% RCP in the microspheres. The prepared formulations were mixed and incubated 
overnight at 4 °C to equilibrate. All formulations were prepared under sterile conditions. 
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Table 1. Composition of the formulations used for the in vitro BMP-2 release study and for 
the in vivo experiment. 
Formulation SLM 
or 
SLG 
(%)  
HA 
(%)  
MS with 
CaCO3 
(mg/mL)  
MS 
without 
CaCO3 
(mg/mL)  
CaCO3 
(mg/mL)  
RCP 
(mg/
mL)  
GDL 
(mM)  
Ca2+ 
soluble 
(µM)  
Ca2+ 
soluble 
(%)  
BMP-2 
(µg/mL)  
SLM with MS  1.5  -  54   -  27  27 -   -   -  16.1  
SLG with MS  1.5  -  54   -  27  27  5  3.18  0.93  16.1  
HA with MS  -  10  -  27  -  27  -   -   -  16.1  
 
Rheology  
The mechanical properties of prepared hydrogels containing BMP-2 loaded microspheres 
were measured by a rheometer (Anton Paar MCR301, Austria). A 20 mm diameter parallel 
plate measuring system was used. After sample addition to the plate, silicon oil was applied 
to the edges to prevent evaporation. All measurements were performed with a normal 
force of 0.1 N. As a pre-characterization, the storage (or elastic) modulus (G’) and loss (or 
viscous) modulus (G’’) were measured at different strains to determine the linear 
viscoelastic region. To determine the linear viscoelastic region in alginate formulations 
(shown in supplementary table S1) four different formulations were prepared. SLG alginate 
(1.5 %, w/v); SLG alginate (1.5 %, w/v) with microspheres (8 %, w/v); SLG alginate (1.5 %, 
w/v) with microspheres (8 %, w/v) and GDL (5mM); and SLG alginate with CaCO3 (4%, w/v) 
and GDL (5mM) were prepared. After pre-characterization, thermosensitive HApN+MS 
formulation was measured at 2% strain, at 1 Hz while heating from 15 °C to 40 °C followed 
by cooling from 40 °C to 15 °C. 
Alginate formulations were measured by a two-step repeating cycle. At the first step of the 
cycle, storage and loss moduli were measured at 1 % strain, at 1 Hz, at 37 °C. At the second 
step, 500 % strain, 1 Hz frequency, 37 °C temperature was applied. The cycle repeated four 
times to characterize thixotropic behavior.  
Release of BMP-2 from hydrogel formulations 
The formulations containing hydrogels and BMP-2 loaded microspheres were prepared as 
described above. 200 µL of hydrogel formulations was added to 24 well plate inserts with 
0.4 µm pore size. 1 mL DMEM with 10% FBS and 1 % P/S per well was added to the reservoir 
plate. The plates were incubated at 37 °C under constant agitation at 300 rpm. When 
removed from the incubator, the plates were put on a hot plate at 37 °C to prevent the gel-
sol transition of HApN hydrogels. At each time point 1 mL medium was collected and 
changed with fresh medium. The collected release media were analyzed by rhBMP-2 ELISA 
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development kit (Peprotech) according to manufacturer’s protocol. As a positive control, 
200 µL of 16.5 µg/mL BMP-2 solution was added to the inserts and 1 mL medium was added 
to bottom wells of the transwell plate. At each time point 1 mL medium was collected and 
changed with fresh medium.  
Conditions for animal experiment 
All animal experiments were performed with prior approval of the ethics committee for 
laboratory animal use (protocol #EMC 116-15-01). 34 male Sprague Dawley (SD) rats at 12 
weeks old were used in this study to evaluate bone formation. The animals were randomly 
assigned and housed in pairs in a specific pathogen-free environment and allowed to adapt 
to the conditions of the animal house for 7 days before starting the study. The animals were 
maintained at 20-26 °C on a 12 h dark/light cycle with ad libitum access to standard rat 
chow and water. To evaluate the effect of BMP-2 loaded in the different formulations, RCP 
microspheres with a constant concentration of rhBMP-2 (3 µg per injection) and 
incorporated in SLG, SLM or HApN hydrogels were subcutaneously injected (total volume 
200 µl per injection) in the dorsum of the animals. As controls, SLM+MS, SLG+MS and 
HApN+MS were implanted without BMP-2 addition. N=6 replicates were used for each 
condition and each animal received 6 randomly assigned injections. All injections were 
performed using a 19 gauge needle on animals under isoflurane inhalation. At 1, 4 and 10 
weeks after implantation, animals were euthanized with CO2 and the specimens were 
harvested for further analysis. To reduce the number of animals used in this study, controls 
were harvested at 1 and 10 weeks after implantation.  
Micro-CT analysis 
When animals were euthanized at 4 and 10 weeks following transplantation, retrieved 
implants were immediately scanned at a resolution of 9 µm, using a SkyScan 1172 system 
(Bruker, Belgium). The following settings were used: X-ray power and tube current were 40 
kV and 0.25 mA, respectively. Exposure time was 5.9 s and an average of three pictures was 
taken at each angle (0.9°) to generate final images. These images were further 
reconstructed by SkyScan NRecon software (Bruker) using a range of 0-0.1 on the histogram 
scale, 20% beam-hardening correction and ring artefact reduction with a value of 5. For 
image processing SkyScan CTAnalyser software (Bruker) was used. Threshold levels of 120 
(lower) and 255 (higher) were set to extract the amount of mineral volume from the tissue 
volume (BV/TV). 
Histology 
For histological examination, specimens were fixed in 4% formalin solution for 48 h and 
decalcified with 10% w/v EDTA for 2-4 weeks. Implants were dehydrated and embedded in 
paraffin. Sections of 6 µm thickness were prepared using a microtome and mounted on 
subbed glass slides (StarFrost, Knittel Glass, Germany). Three selected cross sections from 
Novel in situ gelling hydrogels loaded with RCP as a slow release system 
75 
 
each implant, with a minimum distance of 120 µm apart were deparaffinised and rinsed 
with distilled water to be stained with hematoxylin and eosin (H&E). The sections were 
imaged by NanoZoomer-XR (Hamamatsu, Japan). A square grid (400-800 μm) overlay was 
used to quantify newly formed blood vessels, which were identified based on the presence 
of erythrocytes within a tubular-like structure. The number of blood vessels was counted 
within the implants in a blinded fashion by two examiners and averaged. 
CD68 marker was used to distinguish cells of the macrophage lineage, iNOS and CD206 
markers were used for detection of M1 and M2 macrophage subsets. For detection of CD68, 
iNOS and CD206 positive cells, sections were deparaffinised and washed. In the case of 
CD68 and CD206, antigen retrieval was performed using a citrate buffer (10 mM, pH 6.0) at 
90 ºC for 20 min. For iNOS, 10mM Tris, pH 9.0, 1 mM EDTA Solution, 0.05% v/v Tween 20 
buffer was used. To avoid non-specific binding, slides were pre-incubated 30 min with 10% 
v/v normal goat serum (NGS) (Southern Biotech, USA) in PBS/1%BSA w/v and 2% w/v milk 
powder to block non-specific binding followed by 1 h incubation with either primary CD68 
antibody (Acris, Germany) diluted to 0.5 μg/ml, primary CD206 antibody (Abcam, UK) 
diluted to 2.5 μg/ml or primary iNOS antibody (Abcam) diluted to 2 μg/ml. CD68 stained 
samples where then incubated for 30 min with biotinylated secondary goat anti-mouse 
antibody diluted 1:100 in PBS + 1% w/v BSA + 5% v/v rat serum (Jackson, PA, USA). For 
CD206 and iNOS staining, secondary biotin labeled goat anti-rabbit antibody (Biogenex, UK) 
diluted 1:50 in PBS+ 1% w/v BSA + 5 % v/vrat serum was used. Finally, slides were incubated 
with label streptavidin-AP (Biogenex) diluted at 1:100, rinsed with 0.2 M Tris-HCl pH 8,5 and 
stained with substrate. Substrate consisted in 0,1 mg/ml New Fuchsin (Sigma-Aldrich), 
0,3mg/ml naphtol AS-MX phosphate (Sigma-Aldrich), 0,0025% w/v NaNO2 (Sigma-Aldrich), 
3% v/v di-methylformamide (Sigma-Aldrich) and 0,25 mg/ml levamisole (Sigma-Aldrich) 
dissolved in 0.2 M Tris-HCl (pH 8.5). Slides were counterstained with haematoxylin (Sigma-
Aldrich) and analyzed using confocal microscope. Mouse IgG1 antibody (Dako Cytomation, 
Denmark) and rabbit IgG1 (Dako Cytomation) were used as negative controls. 
Type II collagen occurs exclusively in cartilage, therefore, to investigate the presence of 
cartilaginous tissue within the formulations, collagen II staining was performed on the 
samples as previously described [259]. 
After Nanozoomer-XR imaging Hamamatsu Photonics, all the retrieved implants were 
ranked for CD68, iNOS and CD206-positive cells in terms of both staining intensity and 
number of cells stained by two observers who scored all stainings and were blinded with 
regard to treatment. The results obtained by the two observers were averaged and rated on 
ordinal scale (lowest number= no/minor to highest number=moderate/heavy).  
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Statistical analysis 
To investigate whether there were differences in the number of blood vessels and CD68, 
iNOS and CD206 positive cells between conditions, a Kruskal-Wallis test was applied and 
Dunn’s post-hoc was used for analysis. Micro-CT quantitative data and BMP-2 release data 
were analyzed using one-way analysis of variance and Bonferroni’s post-hoc multiple 
comparison test was applied to the obtained results. A value of P < 0.05 was considered to 
be statistically significant.  
Quantitative data are presented as bars, indicating the mean ± SD, while qualitative data are 
presented as box plots, indicating median, and the interquartile distance with the whiskers 
showing the largest and smallest values. 
RESULTS 
RCP microsphere-alginate in situ gelling hydrogels have shear-thinning behavior  
Strain-dependent oscillatory rheology of RCP microsphere-alginate hydrogels showed an 
extremely broad linear viscoelastic region in addition to network rupture at high strains for 
the alginates containing 8% microspheres (Supplementary Table S1 and Supplementary 
Figure S3). The SLG alginate with microspheres (SLG + 8 % microspheres) broke at 150 % 
strain whereas the formulation containing GDL (SLG + 8 % microspheres+ GDL) was not 
broken at the maximum strain measured, 167% (Supplementary Table S1). This 
demonstrates that addition of GDL to the formulation, releasing 3.18 µM Ca2+ ions (Table 1), 
improved the mechanical properties of the SLG gel. The viscoelastic region was much 
smaller for the control consisting of alginate, CaCO3 particles (1 µm) and GDL. This 
formulation was broken at 40% strain showing the reinforcing effect of the microspheres in 
the formulation. 
Interestingly, the optimized formulations of SLM+MS and SLG+MS were thixotropic. When 
500% strain was applied, a decrease in both loss and storage moduli was observed and the 
hydrogel structure was broken showing the shear-thinning effect (Figure 1A). When the 
stress was removed, the hydrogel recovered almost instantaneously indicating that the gel 
can be formed in situ directly after injection in vivo. This cycle can be repeated several times 
without loss of function. Both of the alginates were injectable due to this shear thinning 
behavior. The formed hydrogels had storage (elastic) moduli between 1-2 kPa for both 
alginate gel formulations. 
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Figure 1. Mechanical properties of the SLM+MS, SLG+MS and HApN+MS composites. A. 
Thixotropic behaviour of the alginate hydrogel formulations containing SLM or SLG alginate 
and microspheres is shown by rheology. Gel is disrupted under shear stress and hydrogels 
recuperate when stress is removed within 30 sec. B. The thermo-responsiveness of the 
HApN hydrogel with microspheres is shown by rheology. Gel is formed when suspension is 
heated to 40 °C and the viscous liquid state forms when the gel is cooled to 15 °C. 
HApN-microsphere formulation have thermoresponsive behavior 
HApN hydrogel grafted with PNIPAM has an intrinsic property of thermo-inducible gel 
formation as shown earlier by D’Este et al. [258]. In combination with microspheres the 
thermoresponsive behavior was retained, which can be seen by the mechanical 
characterization of the hydrogel at increasing and decreasing temperatures between 15 °C 
and 40 °C (Figure 1B). In the cooling phase, there was a change from the gel state to the 
liquid state whereas in the heating phase, liquid to gel transition occurs. Both the storage 
modulus and loss modulus of the formed gel increased to 5 kPa at 37 ° C. 
BMP-2 release from HApN-MS hydrogel was lower than alginate-MS hydrogels 
Apart from the injectability of the hydrogel, the ability of the hydrogels to provide sustained 
BMP-2 release is important for bone formation. Therefore, the release of BMP-2 from these 
formulations was studied compared to hydrogel or microsphere only conditions. Both 
alginate hydrogels with microspheres released BMP-2 slower than alginate without 
microspheres, showing the synergistic effect of microspheres and hydrogels to control the 
release (Figure 2A). During the time-course study of two weeks, 202 ± 42 ng (mean ± SD) of 
BMP-2 was released from SLG+MS formulation and 46 ± 23 ng (mean ± SD) was released 
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from SLM+MS formulation. At the end of the experiment (Day 14), 2.3 µg ± 0.1 µg (mean ± 
SD, n=3) cumulative release was detected from the positive control which was 3.3 µg BMP-2 
initially added to the inserts of the transwells. The numbers indicated that the majority of 
BMP-2 was retained in the alginate-MS formulations. 
 
Figure 2. In vitro BMP-2 release from the A. SLM alginate, SLG alginate formulations and 
microspheres (MS) containing CaCO3 and B. from hyaluronic acid-pN (HApN) formulations 
and microspheres without CaCO3. The cumulative release of BMP-2 in DMEM with 10% FBS 
and 1 % P/S detected by ELISA is demonstrated over time. BMP-2 release from A. SLM 
alginate only (SLM), SLG alginate only (SLG), microspheres containing CaCO3 (MS), SLG 
alginate with microspheres (SLG+MS), SLM alginate with microspheres (SLM+MS); B. only 
microspheres without CaCO3 (MS), hyaluronic acid-pN with microspheres (HApN+MS) and 
hyaluronic acid-pN (HApN) are compared. Statistical difference at 14 days of cumulative 
release analyzed by one-way ANOVA, *p<0.05, *** p<0.001. 
Interestingly, the release from the HApN+MS and from HApN hydrogel only was limited 
(Figure 2B). The total release was 3.7 ± 0.4 ng and 4.2 ± 0.2 ng, a fraction of the 3.3 µg 
loaded into the gels. To confirm that the unreleased BMP-2 was still inside the hydrogel 
after 2 weeks, ten times diluted samples were loaded on a SDS-PAGE gel (Supplementary 
Figure S4). We could detect a band of BMP-2 after 2 weeks of release, which confirmed that 
HApN hydrogel prevented BMP-2 release.  
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Injectable BMP-2 loaded hydrogel formulations induced ectopic bone formation  
BMP-2 loaded in RCP microspheres were injected subcutaneously after encapsulation in the 
three hydrogel formulations tested; alginate SLM+MS, alginate SLG+MS and thermo-
responsive HApN+MS. Identical formulations without addition of BMP-2 were used as 
controls. 1 week post injection histology revealed noticeable differences in terms of 
composite integrity between formulations (Figure 3A). In the alginate formulations, both the 
microspheres and the alginate layer were mostly intact, with some cellular infiltration in the 
fissures that appeared in the gel. However, in the HApN formulation, much of the hydrogel 
had disappeared, many of the microspheres were being degraded and numerous cells could 
be observed within the implants (Figure 3A). After 4 weeks, bone formation was observed in 
one third of the alginate harvested formulations (Figure 3A).  
Bone formation was analyzed at 4 and 10 weeks by micro-CT, showing a similar amount of 
calcified tissue in all three hydrogel formulations tested at 4 weeks (Figure 3B). Interestingly, 
in the alginate formulations cartilaginous regions were found at that time point, suggesting 
that endochondral ossification process was occurring near by the MS (Supplementary Figure 
S5). At 10 weeks, micro-CT confirmed the greatest amount of bone formation when alginate 
SLG was used as a carrier, showing a more than three-fold increase compared to the 4 
weeks scan (mean ± SD, from 4.4 ± 5.4 mm3 mineral volume at 4 weeks to 22.3 ± 11 mm3 at 
10 weeks). When alginate SLM +MS or thermo-responsive HApN+MS were used, the 
amount of calcified tissue found within the implants did not change significantly over time 
(Figure 3B). Moreover, the alginate SLG+MS composite significantly increased the amount of 
mineral volume formed at 10 weeks compared to alginate SLM (22.3 ± 11 mm3 vs. 4.24 ± 3 
mm3)(Figure 3B). As we expected, when alginate formulations were implanted without 
BMP-2, mineral tissue was barely found (Figure 3C). Interestingly, the thermo-responsive 
HApN+MS formulation showed calcified tissue on micro- CT, even without the addition of 
BMP-2 (Figure 3C), but histological analysis did not show bone formation and the composite 
structure was almost degraded with or without BMP-2 addition at the end of the 
experiment (Figure 3A).  
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Figure 3. Alginate hydrogel formulations loaded with BMP-2 induced ectopic bone 
formation. A. H&E sections at 1, 4 and 10 weeks after implantation showing the alginate 
scaffolds (alg), microspheres (indicated by yellow arrows), formed bone (B) and fibrous 
tissue (FT). Controls (empty composites) are shown at 10 weeks. Images are shown at high 
magnification (scale bar is 400 μm). B. Comparison of the mineral volume obtained in the 
different composites with the addition of BMP-2 at 4 and 10 weeks-period. The bars 
represent the mean ± SD (* p < 0.05). C. Reconstructed micro-CT images 10 weeks after 
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subcutaneous injection of alginate SLM+ MS, alginate SLM+ MS and HA+ MS with and 
without BMP-2. 
Inflammatory cell infiltration decreased over time in alginate in comparison to hyaluronan 
formulations  
To investigate the role of inflammation in the bone formation process, we used CD68 as a 
general marker to identify cells of the macrophage lineage. We observed a significant time 
dependent decrease in staining in the alginate SLG (median ± 95% CI, 39 ± 8.3 at 1 week vs. 
7 ± 7.5 at 10 weeks, p < 0.05) (Figure 4A-B). In the alginate SLM formulation CD68-positive 
staining was less pronounced than in SLG alginate at week 1, increased at week 4 and then 
significantly dropped again at week 10 (mean ± 95% CI, 14 ± 3.9 at 1 week and 33.5 ± 7.3 vs. 
10 ± 11 for 4 and 10 week rank, respectively). In the HApN formulation macrophage 
recruitment was slower than in alginate SLG formulation and had the highest CD68-positive 
staining at 10 weeks (median ± 95% CI, from 23.5 ± 6.3 at week 1 to 48.5 ± 5.5 at the end of 
the experiment, p < 0.01) (Figure 4A-B). Furthermore, when we compared the formulations 
to each other at 1, 4 and 10 weeks post implantation, the SLG formulation showed more 
pronounced infiltration of CD68-positive cells at 1 week than SLM (39 ± 8.3 vs. 14 ± 3.9, p < 
0.01) and CD68-positive staining at 10 weeks in the HApN formulation was significantly 
higher than in both, alginate SLM and alginate SLG (10 ± 11 for SLM, 7 ± 7.5 for SLG vs 48.5 ± 
5.5 for HApN, p < 0.05).  
To further investigate whether the different formulations promoted the activation of 
distinct macrophage phenotypes, pro-inflammatory (M1) and anti-inflammatory (M2) 
macrophage subsets were identified. To achieve this, iNOS and CD206 markers were used. 
iNOS, was used as marker for M1 macrophages. The HApN formulation had significantly 
more iNOS-positive staining compared to the alginate SLG formulation at 10 weeks (median 
± 95% CI , 41.25 ± 9.6 vs. 7 ± 8.8, p < 0.05) (Figure 4C).  
CD206-positive staining to identify M2 macrophages did not show any difference between 
formulations at week 1. At 4 weeks, CD206-positive staining was significantly higher in SLM 
than in HApN formulations (28.2 ± 4 vs. 10.5 ± 4.2). At week 10 no significant differences 
were found between them (Figure 4D). 
Injectable formulations loaded with BMP-2 promoted blood vessel growth  
Vascularization is a prerequisite for ossification. In all three formulations blood vessel 
density increased over time (Figure 5A). Interestingly the quantity of blood vessels found 
within the implants differed markedly between formulations, showing more than five-fold 
more vessels in the HApN formulation – mean ± SD; 395 ± 82 counted at 10 weeks– 
compared to the SLM alginate –with 144 ± 79 at 10 week (p < 0.001) (Figure 5A-B). In 
addition, in alginate SLG and HApN the quantity of blood vessels was significantly higher at 
10 weeks than at 1 week (mean ± SD; 144 ± 79 vs. 13 ± 16 in alginate SLG, and 395 ± 82 vs. 
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38 ± 27 in HApN) (Figure 5A). Without BMP-2 no significant increase in the number of blood 
vessels were observed between 1 and 10 weeks in any of the formulations (data not 
shown).  
 
 
 
Figure 4. CD68, iNOS and CD206 positive staining differed between hydrogel formulations. 
A. Two blind observers ranked the implants according to the CD68 positive staining found in 
the composites at 1, 4 and 10 weeks. B. CD68 staining of a representative sample of each 
implant formulation at 1 and 10 weeks (scale bar is 400 μm). The square grid shows the 
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selected magnified area for each composite. CD68-positive cells are indicated by black 
arrows (scale bar is 100 μm). C. Ranked implants by two blind observers according to the 
iNOS positive staining found in the composites at 1, 4 and 10 weeks. D. Ranked implants by 
two blind observers according to the CD206 positive staining found in the composites at 1, 4 
and 10 weeks. The line in the middle of the box is plotted at the median. The box extends 
from the 25th to 75th percentiles and the whiskers are drawn down to the 5th percentile 
and up to the 95th, (* p < 0.05, ** p < 0.01). 
DISCUSSION 
In this study, we have tested in situ gelling HApN formulation with thermo-responsive 
behavior and alginate formulations with shear-thinning behavior as slow-release systems for 
the induction of de novo bone formation. We have found differences in the BMP-2 release 
pattern when loaded in HApN vs. alginate hydrogels. Also, a further decrease in release rate 
was observed when BMP-2 was absorbed to recombinant collagen peptide (RCP) 
microspheres and then combined with alginate hydrogels. Furthermore, we have shown 
that the slow-release gel-microsphere system comprised of SLG alginate supported the 
essential processes needed for bone formation, such as inflammatory cell infiltration, 
vascularization and osteogenesis in vivo and was superior to the SLM alginate and HApN 
formulations. Through analysis of the phenotype of the infiltrating cells and kinetics of blood 
vessel invasion we shed some light on the possible reasons for the differences observed 
between formulations.  
Injectable matrices have been the subject of much research in the fields of drug delivery and 
tissue engineering due to the minimally invasive nature with which they can be delivered 
[245]. We selected alginate and HApN formulations as carriers of microspheres for two 
reasons. First, they are both natural-origin polymers that are commonly used for bone 
regeneration; second, they can form in situ gelling systems. The in situ hydrogel forming 
ability of PNIPAM functionalized HA and alginate has already been shown [258, 260]. 
However, the formulations with microspheres are novel and were developed specifically for 
this study. One advantage of the system with alginate is that it can form a reversible 
hydrogel (thixotropic) which has not been observed in other in situ gelling alginates [25]. 
This reversible behavior of the gel makes handling much easier since the hydrogel can be 
prepared in advance and stored prior to application. Another advantage of both types of 
alginate formulations used in this study was the gelation time, which was so quick that the 
formed gel stayed in the injection site. In addition, the relatively slow degradation time of 
the alginates matched the time required for bone formation. The alginates showed some 
signs of initial degradation on histology by the first week, but after 10 weeks hydrogel was 
still present, which kept the microspheres and protein at the site, supported the formation 
of new bone and delayed the release of BMP-2.  
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Figure 5. Alginate SLG and hyaluronic acid loaded with BMP-2 significantly promoted 
blood vessel ingrowth. A. Representative pictures of each implant formulation at 10 weeks 
(scale bar is 800 μm). The square grid shows the selected magnified area for each composite 
(scale bar is 200 μm). B. In each section, blood vessels were counted. The graphs show the 
absolute number of blood vessels counted per composite formulation at 1, 4 and 10 weeks. 
The line in the middle of the box is plotted at the median. The box extends from the 25th to 
75th percentiles and the whiskers are drawn down to the 5th percentile and up to the 95th, 
(* p < 0.05, ** p < 0.01, *** p < 0.001). 
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Regarding protein release, the type of the hydrogel was found to be important. We 
observed that the combination of alginate and microspheres considerably slowed down the 
release of BMP-2. SLG+MS lead to more BMP-2 release than SLM+MS resulting in more 
bone formation. However, when HApN was used as a hydrogel, with or without the addition 
of RCP-MS, most of it was retained. These data suggest a strong interaction between 
thermo-responsive HApN hydrogel and BMP-2 resulting in the retention of the protein. This 
has been observed previously for HA. In one study, HA-based powder gel composite showed 
slow release of less than 20 % of the total amount of rhBMP-2 [261]. Most likely this lack of 
release prevented the attraction of the necessary cells at the early stages and by the time it 
had been released the material was too degraded to modulate the release rate or 
structurally support bone formation. Whether this affinity for BMP-2 is specific to PNIPAM 
functionalized HA or is a more general phenomenon requires further investigation. 
The mechanical properties of the alginates showed that the storage (elastic) moduli are in 
the range of elastic moduli of endothelial tissue and stromal tissue [262]. However, the 
elastic modulus of HApN with microspheres is higher than that of alginates and comparable 
to elastic modulus of a smooth muscle [262]. These mechanical properties indicate that the 
gels can retain the microspheres in situ, fill a defect and provide initial support during the 
formation of bone. The mechanical properties of these thixotropic alginate hydrogels (1-2 
kPa) are similar to non-in situ gelling alginates [263]. According to Banerjee et al., gels with 
very high elastic moduli are undesirable and thixotropic gels with moderate elastic moduli 
(which were what we used in this study) should be suitable for bone regeneration [264]. 
With regard to HA, 50% cross-linked HA had an elastic modulus of 30 Pa [265], which is far 
lower than the PNIPAM functionalized hydrogel presented in this study (5 kPa). After bone 
fracture, following the initial inflammation a callus forms. The mechanical properties of 
fracture callus have been measured and found to depend on multiple tissue types: the range 
of the indentation moduli was 0.61–1.27 MPa (median = 0.99 MPa) for granulation tissue, 
1.39–4.42 MPa (median = 2.89 MPa) for chondroid tissue and 26.92–1010.00 MPa (median 
= 132.00 MPa) for woven bone [266]. We therefore concluded that an elastic modulus in the 
range of 1-10 MPa is suitable for supporting the regenerative tissue. Given the mechanical 
properties of these hydrogels, it could be feasible to apply them directly to repair non-load 
bearing bone defects. For fractures or defects in the load bearing-bones, the application 
would still require some other kind of mechanical stabilization, be that a traditional cast, 
internal fixation or combination with other stronger biomaterials. 
HA is a commonly used material for cartilage regeneration. Eglin et al. found that thermo-
responsive HApN can be used to support hMSCs for the treatment of degenerated 
intervertebral disc and therefore HA hydrogels were developed as a bone-cartilage interface 
[267]. Injectable HA has been shown to be successful in a rabbit osteochondral defect model 
[268]. Interestingly, one study suggested that HA might impede bone formation by inhibiting 
osteoblast differentiation [269]. Maus et al. used combinations of commercially available 
injectable HA with and without 200 µg BMP-2 in a sheep femoral defect. However, none of 
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the conditions resulted in significant bone formation [257]. Bakhta et al. used hyaluronan-
based hydrogels loaded with 5 µg BMP-2 ectopically and observed significant bone 
formation within the formulations and a mineral volume of 4.4 ± 0.5 mm3 after 8 weeks 
[270]. However, prior to our study, in situ gelling HA had never been used in combination 
with particles to enhance cell adhesion and to promote bone tissue formation. We used 
microspheres rich in RGD motifs as BMP-2 carrier and failed to show bone formation after 
10 weeks. Unlike Bakhta et al., who implanted the composites intramuscularly, which is 
more conducive to supporting de novo bone formation, we injected our composite 
subcutaneously and this might account for the discrepancy observed. 
How to modulate inflammation has become a hot topic in bone repair in the past decade 
[271-274]. Several groups have studied both the influence of different biomaterials upon 
macrophage polarization in vitro [275-279] and the positive dose-dependent relationship 
between the dosage of BMP-2 and the inflammatory volume [62, 196, 233, 280, 281]. Most 
in vivo bone formation studies have investigated the inflammatory response involved by 
using a single marker to identify monocyte-macrophage-osteoclast cells such as TRAP or 
have relied on generic histology (e.g. H&E) to assess inflammation [233, 280, 282, 283]. In 
our study, we used CD68, iNOS and CD206 as markers to identify macrophage presence and 
to indicate their phenotype within our tested composites. The BMP-2 dose used in this 
study was low, to prevent potential side-effects associated with higher doses (such as 
inflammation), to allow us to better investigate the effects of the materials. We observed a 
late CD68+ cell infiltration in the HApN composites, which increased over time. It has been 
reported that macrophages can specifically recognize HA through receptors such as CD44 or 
the hyaluronan receptor for endocytosis, HARE [284] and that the HA–CD44 interaction is 
involved in multiple cellular functions such as inflammation [285]. This might explain the 
high levels of inflammatory cell infiltrate observed at the later time points in the HApN+MS 
group. In contrast, in alginate formulations, CD68+ staining was lower at 10 weeks than at 1 
week, and bone formation was successfully achieved. It is known that alginates from wound 
dressings interact with wound macrophages [286] and alginate-collagen composites have 
been shown to locally integrate with host tissue in an abdominal wall defect model [287]. In 
our study, at 4 weeks, there was more CD206+ staining in the alginate composites than in 
the HApN+MS formulation, suggesting a possible polarization of the monocytes towards the 
anti-inflammatory/tissue remodeling M2 phenotype. Moreover, there were significantly 
more iNOS+ cells in the HApN+MS formulation than in the alginate formulations at 10 
weeks, which is more indicative of a pro-inflammatory situation. Taken together the results 
suggest that within alginate formulations there was an initial inflammatory phase that 
resolved over time, leading to bone formation. In contrast, in the HApN+MS formulation the 
presence of pro-inflammatory cells increased over time and there were with significantly 
fewer anti-inflammatory CD206 positive cells. This likely also negatively influenced the bone 
formation process in the HApN+MS gels.  
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Vascularization is another critical factor for successful bone formation. It has been 
demonstrated that HA-based scaffolds promote angiogenesis when used in a wide variety of 
applications, such as abdominal wall defect repair, brain injury or heart disease models 
[288-290]. Moreover, Cui et al. demonstrated the ability of HA-RGD scaffolds to support 
angiogenesis in the cortex of the brain [291]. Similarly, alginate-based beads loaded with 
VEGF had been used subcutaneously for bone tissue engineering, promoting angiogenesis 
[292]. Furthermore, a study in which alginate and alginate-RGD hydrogel were injected into 
the infarct area of rats showed that both increased arteriole density but that the greatest 
angiogenic response was in the alginate-RGD hydrogel condition [293]. Our findings agree 
with the results obtained in previous studies and we have demonstrated that both 
thermoresponsive HA and alginate enriched with RGD microspheres are able to promote 
vasculature formation ectopically when loaded with BMP-2. It is, however, clear that in this 
case more does not necessarily mean better: although significantly more vessels were 
present in the HA implants than in the alginates, this did not lead to the formation of any 
bony tissue.  
CONCLUSIONS  
In situ gelling hydrogels encapsulating BMP-2 loaded RCP microspheres represent an 
injectable slow-release protein delivery system. Alginate formulations effectively promoted 
bone formation in an ectopic model. While there was successful infiltration of cells into all 
three formulations, differences between materials were observed in the macrophage 
phenotype and invasion kinetics. Also, while there was ample vascularization in all three 
materials there were clear differences in the total number of blood vessels with the higher 
number present in the HA formulation not increasing the success of de novo bone 
formation. Thus, alginate SLG combined with RCP-MS and loaded with low dose BMP-2 
displayed optimal protein release rate, cellular invasion, material degradation rate and 
vascularization kinetics to support bone formation. This study presents a novel cell-free 
injectable slow-release system that has potential as a void-filling material for the induction 
of new bone formation.   
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SUPPLEMENTARY INFORMATION 
 
Supplementary Figure S1. Morphology of microspheres shown by scanning electron 
microscopy (SEM). The CaCO3 crystals are visible on the microspheres on the left. 
SEM: CaCO3 removed MS  
Calcium (Ca) 
 
Not detected 
SEM: CaCO3 containing MS 
Calcium (Ca) 
  
Supplementary Figure S2. Energy-dispersive X-ray spectroscopy mapping of microspheres 
before and after CaCO3 removal. 
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Supplementary Table 1. Table showing the strain % at which the structure breaks, as shown 
by the amplitude sweeping test analyzed by rheology. 
Type of structure  Strain % at which the structure breaks  
Alginate only 12 
Alginate (SLG-20) + 8 % microspheres 150 
Alginate (SLG-20) + 8 % microspheres +GDL >167 
Alginate +CaCO3 (1 µm size) + GDL 40 
 
 
Supplementary Figure S3. Strain-dependent oscillatory rheology of in situ gelling alginate 
hydrogels (HG) and of the negative controls (references) consisting of an alginate hydrogel, 
crosslinked at higher calcium concentrations and an alginate hydrogel containing CaCO3 
particles.  
Chapter 4 
90 
 
 
Supplementary Figure S4.  SDS-PAGE of the BMP-2 bands ( shown inside blue rectangles). 
Lanes from left to right are: control BMP-2 solution at 15 µg/mL; marker; empty lane; HA 
hydrogel after release diluted 10 times before loading; empty lane, HA hydrogel loaded with 
BMP-2 (before release) diluted 10 times before loading; marker. The density of BMP-2 band 
after release is more intense than before release. This might be related to the higher 
interaction between BMP-2 and HA initially. 
 Supplementary Figure S5.  Endochondral ossification was observed within alginate 
composites since 4 week-period to the end of the experiment. Representative picture of 
alginate SLM formulation stained by H&E at 4 weeks after implantation.  The magnification 
shows collagen II positive cells within the central region of the implant. 
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ABSTRACT 
We aim to reduce the clinically used supra-physiological dose of BMP-2 (usually 1.5 mg/mL) 
that has a risk of adverse events, by using a more effective release system. We have 
previously developed a slow release system based on an injectable hydrogel composed of 
BMP-2 loaded recombinant collagen-based microspheres and alginate. In this current study, 
we investigate time and dose dependent subcutaneous ectopic bone formation for this 
system and the bone regeneration capacity in a calvarial defect model. Here, we report that  
BMP-2 doses 10 µg, 3 µg and 1 µg per implant (50 µg/mL, 15 µg/mL and 5 µg/mL 
concentration respectively) successfully induced ectopic bone formation subcutaneously in 
rats in a time and dose dependent manner as shown by micro CT and histology. In addition, 
we show the spatio-temporal control of BMP-2 retention for 4 weeks in vivo by imaging of 
fluorescently labelled BMP-2. In the subcritical calvarial defect model, micro-CT revealed a 
higher bone volume for the 2 µg BMP-2 per implant (50 µg/mL concentration) than the 
lower dose used (0.2 µg per implant, 5 µg/mL). With 50 µg/mL BMP-2 complete defect 
bridging was obtained after 8 weeks. The BMP-2 concentration of 5 µg/mL was not 
sufficient to heal a calvarial defect faster than the empty defect or biomaterial control 
without BMP-2. Overall, this injectable BMP-2 delivery system showed promising results at a 
50 µg/mL BMP-2 concentration in both the ectopic and calvarial defect model in rats 
showing the potential of this composite hydrogel in bone regeneration therapies. 
Key words: bone morphogenetic protein-2, slow release, injectable delivery system, ectopic 
bone formation model, calvarial bone defect model 
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INTRODUCTION 
Autologous bone is widely used in bone grafting surgery. However, the limited availability of 
autologous bone and the discomfort related to the harvesting procedure, has diverted the 
field to seek for alternative methods involving biomaterials [231]. Bone morphogenetic 
proteins (BMP-2 and BMP-7), being successful in inducing bone formation, have been 
translated to clinics [194]. BMP-2 absorbed on collagen sponge has been approved by Food 
and Drug Administration for spinal fusion, tibial nonunions and oral-maxillofacial 
reconstructions [57, 58]. However, adverse events observed in clinics have limited the use of 
BMP-2 especially for off-label applications [63, 195, 196, 249]. These adverse events, mainly 
inflammation [233] and swelling [142], were associated to the supraphysiological dose of 
BMP-2 loaded in the collagen sponge [66] in combination with the strong burst release. Half 
of the loaded BMP-2 was released from the collagen sponge in the first two days in vivo 
[65]. Possibly these adverse events can be mitigated by using an appropriate release system 
comprising lower BMP-2 dose [234, 294]. Such a system might then broaden the potential 
use of BMP-2 in orthopaedic and maxillofacial surgery applications. 
The dose or concentration of BMP-2 has been reported to be very important for bone 
formation [295-297]. Since no naturally bone-forming cells are present within the 
intradermal environment, subcutaneous ectopic bone can only be formed by injecting bone 
forming cells or by an osteoinductive protein such as BMP-2 that can recruit progenitor cells 
[298]. The concentration or dose of BMP-2 required to induce bone formation ectopically 
depends on the type of  carrier material used. For example, using 5 µg BMP-2, 32% bone 
formation with 9 mm3 β-tricalcium phosphate was achieved whereas hydroxyapatite with 
same amount of BMP-2 only formed 3 % bone in a rat ectopic model [235]. An amount of 5 
µg rhBMP-2, implanted with 6 mm diameter collagen sponge, was required to induce a 
small intramuscular bone in mice with a maximum volume of 5 mm3 [236]. Silk fibroin 
particles (10 mg) loaded with 5 µg BMP-2 induced a small volume (2 mm3) of ectopic bone 
at 4 weeks in rats [237]. A low dose of BMP-2 (less than 1 µg) delivered on a collagen sponge 
or with brushite calcium-phosphate particles did not form bone at all in the palatal 
submucosa of rats [238], confirming the presence of a threshold dose. This threshold 
depends on the type of the material, application site and is associated with the release 
kinetics/ degradation time of the material and subsequent cellular infiltration rate [295]. 
We have previously developed an in situ gelling sustained BMP-2 release system that 
successfully induced ectopic bone formation. This hydrogel system is based on BMP-2 
loaded microspheres from a recombinant protein based on collagen I (RCP) embedded in 
alginate. The major advantages of the developed system have been shown to be its 
thixotropic behaviour, resulting in easy handling and injectability, good BMP-2 release 
profile and good performance in vivo in terms of cellular infiltration, degradation and bone 
formation (Fahmy-Garcia et al., manuscript submitted). The aim of the current study is to 
investigate time and dose dependent bone formation using this BMP-2 releasing hydrogel in 
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an ectopic bone formation model and, in addition, to test the bone regeneration capacity of 
two selected doses of BMP-2 in an orthotopic model. Hereto, we have subcutaneously 
injected formulations containing 4 different doses of BMP-2 (10 µg, 3 µg, 1 µg, 0.3 µg per 
implant; 50 µg/mL, 15 µg/mL, 5 µg/mL, 1.5 µg/mL concentration respectively) and an empty 
control subcutaneously on the dorsum of immune competent rats and followed ectopic 
bone formation over a time course of 10 weeks by micro-CT with histology at the end-point 
of 10 weeks. To study the spatio-temporal release of BMP-2 in vivo, formulations containing 
3 different doses of fluorescently labelled BMP-2 were injected subcutaneously in rats and 
monitored over time course of 10 weeks by in vivo fluorescence imaging. Finally, two doses 
of BMP-2 (50 and 5 µg/mL) were further investigated in a calvarial defect model. For this 
purpose, 40 µL of the composite hydrogel formulation containing 2 µg BMP-2 or 0.2 µg 
BMP-2 was injected in 5 mm subcritical calvarial defects in immune competent rats and 
bone formation was studied by longitudinal imaging for 10 weeks by micro-CT.  
MATERIALS AND METHODS 
Materials  
Recombinant protein based on human collagen I (RCP) is a product of Fujifilm, which is 
commercially available as Cellnest™. RCP is produced by genetically modified yeast Pichia 
pastoris in a fermentation process as described elsewhere [203, 204, 206]. RCP is a 571 
amino acids  protein, having an isoelectric point (pI) of 10.02 and a molecular weight of 51.2 
kDa.  
The recombinant human bone morphogenetic protein-2 (rhBMP-2, amino acids 283 to 396 
plus an N-terminal Met-Ala) was expressed in E. coli, isolated from inclusion bodies, 
renatured and purified as previously described [209]. Lyophilised BMP-2 was dissolved in 
distilled water and the concentration was determined by UV/Vis spectrophotometry. 
Freshly dissolved BMP-2 was used for the experiments. For the fluorescence measurements, 
rhBMP-2 was fluorescently labeled using DyLight 800 (ThermoFisher Scientific, Waltham, 
MA, USA). For the labeling, dissolved BMP-2 solution was adjusted to pH 4.5 by addition of a 
2M sodium acetate (pH 4.5) solution. Subsequently DyLight™ 800 NHS Ester, dissolved in 
dimethyl sulfoxide (DMSO), was added in a 5-fold molar excess and the mixture was 
incubated for 4 hours at 4°C while shaking. After incubation, the protein was separated from 
non-coupled dye by anionic exchange chromatography using a HiTrap SP HP column (GE 
Healthcare). Since the protein could not be eluted even at 2 M sodium chloride salt 
concentrations, it was recovered using an aqueous 6 M guanidinium hydrochloride solution. 
The protein was subsequently dialysed to 1 mM hydrochloric acid and finally to distilled 
water.  
Pronova SLG 20 (sterile alginate where over 60% of the monomer units are guluronate) was 
ordered from Novamatrix (Sandvika, Norway). Hexamethylene diisocyanide (HMDIC), corn 
oil, sodium chloride, calcium carbonate (CaCO3) and glucono delta lactone (GDL) were 
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purchased from Sigma-Aldrich (St. Louis, MO, USA). Ethanol, acetone and hydrochloric acid 
were purchased from Millipore (Billerica, MA, USA). The ELISA development kit and reagents 
for BMP-2 quantification were ordered from Peprotech (Rocky Hill, NJ, USA). Dulbecco’s 
Modified Eagle’s Medium (DMEM), fetal bovine serum (FBS), and penicillin-streptomycin 
(P/S) were ordered from Thermofisher Scientific (Waltham, MA, USA).  
RCP microsphere preparation 
RCP-calcium carbonate composite microspheres were produced by emulsification as 
described previously (Mumcuoglu et al., manuscript in press). Briefly, a 20% aqueous RCP 
solution was prepared and mixed with CaCO3 fine powder (with a size of <1 µm) in a 1:1 
(w/w) ratio of RCP to CaCO3. This suspension was emulsified in corn oil at 50°C while stirring 
the emulsion at 800 rpm for 20 min. After cooling down the emulsion, the emulsified 
microspheres were washed three times with acetone. After overnight drying at 60°C, 
microspheres were sieved to 50-72 µm size using sieves (Retsch GmbH, Haan, Germany). 
Particles were subsequently crosslinked by hexamethylene diisocyanide (HMDIC) by mixing 
and stirring of 1 g of spheres, and 1mL of HMDIC in 100 ml ethanol for 1 day. Non-reacted 
crosslinker was removed by washing several times with ethanol. CaCO3 was left in the 
particles since Ca2+ ions are used to crosslink alginate in the final hydrogel formulation. 
Particles were then gamma sterilised at 25 kG (Synergy Health, Etten Leur, The 
Netherlands).  
Preparation of the RCP microsphere-alginate hydrogel formulations 
SLG-20 alginate (NovaMatrix, Sandvika, Norway) was dissolved in 0.9 % sterile sodium 
chloride to create a 2% w/v solution. Sterile microspheres (68 mg) were incubated with 170 
µL BMP-2 containing solution at 4 °C overnight. Initial BMP-2 concentrations used were 
379.4 µg/mL, 113.8 µg/mL, 37.9 µg/mL, 11.4 µg/mL, to yield final BMP-2 concentrations in 
the hydrogel formulation of 50 µg/mL, 15 µg/mL, 5 µg/mL and 1.5 µg/mL respectively. Next 
day, when all BMP-2 containing liquid was absorbed, 1014 µL of the 2% w/v SLG solution 
was added and the swollen microspheres were resuspended. Then, 106 µL of 0.06 M fresh 
glucono delta lactone (GDL) solution was added and mixed immediately. GDL was used to 
dissolve minute amounts of CaCO3 thereby crosslinking alginate and increasing the 
mechanical property of the formulation. The formulations were thoroughly mixed passing 
through 19 G needle immediately after addition of all components and stored overnight at 4 
°C to equilibrate. Next day, the prepared formulations were mixed again prior to 
experiments. 
 In vitro release of BMP-2 from hydrogel formulations 
Hydrogel formulations were prepared as described above containing either fluorescently 
labelled or wild-type BMP-2. Then 200 µL of each hydrogel was added to each well of 24 
well plate inserts with 0.4 µm pore size. 1 mL DMEM with 10% FBS and 1 % P/S per well was 
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added to the reservoir plate. The plates were incubated at 37 °C under constant agitation at 
300 rpm. At each time point, all medium (1 mL) was collected from the reservoir plate and 
changed with fresh medium (1 mL). Positive controls were 10 µg, 3 µg or 1 µg wild type or 
fluorescently labelled BMP-2 in 1 mL DMEM medium. At every time point, 100 µL of these 
positive controls was sampled. The collected release media and control samples were 
analysed by the rhBMP-2 ELISA development kit according to manufacturer’s protocol. To 
calculate the fraction released at each time point, the concentrations detected in the 
release medium of the hydrogel samples were normalised to the concentrations of the 
positive controls to correct for loss by adsorbance to the tube and/or degradation of the 
protein.  
Study design and ethics 
All animal experiments were performed with prior approval of the Erasmus Medical Centre 
ethics committee for laboratory animal use (project number: AVD101002015114 and 
protocol numbers: EMC 15-114-03 and EMC 15-114-04). 10 week old male Sprague Dawley 
(SD) rats (Charles River) were used. The animals were randomly assigned and housed in 
pairs in specific pathogen free (SPF) conditions and allowed to adapt to the conditions of the 
animal house for 7 days before implantation. The animals were maintained at 22 ± 5°C on a 
12 h dark/light cycle with ad libitum access to standard rat chow and water. At 10 weeks 
after implantation, animals were euthanised with CO2 and the specimens were harvested 
for micro-CT analysis and histology.  
Subcutaneous injection of in situ gelling formulations to study ectopic bone formation 
To evaluate the effect of different doses of BMP-2 on ectopic bone formation, the hydrogel 
compositions were subcutaneously injected (total volume 200 µL per injection) in the 
dorsum of the rats (20 rats in total). Each animal received 4 or 5 randomly assigned 
injections. All injections were performed on animals under isoflurane inhalation. To study 
the BMP-2-dose effect on bone formation, four different BMP-2 concentration were used 
(50, 15, 5, 1.5 µg/mL) resulting in total doses of 10 µg, 3 µg, 1 µg and 0.3 µg BMP-2 per 
implant (n=8 per group), respectively. As a control, alginate with microspheres but without 
BMP-2 was injected (n=6). To investigate the spatio-temporal distribution of BMP-2 in the 
implanted material in vivo, 200 µL hydrogel containing fluorescently labelled BMP-2 was 
injected at different doses: 10 µg, 3 µg and 1 µg (n=6). Longitudinal imaging was performed 
by microCT and IVIS biweekly until the end of the experiment (10 weeks). 
Calvarial defect model to study bone regeneration with in situ gelling formulations 
To evaluate the effect of two hydrogel formulations with a selected dose of BMP-2 on 
orthotopic bone formation, two defects of 5 mm diameter were created in the rat calvaria 
(18 rats in total). Prior to the surgery, animals received intraperitoneal injections of 0.05 
mg/kg of buprenorphine (Temgesic®, Indivior, UK) and 5 mL/kg sterile normal saline to 
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account for fluid loss. Surgeries were performed under 2.5% isoflurane anesthesia. The 
animal skulls were shaved and disinfected with ethanol swabs. Then, an incision was made 
through the skin of the calvarium and the periosteum, and full-thickness flaps were 
reflected. The defect was irrigated with 0.1 ml of 1% xylocaine with 1:200000 epinephrine 
(AstraZeneca, NL) along the sagittal midline of the skull. Under copious sterile saline 
irrigation, two 5-mm-diameter bone defects were prepared using a micro trephine drill with 
5 mm diameter (Fine Science Tools, Germany) in each animal and any visible debris or bone 
chips were removed. Then, 40 µL of hydrogel formulation with BMP-2 or, as a control, 
without BMP-2 was injected into the defect. As sham control, empty defects were used (5 
rats, 10 defects). As a biomaterial control alginate with microspheres were injected to the 
defects (5 rats, 10 defects). Alginate with microspheres loaded with 50 µg/mL BMP-2 (3 rats, 
3 defects) was used to study healing with a high dose; alginate with microspheres loaded 
with 5 µg/mL (5 rats, 10 defects) was used to study healing with a low BMP-2 dose. The 
animal number of the 50 µg/mL BMP-2 cohort was kept small because it was expected to 
induce bone formation based on our results of ectopic bone formation study. After 
implantation, the periosteum and the skin above the defects were repositioned and sutured 
with polylactic acid sutures (Vycril 4.0, Ethicon, Johnson Prod., São José dos Campos, Brazil). 
All animals received three postoperative doses of buprenorphine for analgesia every 10 h 
during the next three days. Longitudinal imaging was performed biweekly by micro-CT until 
10 weeks. At 10 weeks after implantation, animals were euthanised with CO2 and the 
specimens were harvested for micro-CT analysis and histology. To reduce the number of 
experimental animals, this study was combined with another study and the biomaterial only 
and 50 µg/mL BMP-2 groups were used as controls for that other study (Fahmy-Garcia et al, 
in preparation). 
Micro-CT imaging 
Micro-CT  (Quantum FX , Perkin Elmer, Waltham, MA, USA) was used to image animals after 
1 week, 2 weeks, 4 weeks, 6 weeks, 8 weeks, 10 weeks after injection and also to image the 
implants retrieved at 10 weeks. To image the ectopic bone in vivo the following parameters 
were used: Field of view: 73mm, Voltage: 90kV, Current: 160 µA, Scan Time: 120 sec. To 
image the ectopic implants field of view of 20 mm, scan time of 120 sec. was used. To image 
the calvarial defects a 30 mm field of view, scan time of 3 min. was used. The trabecular and 
cortical bone mineral density (BMD) was determined on the basis of calibration scanning, 
using two phantoms with known density (0.25 g/cm3 and 0.75 g/cm3 ; Bruker MicroCT) 
measured under identical conditions. For image processing, Analyze software version 11.0 
was used (Mayoclinic, Rochester, MN, USA). Threshold levels were set to 0.11 g/cm3, 400 
Hounsfield units. 
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Fluorescence imaging in vivo 
An IVIS Imaging System 200 (Perkin Elmer, Waltham, MA, USA) was used to image 
fluorescent BMP in the animals immediately after the injection, at 3 days, 1 week, 2 weeks, 
4 weeks, 6 weeks, 8 weeks and 10 weeks after injection. Imaging parameters were set to: 
exposure time 20 sec, excitation 745nm, emission 820nm and 840nm. For the image 
analysis, the region of interest was selected as circles of 3.0 ±0.1 cm2 area for each implant 
and total the radiant efficiency [p/s] / [µW/cm²] was calculated by the Living image® 
software (PerkinElmer, Waltham, MA, USA). As a region of interest 3 cm2 area was selected 
since this was the magnitude of area where signal was detected directly after injection.  
Histology 
For histological analysis of the subcutaneous ectopic bone formation, specimens were fixed 
in 4% formalin solution and decalcified with 10 % EDTA for 2-4 weeks. Implants were 
dehydrated and embedded in paraffin. Sections of 6 µm in thickness were prepared using a 
Leica microtome (Wetzlar, Germany) and mounted on subbed glass slides (Thermofisher 
Scientific, Waltham, MA, USA). Three cross sections of at least 200 µm apart from each 
other were collected from each implant. The sections were de-paraffinised and rinsed with 
distilled water to be stained with hematoxylin and eosin (H&E). The sections were imaged 
by NanoZoomer-XR (Hamamatsu, Japan). 
Statistical analysis 
The quantitative micro-CT data of ex vivo samples were analysed using one-way analysis of 
variance (ANOVA) and a Bonferroni post-hoc multiple comparison test. In vivo calvaria 
micro-CT data were analysed using two-way analysis of variance (ANOVA) and a Bonferroni 
post-hoc multiple comparison test. A value of p < 0.05 was considered to be statistically 
relevant. Linear regression analysis of micro-CT data was done by Graph-pad to analyse the 
time dependent bone formation.  
RESULTS 
BMP-2 was retained for at least four weeks in vivo  
To monitor the retention of BMP-2 in vivo, composite hydrogels (alginate with RCP 
microspheres) with three different doses of fluorescently labelled BMP-2 were used. First, 
we confirmed in vitro that the release of fluorescently tagged (fluo) BMP-2 from the 
hydrogels was similar to wild type BMP-2 (Figure 1). The difference between the release of 
the two proteins was less than 10 % showing that labelled protein can be used to study 
retention of BMP-2 in vivo. Then, the fluorescence signal (shown as radiance efficiency) of 
the 3 doses injected subcutaneously was followed in vivo by fluorescence imaging. As shown 
in Figure 2, the fluorescence signal generated by the three different BMP-2 doses decreased 
until week 4. After 4 weeks, all fluorescence curves levelled off. Interestingly, the 
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fluorescence values did not drop to the background value indicating the presence of some 
remaining BMP-2 in the hydrogels. The curves corresponding to different doses were not 
significantly different due to high variation between animals.  
 
Figure 1. In vitro release of fluorescently labelled and non-labelled BMP-2 from the RCP 
microspheres with alginate hydrogel, showing no major difference between labelled and 
non-labelled BMP-2 release in vitro in DMEM with 10% FBS, 1%P/S. 
 
Figure 2. (a) BMP-2 is retained in RCP microspheres with alginate hydrogels in vivo for at 
least 4 weeks. The total radiance efficiency of the fluorescence signal is shown for three 
different doses of fluorescent BMP-2 (10µg, 3 µg and 1 µg) containing RCP microspheres 
with alginate that were injected subcutaneously in Sprague-dawley rats (n=6 injections). (b) 
Representative image of in vivo fluorescence imaging.  
Microspheres with alginate hydrogel induced BMP-2 dose dependent ectopic bone 
formation 
The effect of the BMP-2 dose on subcutaneous ectopic bone formation was investigated 
over a time period of 10 weeks using 4 different BMP-2 doses (representative micro CT 
images are shown in Figure 3a). At the end point of 10 weeks, the bone volume clearly was 
found to be dose dependent (Figure 3b). The highest dose of 10 µg (50 µg/mL 
concentration) induced the largest volume of ectopic bone, while the lowest doses of 0.3 µg 
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(1.5 µg/mL) and 0 µg BMP-2 failed to form bone. The composite hydrogel containing 1 µg 
BMP-2 (5 µg/mL), forming just a minute volume of bone, is the threshold to induce ectopic 
bone in rats. The bone mineral density, did not differ significantly (Figure 3c): 0.5 g/cm3 
density for 3 and 10 µg BMP-2 and 0.35 g/cm3 for 1 µg BMP-2. For comparison tibia of 
animals were extracted and imaged using the same instrumental settings. The cortical bone 
of the tibia had a density between 1.2-2.0 g/cm3 and the trabecular bone had a density 
between 0.15-0.5 g/cm3 showing that ectopic bone formed subcutaneously had a density in 
the range of trabecular bone. 
 
Figure 3. Ectopic bone formation at 10 weeks is BMP-2 dose dependent. (a) Representative 
images of microCT of implants retrieved at 10 weeks. (b) The volume of ectopic bone in 
mm3. (c) Bone mineral density after thresholding to 0.11 g/cm3, 400 Hounsfield units. Four 
different doses of BMP-2 (10µg, 3 µg, 1 µg, 0.3 µg, 0 µg) containing RCP microspheres with 
alginate (200 µL) were injected subcutaneously in Sprague-dawley rats (n=8 injections). Data 
is shown as mean ± SD, one-way ANOVA was performed to compare treatment groups, 
asterisk ** p<0.05, *** p<0.001 shows statistical significance. 
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Microspheres with alginate hydrogel containing different doses of BMP-2 showed 
different kinetics of bone formation 
Longitudinal micro-CT imaging of rats for 10 weeks revealed a dose dependent rate of 
ectopic bone formation (Figure 4a and 4b). The volume of ectopic bone in the 10 µg BMP-2 
group increased linearly between 1 week and 8 weeks with a rate of 16.9 ± 0.8 mm3/week 
(r2=0.99), after which a plateau was reached. In the 3 µg BMP-2 group, a two phase linear 
trend was observed. Between 2 and 6 weeks, a linear increase of bone volume with a rate of 
10.2 ± 0.5 mm3/week (r2=0.99) was found, while a slower linear trend was observed 
between 6 and 10 weeks with a rate of 3.4 ± 0.4 mm3/week (r2=0.99). Although the amount 
of ectopic bone formed by 1 µg BMP-2 was very small with a volume of only 3.0 ± 5.5 mm3 
(mean ± SD) at week 10, the bone volume linearly increased between 1 week and 10 weeks 
(rate=0.36 ± 0.1 mm3/week, r2=0.96). 
Significant mineralization could be observed after two weeks (Figure 4c). A linear increase in 
bone density was observed for 10 µg BMP-2 between 2 weeks and 10 weeks with a rate of 
0.025 ± 0.002 g/cm3 per week (r2=0.98). In contrast to the bone volume, the mineral density 
did not reach a plateau at 10 weeks suggesting that mineralization can continue for longer 
than 10 weeks. Similar to 10 µg, 3 µg BMP-2 showed a linear increase between 2 and 10 
weeks with a rate of 0.019 ± 0.002 (r2=0.96). The 1 µg BMP-2 comprising hydrogel clearly 
mineralised slower than the other two doses with a rate of only 0.005 ± 0.001 (r2=0.97). 
 
Figure 4. Ectopic bone volume and density increase over time course of 10 weeks is BMP-2 
dose dependent. (a) Representative micro-CT images of bone formed by 10 µg BMP-2 over 
10 weeks. (b) The volume of ectopic bone in mm3 after thresholding. (c) Mineral density of 
bone in g/cm3 after thresholding. Threshold was set to 0.035 g/cm3 to discriminate 
mineralised tissue from soft tissue. Five different doses of BMP-2 (10µg, 3 µg, 1 µg, 0.3 µg, 0 
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µg) containing RCP microspheres with alginate were injected subcutaneously in Sprague-
dawley rats (n=8 injections). Data is shown as mean ± SD. Since 0.3 µg and 0 µg BMP-2 did 
not form any bone, they are not represented in this figure. 
Ectopic bone formation confirmed by histology 
The morphology of ectopic bone induced by five different doses of BMP-2 (10 µg, 3 µg, 1 µg, 
0.3 µg, 0 µg) containing hydrogel was evaluated by histology at 10 weeks. As seen in Figure 
5 bone tissue could be identified for the 10 µg, 3 µg, and 1 µg BMP-2 comprising hydrogels 
and no bone was found for the two lowest doses of 0.3 µg and 0 µg. The area of ectopic 
bone was the largest for the 10 µg samples (Figure 5), thereby confirming the CT data 
(Figure 3). Interestingly, for all BMP-2 doses, remnants of microspheres and gels could be 
observed indicating that the implants were not yet fully degraded at 10 weeks. This result is 
in line with the long term retention of BMP-2 as observed by fluorescence imaging. Bone 
formation was not only observed at the periphery of the hydrogel but also in some samples 
within the hydrogel construct. Microspheres were also observed within the hydrogel 
construct. Some of the microspheres were intact, some were infiltrated with cells. The 
microspheres which were infiltrated changed the spherical morphology probably as a sign of 
degradation. Small ossicles were detected around some microspheres. Around the implants, 
a layer of fibrous tissue was also observed which is a typical foreign body response upon 
implantation [299]. 
Microspheres with alginate hydrogel containing 50 µg/mL BMP-2 induced bone formation 
in a rat calvarial defect model 
The regeneration capacity of the composite hydrogels with BMP-2 was tested in a 
subcritical-sized calvarial defect model. Hereto, biomaterial only, 5 µg/mL  BMP-2  loaded 
biomaterial or 50 µg/mL BMP-2  loaded biomaterial were injected into a 5 mm calvarial 
defect and empty (sham) was used as a control (Figure 6a). The bone volume of 50 µg/mL 
BMP-2 was significantly higher than all other groups (Figure 6b), showing the regenerative 
capacity of this 50 µg/mL concentration of BMP-2 in the composite hydrogel formulation. 
The low concentration (5 µg/mL) did not form any additional bone compared to the 
biomaterial only or empty (sham) control. Interestingly, the bone volume of the empty 
defect was slightly higher at week 2 compared to the biomaterial only, albeit the difference 
was not statistically significant. At the end of the experiment, biomaterial and empty groups 
produced similar bone volumes. The bone mineral density gradually increased over time 
(Figure 6c). At week 2, 50 µg/mL BMP-2 group had a lower density compared to 5 µg/mL 
BMP-2 group. This effect reversed later at week 8 and 10, 50 µg/mL BMP-2 induced higher 
density compared to 5 µg/mL BMP-2 treated group.    
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Figure 5. BMP-2 concentration dependent bone formation of alginate-RCP hydrogels was 
confirmed by histology. H&E staining revealed ossification for (a) 10 µg, (c) 3 µg, (d) 1 µg, 
while no bone was observed for (e) 0.3 µg, and (f) 0 µg BMP-2. (b) A closer representation of 
10 µg BMP-2 sample showing bony tissue around microspheres. RCP microspheres (MS), 
alginate hydrogel (Alg.), bone formation (B), and fibrous tissue (FT) are indicated. Scale bar 
is 250 µm for a,c,d,e,f and 100 µm for f.  
DISCUSSION 
The aim of this study was to investigate whether a slow release system can be used to lower 
effective BMP-2 dose. In addition, we aimed to investigate the effect of the BMP-2 dose 
delivered by an in situ gelling hydrogel formulation on ectopic bone formation and, 
investigate the bone repair capacity of two selected doses of BMP-2 in a bone defect model. 
The composite hydrogel provided sustained release of BMP-2 for 4 weeks as shown in vivo 
by fluorescence imaging making use of fluorescently tagged BMP-2. Ectopic bone was 
formed for three different doses of BMP-2 (50, 15 and 5 µg/mL in a 200 µL implant) in a 
dose and time dependent manner, the highest BMP-2 dose showing the fastest bone 
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growth and highest bone volume at 10 weeks. The bone-forming dose of 50 µg/ml (2 µg per 
implant in a 5mm defect) in the ectopic model was confirmed to be also effective in a 
subcritical calvarial bone defect model.   
 
Figure 6. (a). Representative micro-CT images of calvaria (superior view) at week 10 after 
surgery and implantation. (b). Bone volume showing the regeneration of calvaria defects 
over 10 weeks. The bone volume of 50 µg/mL BMP-2 containing biomaterial was 
significantly higher at all time points compared to 5 µg/mL BMP-2, biomaterial and empty 
groups (** p<0.01 or *** p<0.001). (c). Bone density showing the regeneration of calvaria 
over 10 weeks. Bone density induced by 50 µg/mL BMP-2 was lower than that of 5 µg/mL 
BMP-2 group at week 2 (* p<0.05). At week 8 and 10, density of induced bone tissue was 
higher in 50 µg/mL BMP-2 than 5 µg/mL BMP-2 group (* p<0.05). Treatment groups were 
empty control (n=10), biomaterial only (n=10), 5 µg/mL BMP-2 containing biomaterial 
(n=10) and 50 µg/mL BMP-2 containing biomaterial (n=3). Data is shown as mean ± SD, two-
way ANOVA was performed to compare treatment groups. 
The BMP-2 delivery system used in this study was selected based on a previous study where 
a hydrogel composed of SLG alginate and BMP-2 loaded RCP-microspheres provided 
superior ectopic bone formation compared to other hydrogel formulations (Fahmy-Garcia et 
al., manuscript submitted). The advantages of this delivery system are the easy handling due 
to its thixotropic behaviour, sustained BMP-2 release profile and the presence of cell 
attachment sites by the use of the RCP microspheres. In our current study, we show that in 
situ gelling hydrogel composite successfully regenerates bone with a concentration of 50 
µg/mL BMP-2 (2 µg per implant in a 5 mm defect). In other preclinical studies with BMP-2 
carriers, the BMP-2 dose needed to heal critical sized defect was generally higher; in a rat 
calvarial model similar to our model, complete healing of the defects was achieved with 
PLGA membranes adsorbed with 5 mg/mL of BMP-2 [300]. In another study using a 8 mm 
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rat calvarial model, 0.5 µg and 1 µg BMP-2 per implant delivered with gelatin particles did 
not result in complete bone bridging [301]. Partial healing of 8 mm rat calvarial defects of 
approximately 20% and 60% was observed with a composite comprising segmented 
polyurethane, poly[lactic-co-glycolic acid], and β-tricalcium phosphate loaded with 1.6 μg 
and 6.5 μg rhBMP-2, respectively [302]. Besides, other BMP-2 carriers in general induced 
lower ectopic bone volumes. For example, silk fibroin (2 mm3) [237] and collagen sponge 
(5mm3) [236] formed max 5 mm3 ectopic bone using 5 µg BMP-2, which is lower than 41 
mm3 induced with 3 µg (15 µg/mL) BMP-2 in our ectopic model. Considering these earlier 
studies, our study shows that the in situ gelling formulation of RCP microspheres with 
alginate is a promising BMP-2 delivery system that might reduce the required effective dose 
of BMP-2 and thus potentially mitigate the adverse effects of BMP-2. 
Besides the required threshold or effective dose of BMP-2 to induce bone formation, the 
hydrogel matrix also affects the bone formation process to which characteristics of the 
biomaterial, such as release, integrity, degradation and cell infiltration, should be aligned. 
Factors such as speed of bone formation, amount and location of the formed bone are 
important to be considered.  The natural fracture healing process occurs around 4 weeks in 
rodents, [44] and it can take up to 3-4 months in humans [303]. In our ectopic model, the 
kinetics of bone formation was shown to be linear for the 10 µg BMP-2 group between week 
1 and week 8, while the main release of BMP-2 was observed in the first 4 weeks, both 
processes matching the time frame of natural bone healing processes [41]. Interestingly, 
after 4 weeks, a small portion of BMP-2 was retained inside the hydrogel probably due to 
the strong interaction between BMP-2 and RCP microspheres as shown earlier (Chapter 3). 
This portion of BMP-2 will only be released upon further degradation of the material and 
could probably contribute to the bone volume increasing also after 4 weeks. With 10 µg 
BMP-2, ectopic bone volume reached a plateau at 8 weeks. This suggests that bone 
formation can be confined to the hydrogel area. Therefore this hydrogel formulation might 
eliminate the risk of excessive surrounding soft tissue calcification, which is a major concern 
in currently used BMP-2- based therapies [66]. 
Our ectopic model results indicated that hydrogels containing 3 µg and 10 µg BMP-2 are not 
only forming bone at the periphery of the implants but in the entire implant. Qualitative 
analysis of 3D micro-CT images revealed that the bone formation started at different 
locations throughout the implant around week 2. These results corroborate our previous 
findings (Chapter 4) that the hydrogel allows bone forming cells to infiltrate the gel at early 
time points.  
Interestingly, hydrogels without or with a very low dose of BMP-2 seem to slightly, though 
not significantly, impede bone formation in the calvarial defect model at the early time 
points when compared to the empty control.  After 10 weeks it was not different from the 
empty control. It is possible that empty defect induces higher initial inflammation and faster 
infiltration of inflammatory cells compared to RCP microspheres with alginate and therefore 
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the healing process starts earlier. Alginate is known for poor cell attachment [304, 305]. 
Possibly, alginate slightly delays cell infiltration compared to natural bone healing 
environment where there is fibrin clot hosting the infiltrated cells. These effects can be 
examined in a future study. However, as differences did not reach statistical significance and 
the endpoint healing for both groups was similar, we do not expect an inhibitory effect of 
the hydrogel matrix in overall bone healing. Overall, the benefit of having a slow release 
system outweighs this minor effect since the BMP condition healed much better than the 
control. 
CONCLUSION 
The injectable slow release BMP-2 delivery system resulted in a time and dose dependent 
bone formation in an ectopic and orthotopic model. This delivery system composed of 
alginate and RCP microspheres, provides sustained release of BMP-2, provides cell 
attachment and induces bone formation at a relatively low dose of BMP-2, making it 
promising for bone regeneration therapies.  
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In situations where self-healing of bone is insufficient, for example in non-unions or delayed 
unions, a surgical procedure using bone grafts is necessary. Due to the limited availability of 
autografts and the disease transmission risk associated to the use of allografts [306], the 
bone tissue engineering field has been seeking for alternatives. The choice of biomaterials 
and other components such as drugs or cells is important for the design of a successful bone 
tissue engineering construct [6]. Although each strategy has advantages and drawbacks, we 
have chosen a cell-free approach using only biomaterials and a growth factor. Cell-free 
systems are generally less costly and easier to be translated to the clinics [307]. 
Furthermore, we have chosen for bone morphogenetic protein-2 (BMP-2) as a growth factor 
because it is an FDA approved growth factor for bone regeneration and its effect on bone 
formation is well known[58]. As a BMP-2 carrier, we have used microspheres based on a 
recombinant protein derived from collagen I (RCP). Collagen I is the major organic 
extracellular matrix (ECM) component in bone. We aimed to design and compare different 
compositions of biomaterials in terms of BMP-2 release profile and bone regenerative 
capacity with a final goal to develop formulations that can induce or augment bone healing. 
In this design, we chose a simple approach to load the spheres by adsorption. As explained 
in chapter 2, adsorption is an easier process to be translated to the clinic compared to 
encapsulation or covalent linking in terms of handling and process control. This approach 
appeared to be successful in retaining BMP-2 due to a specific interaction between RCP and 
BMP-2 as described in Chapter 3. This interaction between RCP and BMP-2 has similar 
affinity constants as that of between BMP-2 and glycosaminoglycans [308]. In the study of 
Grunert et al. and in our study, both affinity constants were in the nanomolar range [104]. 
We then investigated the effectiveness of these BMP-2 loaded microspheres in vivo in a 
subcutaneous ectopic bone formation model. In this much more complex environment 
many other factors play a role as discussed later in this chapter. After the observation that 
the microsphere paste yielded only small amounts of bone, we designed a hydrogel scaffold 
to deliver the microspheres. The role of the hydrogel was to create a platform for the 
regenerating cells and also to confine the BMP-2 loaded microspheres in situ. In particular, 
alginate proved to be successful as a delivery hydrogel. We have shown that alginate further 
slowed down the release of BMP-2 and decreased the degradation rate of the RCP spheres 
to match the time frame of the bone formation process. In our study, a 5 mm calvarial 
defect completely healed using 50 µg/mL concentration of BMP-2 (2 µg per implant); thus, 
we reach the aimed bone volume (27 mm3) with this concentration (chapter 5). The same 
concentration in the ectopic bone model induced around 100 mm3 bone which was half of 
the injection volume. In a study where these models have both been employed, a composite 
implant of poly(lactic-co glycolic acid)/poly(propylene fumarate)/gelatin with 6.5 µg BMP-2 
completely healed a 5 mm femoral defect [309]. However, it only induced 4 mm3 ectopic 
bone volume of the 50 mm3 implant in a subcutaneous ectopic model.  
In order to further develop our formulations, we discuss how the material properties can 
be adjusted for a better in vivo performance. Several factors such as degradation rate, 
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interaction with the matrix, mechanism of drug release, host environment, carrier geometry 
contribute to the in vivo performance of a material, as indicated by Li et al. [65]. Here, some 
of these parameters are discussed in the light of our biomaterial.  
Degradation rate 
The material degradation rate has a huge effect on the regeneration of new tissue [310]. 
Non-degradable materials such as solid titanium implants do not allow tissue regeneration. 
If the scaffold degrades too slowly it might inhibit bone formation and delay the repair. 
Materials with insufficient interconnecting pores and a slow degradation rate possess a risk 
of encapsulation by a bony shell and as a result to become isolated from the remodelling 
process[65]. On the other hand, quickly degraded materials will not serve as a good scaffold 
for the regenerating tissue and will not support migrating cells.  
Therefore, modulation of the timing of degradation is very crucial. This is also shown for our 
initial delivery system consisting of bare RCP microspheres carrying BMP-2 (Chapter 3b). The 
RCP microspheres that carried no BMP-2 or a low dose BMP-2 could not be retrieved at all 
at the end of the experiment (week 12) because they were fully degraded while no bone 
was formed. This confirms the results of Parvizi showing that non-loaded thermally 
crosslinked RCP microspheres were degraded mostly in the first month after subcutaneous 
injection [311]. Although we have not analyzed degradation by histology at early time 
points, our results point towards premature degradation of the microspheres. Due to this 
fast degradation, BMP-2 might have been released too rapidly and this resulted insufficient 
recruitment of progenitor cells. As a result, there was even a decline in the ectopic bone 
formation after 6 weeks, indicating that in the absence of a scaffold and a growth factor 
bone can start to resolve in a subcutaneous ectopic environment. Upon addition of an 
alginate hydrogel to the system (chapter 4 and 5), we detected some microspheres even at 
the end of the experiment at week 10, showing that alginate decreased the degradation 
time of the RCP microspheres compared to the bare microsphere formulation. Alginate 
apparently shielded the microspheres from quick invasion by cells and subsequent 
degradation. It is known that alginate hydrogels alone have variable degradation rates 
depending on the crosslinking degree, molecular weight and concentration [312]. In our 
system, the ionically crosslinked alginate matrix was only partially degraded at week 10. The 
higher ectopic bone volume obtained with the alginate hydrogel formulations in chapter 4, 
and the complete healing of the calvarial defect in chapter 5 suggests that the degradation 
rate of these formulations is matching well with the speed of the bone regeneration 
process.  
Interaction with the matrix 
Interactions of cells with the provided biomaterial matrix are extremely important because 
progenitor cells and inflammatory cells need to be recruited and reside at the regeneration 
site [313]. The recruited cells need a suitable microenvironment to be able to proliferate 
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and differentiate towards bone forming cells [314]. ECM proteins such as collagen can be 
suitable biomaterials for bone tissue engineering since collagen is the major component of 
bone organic matrix. Besides its function as cell attachment site, the biomaterial could serve 
as a matrix to bind secreted factors. This is important to maintain the activity of secreted 
factors in a regenerating tissue [315]. In our studies we used three types of biomaterials; 
recombinant peptide based on collagen I (RCP), alginate, and thermoresponsive, PNIPAAM 
modified hyaluronic acid.  
In Chapter 4 and 5, it was clear that cells preferably attached to the RCP microspheres but 
not the alginate hydrogel. The presence of multiple RGD sequences in the collagen I derived 
protein most probably enhances the ‘attractiveness’ of the microspheres to adhere to. 
Interestingly, in the calvarial defect model the formulation with alginate and non-loaded 
microspheres (i.e. without BMP-2) even seemed to delay bone formation compared to an 
empty defect (Chapter 5). This can be a result of the lack of interaction between alginate 
and the cells. Cells in general can infiltrate into an alginate gel depending on the porosity of 
the gel [316], but cell attachment to the alginate gel is very poor [304, 305]. On the other 
hand, as we have seen in chapter 3b when only microspheres were injected, the paste was 
degraded too quickly as a result of the strong interaction between cells and the 
microspheres, which negatively affected the bone formation process. These results 
suggested that fine-tuning of the cellular infiltration rate is important for successful bone 
formation.  
Interestingly, the hyaluronic acid formulation failed to induce bone formation (chapter 4). 
This result was further explored by investigating the infiltration of macrophages. 
Macrophages increased over time in the hyaluronic acid formulation, indicative for a 
progressing inflammatory reaction. On the other hand, in the SLG alginate formulation the 
number of infiltrated macrophages decreased over time. There might be two main reasons 
why hyaluronic acid failed to induce bone formation. Firstly, it retained most of BMP-2 as 
shown in the in vitro release experiments. Secondly, the timing of the inflammation did not 
match with the timing of bone formation process. It is known that inflammation is 
predominant typically in the first week of bone healing [44]. Therefore, this prolonged 
inflammation might have inhibited bone formation. However, the reason for the different 
inflammatory response to alginate and hyaluronic acid is yet to be elucidated. 
Drug release profile 
To obtain a sustained release profile and to control the initial burst release, the drug 
delivery material can be modulated [317]. In our case the BMP-2 release profile was altered 
by changing the particle characteristics (Chapter 3a). We have shown that the crosslinking 
method and the size of RCP particles influenced the release of BMP-2. Small-sized RCP 
microspheres had only 30 % release in vitro in the first two weeks and the rest of BMP-2 
could only be released by degrading the particles. In addition, the interaction between the 
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drug and the matrix contributes to the resulting release profile. In our study, a specific 
interaction based on intermolecular forces occurs between BMP-2 and RCP (chapter 3). Due 
to this affinity of BMP-2 to the RCP matrix and its resulting in vitro release profile, we have 
hypothesized that microspheres can be a potential system to deliver BMP-2 and to induce 
bone formation. However, the in vitro release profile is not the only factor indicative for the 
effectiveness of the delivery system. The intrinsic degradation rate of the material and the 
host response are the two main contributors to the release profiles in vivo. Although we 
have not studied the in vivo release of BMP-2 from only microspheres, it is possible that 
rapid degradation of spheres influenced the resulting bone formation by changing the 
release kinetics. 
The question, which release kinetic of BMP-2 is optimal, has been very controversial. In a 
study of Brown et al., it is postulated that “the ideal pharmacokinetics for BMP-2 includes 
both a burst and sustained release is generally accepted”[227]. In their study, a burst 
release has been indicated as essential to enhance bone formation, while a sustained 
release without the burst did not form significantly more bone than the scaffold without 
rhBMP-2. However, only polyurethane (PUR) and PUR/microsphere [PUR/poly(lactic-co-
glycolic acid)] composite scaffolds were tested in that study [227]. On the other hand, the 
clinical concerns of using BMP-2 which stem from the adverse events observed [318] are 
mainly associated to the burst release profile of BMP-2 [319]. Moreover, a sustained release 
profile of BMP-2 might be advantageous for bone healing since BMP-2 can retain longer 
term in the tissue, as shown by Jeon et al. [320] and as such continue to stimulate bone 
formation. In another study, reducing burst release has been shown to significantly increase 
the spinal fusion, when the initial burst release of BMP-2 from collagen sponge was reduced 
from 50% to 25% by addition of a cartilage oligomeric matrix protein (COMP) to the collagen 
sponge[321]. In the presence of COMP, the delivery of 2μg BMP-2 achieved a similar 
outcome to 10μg of BMP-2 alone when tested in spinal fusion model in rats.  
In our study, the BMP-2 loaded RCP microspheres exhibit a small burst release of only up to 
20 percent in the first 24 hours (Chapter 3). This burst release was reduced even further by 
using alginates (Chapter 4). The absence of a burst release and the prolonged retention of 
BMP-2 were confirmed in vivo by fluorescence imaging (Chapter 5). A gradual decrease of 
BMP-2 signal was observed for 4 weeks with a small amount of BMP-2 retained even at the 
end of the experiment (week 10). This clearly showed the long term retention of BMP-2 in 
the subcutaneous tissue when delivered with alginate and microspheres. Especially, 
obtaining a large volume of ectopic bone at the end of the experiment indicated that the 
drug release profile of BMP-2 from the composite hydrogel formulation matched the 
ectopic bone formation rate.  
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Materials better mimicking ECM composition and organization 
In order to design better tissue engineering materials, we should understand how cells 
remodel (degrade and deposit) their own ECM [322, 323]. However natural ECM is much 
more complicated than the currently available biomaterials, in the sense that ECM contains 
many types of proteins, glycosaminoglycans and secreted factors. To mimic natural 
materials to a certain extent, smart materials that can selectively bind certain types of cells 
and certain types of secreted factors can be developed as a first step. In this way, we might 
be able to engineer the tissue by directing the type of cells and factors that will reside 
inside. In this thesis, we have used the well-known integrin binding peptide (arginine-
glycine-lysine) or RGD to promote cell attachment. However, this peptide is not selective for 
a particular cell type [324]. In the future, recombinant proteins can be designed with a more 
selective binding peptide (based on the surface markers of cells) to recruit or host certain 
stem cells such as mesenchymal stem cells (MSCs) or osteoprogenitor cells. 
ECM is organized in a specific way, meaning that the composition of ECM, its nano- and 
micro-scale architecture and the topography of the components are important elements in 
its organization. We have used collagen I based microspheres as a delivery system. To mimic 
the natural bone ECM composition and nanoscale architecture more closely, for example 
hydroxyapatite deposited collagen-like nanofibers can be designed and combined with a 
delivery system for BMP-2. As a first step towards such a system, RCP scaffolds were 
biomineralized with nanocrystalline hydroxyapatite and amorphous calcium phosphate 
[325]. Those biomimetic mineralized scaffolds enhanced MSC interaction and differentiation 
[326]. It is also known that the porosity and topography of the scaffold is very important for 
the cellular behaviour [327, 328] and nutrient support [231]. In a study where RCP scaffolds 
with linear pore structures were used, the pore size influenced the migration of ostoblast-
like cells in this scaffold [329]. In the future, such scaffolds can be combined with the BMP-2 
delivery system of this study to further enhance the functionality of the system. 
Application area and mechanical loading 
In our studies, the bone formation capacity of composite in situ gelling hydrogels was tested 
in a subcutaneous (ectopic) model and in a calvarial bone model, which are both non-load 
bearing. After obtaining successful bone formation in these models, we think that the 
applications of the hydrogels in non-load bearing bones such as calvarium or around the 
orbital cavity and in small defects in the mandibular or jaw bones in the maxillofacial surgery 
are possible [330]. There are several specific examples that application of tissue engineering 
products are suitable. For example, for maxillary reconstruction of flap after a large 
keratocyst, a tissue engineering material containing stem cells has been tested in a case 
study [331]. In another study, platelet gels have been tested in jaw bones with osteolytic 
lesions [332]. The reconstruction of critical size mandibular bone defects is a challenge in 
oral and maxillofacial surgery. For this application therefore cell-containing scaffolds have 
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been tested earlier [333, 334]. Another potential application is sinus augmentation, which is 
performed before the dental implant surgery in case of bone loss. For this sinus 
augmentation application, different sources of cells have been tested earlier [335, 336]. 
Mechanical loading is a very important parameter for the regeneration of load-bearing 
bones [337]. How the composite hydrogel loaded with BMP-2 will perform when mechanical 
forces are applied is difficult to predict. Since the mechanical properties of these hydrogels 
are far lower than that of bone and inorganic materials, they are not good candidates for 
treatment load bearing bones [338] unless used in combination with fixation techniques 
such as using plates and screws or used in combination with stiffer materials. In addition, 
the BMP-2 release may vary under mechanical loading as has been proposed in a nonhuman 
primate study on spinal arthrodesis, in which a BMP-2 loaded collagen sponge even 
prevented bone induction probably due to squeezing protein out of the sponge [339]. 
Large animal studies and clinical translation 
Since the bone regeneration process is faster in rodents than in humans, the use of large 
animal tests before going to clinical trials is generally necessary. Besides, rodents could 
tolerate a quicker release rate due to their faster metabolic rate [65]. Therefore, a delivery 
system selected based on trials with rodents is not necessarily the best delivery system for 
humans. The selection of a suitable animal model depends on the application of the 
product. For example, for maxillofacial applications of this type of hydrogels, monkey [340], 
dog [341] or bovine bone [342] models can be used. For mandibular defects, canine [334] 
and rabbit models [333] have been used, while for segmented mandibular defects a mini-pig 
model has been applied [343]. Besides the animal, it is important to select the most relevant 
model for the intended application. For example, for long bone fractures there are single or 
segmental defect models for tibia. For long bone fracture applications, collagen sponge with 
BMP-2 was tested in a rabbit ulnar osteotomy model [344] and goat long bone fracture 
models[345]. For segmental fracture applications of this BMP-2 loaded collagen sponge, 
segmental defect models in rat femora [346], rabbit radii [347], rabbit ulnae [348], canine 
radii [349] have been used. 
Clinical translation of a product in general is a long process not only because of regulations 
and legislations but also it is a process where the product is improved to perform best in 
humans [350-352]. There is always a trade-off between creating more complex designs for 
better therapies and easier and faster clinical translation of the therapies. For example, an 
acellular scaffold should face less regulatory inspection compared to cell-containing 
products according to Webber et al. [353], because of the risks associated with possible 
immunogenicity, teratoma formation, and cell culture adaptation/morphogenesis. Addition 
of growth factors increases the complexity of the product and increases the potential 
outcomes such as risk of adverse effects [318]. It is also important to note that during the 
regulatory approval process through the U.S. Food and Drug Administration (FDA), a tissue 
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engineering product can fall into four categories: tissues, biological products, drugs, or 
medical devices. For example, a simple scaffold material can be classified as a medical 
device; however, when additional components such as cells or biologicals are added, 
product falls into more than one category which complicates the approval process. It is also 
important to know that BMP-2 adsorbed collagen sponge (INFUSE® Bone Graft, Medtronic) 
has been approved as a Class III medical device by FDA. Although the regulatory approval 
pathway depends on the exact application, it is expected that our formulation of alginate, 
RCP microspheres and BMP-2 as a combination product can be translated to the clinic.  
Conclusion 
The main research question of this thesis was: Which of the four designs of BMP-2 delivery 
system with which composition and release profile will induce bone healing? It turned out 
that SLG alginate with BMP-2 loaded RCP microspheres was effective to deliver BMP-2 and 
induces ectopic bone formation. In addition, this formulation was effective to stimulate 
calvarial defect healing. In a more general sense, this thesis contributed to the deeper 
understanding of the importance of the design of a delivery system and a scaffold for bone 
regeneration. We have developed a potential material that can be used as a basis for bone 
regeneration therapies and can be further tuned for specific applications.  
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SUMMARY 
The research described in this thesis aimed to develop a bone regeneration therapy using 
biomaterials and growth factors. First, the current literature and current therapies involving 
growth factor delivery for bone regeneration was reviewed (chapter 2). We mainly focused 
on bone morphogenetic protein-2 as a growth factor due to its potential and its widespread 
use in bone regeneration therapies. The protein delivery therapies were divided in non-
covalent delivery and covalent coupling strategies mentioning advantages and drawbacks of 
each system. We have indicated that the release profile of the delivered protein via non-
covalent linking is important for the performance of the medicinal product. Based on the 
literature, in order to eliminate the adverse effects of clinical BMP-2 product, the release 
profile of BMP-2 should be improved.  
In chapter 3a RCP microspheres were developed for BMP-2 delivery. Collagen I based 
recombinant protein was (RCP) chosen for this purpose, because collagen I is the main 
component of the organic extracellular matrix in bone. A small library of different RCP 
microspheres was created to study the effect of several physicochemical characteristics on 
the BMP-2 release profile. Among several parameters investigated, size and crosslinking 
affected the BMP-2 release. We have selected small sized, densely chemically crosslinked 
particles for further studies because this type of particle demonstrated the lowest initial 
burst release. Typical release curves for this particle type had a small initial burst release in 
the first two days and a subsequent slower release up to around 30% release of BMP-2 
within two weeks. When the particles were degraded after two weeks of release, the 
remaining BMP-2 was liberated suggesting that the degradation will contribute significantly 
to the in vivo release profile of BMP-2. Based on the release curves, we hypothesized that 
there is an interaction between BMP-2 and RCP. Therefore, surface plasmon resonance 
(SPR) was used to study the interaction of these proteins. This SPR technique indeed 
confirmed the affinity between BMP-2 and RCP with binding constants in the nanomolar 
range. Using BMP-2 variants to study the interacting domain of BMP-2 with RCP, we found 
that the N-terminal domain of BMP-2 is involved in this binding. 
The BMP-2 adsorbed microspheres were tested in a rat ectopic bone formation model in 
chapter 3b. The microspheres in a form of paste containing 83 µg/mL, 8.3 µg/mL or 0.83 
µg/mL BMP-2 were injected subcutaneously to rats. At the end of the experiment, only the 
high dose BMP-2 containing group could be retrieved and only this group induced a small 
amount of ectopic bone (2.5 mm3). The other doses failed to induce bone formation and 
microspheres were degraded completely in the end of the experiment indicating that only 
microspheres is not optimal for bone therapy. 
To improve bone formation, we have combined microspheres with in-situ gelling hydrogels 
in chapter 4. Two types of alginate, SLM and SLG, and one type of thermosensitive 
hyaluronic acid were developed for this study. These hydrogels were designed not only to 
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deliver and keep the microspheres at the site but also to act as a scaffold for the 
regenerating tissue and to fill a defect. The alginate formulations with microspheres 
interestingly showed a thixotropic behaviour which has allowed the handling of the material 
to be much easier compared to non-reversible in-situ gelling hydrogels. In addition, the 
alginate hydrogels contributed to the retention of BMP-2 and eliminated its burst release. 
Interestingly, thermosensitive hyaluronic acid retained most of the BMP-2. When the 
alginate and hyaluronic acid formulations were compared in an ectopic model in rats, clear 
differences in bone formation and inflammation were observed. SLG-alginate with 
microspheres induced the most bone volume at week 10. In contrast, the hyaluronic acid 
formulation gave no bone and an interesting inflammatory profile, in which the 
inflammation markers increased over weeks until the end of the experiment. This was 
different from the alginates for which there was a higher inflammation initially which 
decreased over-time.  Overall, SLG alginate with microspheres formulation was selected as 
the best formulation for a potential bone regenerative product due to the highest ectopic 
bone volume induced and favourable inflammatory profile.  
The SLG alginate-RCP microspheres formulation was selected for further studies in ectopic 
and orthotopic bone formation models in rats as described in chapter 5. First, the effect of 
BMP-2 dose delivered was tested in the ectopic bone model using 10, 3, 1, 0.3 and 0 µg 
BMP-2 per implant. The bone volume at 10 weeks was the highest with 10 µg (50 µg/mL) 
which was approximately 100 mm3, half the volume of the injected hydrogel. The second 
highest dose of 3  µg (15 µg/mL) BMP-2 induced moderate bone formation. The density of 
bone formed by 10 µg and 3 µg were similar at 10 weeks. A lower dose, 1 µg (5 µg/mL) 
BMP-2, induced a small volume of bone, less than 5 mm3, in some of the implants. Negative 
control (0 µg) and 0.3 µg did not induce bone formation. This study showed the existence of 
a threshold of BMP-2 dose for ectopic bone formation. In a subsequent calvarial defect 
experiment, 50 µg/mL and 5 µg/mL BMP-2 containing hydrogels were tested. The high 
concentration (50 µg/mL) regenerated the calvaria completely in 10 weeks and induced 
significantly more bone volume compared to empty or biomaterial controls. The lowest 
concentration (5 µg/mL) did not induce more bone than the controls with biomaterial only 
or the empty controls. This study showed that the effective concentration of BMP-2 to 
induce both ectopic and orthotopic bone is higher than 5 µg/mL, and optimally between 15-
50 µg/mL.  
Finally, the in vivo retention profile was studied using a fluorescently labelled BMP-2 and in 
vivo imaging for 10 weeks as described in chapter 5. Studying the retention of BMP-2 in vivo 
was important in the understanding of temporal availability of BMP-2 in the tissue and of 
the in vivo release profile of BMP-2. Fluorescent imaging showed that BMP-2 was gradually 
decreased over a period of at least 4 weeks, a time frame that matches well with typical 
bone regeneration processes. This in vivo retention profile is more favourable compared to 
the commercial BMP-2 carrier (collagen sponge) which releases half of the BMP-2 within 2 
days and the rest within first week.  
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Overall, we have developed a potential product for bone regeneration based on BMP-2 
loaded RCP microspheres and alginate. This material might find a broad application area for 
bone regeneration due to the slow release profile of BMP-2 and its injectability. After 
selecting a suitable application, for example in maxillofacial surgery, the material should be 
tested in a relevant large animal model. If successful in a large animal model, the developed 
injectable slow release system would be ready for further testing in clinical studies. 
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NEDERLANDSE SAMENVATTING 
Het doel van het onderzoek beschreven in dit proefschrift is om een therapie voor 
botregeneratie te ontwikkelen met behulp van biomaterialen en groeifactoren. Als eerste is 
een overzicht gemaakt van de stand van de literatuur en bestaande therapieën voor 
botgeneratie die gebruik maken van afgiftesystemen voor groeifactoren (hoofdstuk 2). 
Hierbij lag de nadruk op de groeifactor bone morphogenetic protein-2 (BMP-2) vanwege het 
wijdverspreide gebruik er van in therapieën voor botregeneratie. De therapieën die gebruik 
maken van afgiftesystemen werden hierbij opgedeeld in niet-covalente en covalente 
koppelingstrategieën waarbij voor- en nadelen van de betreffende systemen werden 
behandeld. Het afgifteprofiel van het niet-covalent gebonden eiwit blijkt erg belangrijk voor 
de medicinale werkzaamheid van het product. Gebaseerd op deze literatuur is onze 
conclusie dat het afgifte-profiel van BMP-2 verbeterd moet worden om de negatieve 
bijeffecten ervan te elimineren.  
In hoofdstuk 3a werden microscopisch kleine bollen van RCP ontwikkeld voor 
gecontroleerde BMP-2 afgifte. RCP is een recombinant eiwit gebaseerd op collageen I en is 
gekozen omdat collageen I het hoofdbestanddeel is van de organische extracellulaire matrix 
in bot. Een kleine set van verschillende RCP bolletjes werd gemaakt om het effect van 
diverse fysisch-chemische eigenschappen op het BMP-2 afgifteprofiel te bestuderen. Vooral 
de bolgrootte en manier van crosslinking bleken de BMP-2 afgifte sterk te beïnvloeden. 
Vanwege de relatief kleine initiële afgifte (de zogeheten ‘burst-release’) werden kleine, 
chemisch gecrosslinkte RCP-deeltjes geselecteerd voor de vervolgstudies. Het afgifteprofiel 
voor dit type deeltjes bestond uit een kleine initiële afgifte in de eerste twee dagen gevolgd 
door een langzame afgifte gedurende twee weken tot circa 30% van de BMP-2. De rest van 
de BMP-2 werd pas afgegeven door de deeltjes af te breken met enzym. Dit geeft aan dat 
degradatie een belangrijke rol zal spelen bij afgifte in het lichaam. De afgifte profielen 
suggereerden een duidelijke interactie tussen BMP-2 en RCP. Om dit verder te onderzoeken 
werd gebruik gemaakt van Surface Plasmon Resonance (SPR). Deze techniek bevestigde 
inderdaad het bestaan van een affiniteit tussen BMP-2 en RCP met bindingsconstanten in de 
nanomolair range. Door gebruik te maken van verschillende BMP-2 varianten om de 
interactie te bestuderen, werd duidelijk dat het N-terminal domein van BMP-2 betrokken is 
bij deze binding. 
Zoals beschreven in hoofdstuk 3b, werden de door adsorptie van BMP-2 geladen RCP 
deeltjes getest in een ectopisch botvormingsmodel in ratten. In de vorm van een pasta 
werden de deeltjes, geladen met 83 µg/mL, 8.3 µg/mL of 0.83 µg/mL BMP-2, subcutaan 
geïnjecteerd. Aan het einde van het experiment, bleek alleen de hoogste dosis BMP-2 een 
kleine hoeveelheid ectopisch bot te geven (2.5 mm3). De andere doses gaven geen enkele 
botvorming te zien en de deeltjes waren volledig gedegradeerd. Dit geeft aan dat BMP-2 
geladen RCP deeltjes alleen niet optimaal zijn voor botvorming 
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Om de botvorming te verbeteren zijn in hoofdstuk 4 de deeltjes gecombineerd met in situ 
gelerende hydrogelen. Hiertoe werden twee typen alginate gebruikt, SLM and SLG, en een 
thermosensitief hyaluronzuur. Deze hydrogelen dienen als afgiftesysteem voor de RCP-
deeltjes en om de deeltjes bij elkaar te houden op de plek van injectie maar ook als basis 
voor het regenererende weefsel en om het defect te vullen. De alginaat-formuleringen 
waren goed hanteerbaar en injecteerbaar vanwege hun thixotropische eigenschappen. 
Daarnaast droegen de alginaat gelen bij aan het vasthouden van de BMP-2 en het verder 
verlagen van de initiële afgifte. De thermosensitieve hyaluronzuur gelen hielden vrijwel alle 
BMP-2 vast. Vergelijking van deze alginaat en hyaluronzuur formuleringen in een ectopisch 
botmodel in ratten gaf grote verschillen te zien in botvorming en ontstekingsverschijnselen. 
Vooral de SLG-alginaat formulering met de BMP-2 geladen RCP-deeltjes gaf het meeste 
botvolume na 10 weken. De hyaluronzuur formulering gaf daarentegen geen bot en een 
interessant ontstekingspatroon te zien waarin de ontstekingsindicatoren toenamen 
gedurende het experiment. Voor de alginaten zagen we juist een sterkere ontsteking in het 
begin die af nam in de loop van het experiment. Op basis van deze resultaten, werd de 
formulering met SLG-alginaat gekozen als beste basis voor een botregeneratieproduct 
Deze SLG-alginaat formulering werd vervolgens gebruikt voor vervolgstudies naar 
ectopische en orthotopische botvorming in ratten zoals beschreven in hoofdstuk 5. Als 
eerste werd het effect van de BMP-2 dosis getest in het ectopisch botmodel met beladingen 
van 10, 3, 1, 0.3 en 0 µg BMP-2. Na 10 weken was het botvolume het grootst voor de 
hoogste dosis van 10 µg (50 µg/mL). Deze BMP-2 hoeveelheid gaf ongeveer 100mm3 bot, 
wat de helft van het volume is van de geïnjecteerde hydrogel. De op één na hoogste dosis 
van 3 µg (15 µg/mL) BMP-2 gaf duidelijk minder bot. De dichtheid van het gevormde bot na 
10 weken was vergelijkbaar voor de 10 µg en 3 µg BMP-2 formuleringen. De formulering 
met 1 µg (5 µg/mL) BMP-2 gaf maar heel weinig botvorming, met minder dan 5 mm3 bot in 
sommige implantaten. De negatieve controle (0µg) en 0.3 µg BMP-2 vormden geen 
ectopisch bot. Deze studie laat duidelijk zien dat er een minimum grenswaarde van de BMP-
2 dosis bestaat om ectopische botvorming te induceren. Vervolgens werden hydrogel-
formuleringen met 50 µg/mL and 5 µg/mL BMP-2 getest in een calvarium defect model. De 
hoogste concentratie (50 µg/mL) gaf volledige regeneratie van het calvarium defect in 10 
weken en significant meer botvolume dan de lege controle en de controle met formulering 
zonder BMP-2, dus alleen het biomateriaal. De laagste BMP-2 concentratie (5 µg/mL) gaf 
niet meer bot dan deze controles. Deze in vivo studie laat zien dat de effectieve BMP-2 
concentratie om ectopisch en orthotopisch bot te vormen groter is dan 5 µg/mL, en 
waarschijnlijk optimaal is tussen 15 en 50 µg/mL.  
Tot slot werd het in vivo afgifteprofiel bestudeerd met behulp van fluorescent gelabelde 
BMP-2 en in vivo beeldvorming gedurende 10 weken zoals beschreven in hoofdstuk 5. Deze 
studie was belangrijk om inzicht te krijgen in de lokale beschikbaarheid van BMP-2 in het 
weefsel en het in vivo afgifteprofiel van BMP-2. Fluorescentiemetingen lieten een 
geleidelijke afname van BMP-2 zien gedurende 4 weken. Deze tijdsduur komt goed overeen 
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met de typische tijdsduur van botregeneratieprocessen. Daarnaast is dit geleidelijke in vivo 
afgifteprofiel veel beter dan dat van de commerciële BMP-2 carrier (collageen spons) die de 
helft van de BMP-2 af geeft binnen 2 dagen en de rest binnen een week.  
Concluderend, is in dit onderzoek een potentieel product ontwikkeld voor botregeneratie 
gebaseerd op een hydrogel formulering van BMP-2 geladen RCP-deeltjes en alginaat. Dit 
materiaal is mogelijk inzetbaar in een breed toepassingsgebied binnen de botregeneratie 
vanwege het geleidelijke BMP-2 afgifteprofiel en goede injecteerbaarheid. Na selectie van 
een geschikte toepassing, bijvoorbeeld voor op het gebied van aangezichtschirurgie, moet 
het materiaal getest worden in een relevant groot proefdiermodel. Bij goede resultaten is 
het ontwikkelde injecteerbare afgiftesysteem klaar om verder getest te worden in klinische 
studies.  
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PhD portfolio 
Summary of PhD training and teaching 
Name PhD student: Zahide Didem Mumcuoglu Guvenc 
Erasmus MC Department: Orthopaedics 
Research School: Molecular Medicine 
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Promotor: Prof. Dr. Gerjo van Osch 
Co-promoter: Dr. Sebastiaan Kluijtmans 
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Republic 
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2015 
2015 
2015 
2016 
2017 
 
1 
3 
 
4 
4 
1 
Specific courses (e.g. Research school, Medical Training) 
- Translational Imaging Workshop by AMIE 
- Intellectual property course, Fujifilm, Tilburg 
- Microscopic Image Analysis: From Theory to Practice 
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- Protein structure course 
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2014-2015 
2015 
2015 
2015 
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2 
Seminars and workshops 
- Workshop on Microsoft Excel 
- Minisymposium  “From Biomaterials Design to Clinical 
Applications”, Eindhoven 
- Symposium on Career Perspectives for Young Biomedical 
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- Masterclass Cell-Based Bone Regeneration, Nijmegen 
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- Molecular Medicine Day, Rotterdam 
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2015 
 
2015 
 
2015 
2016-2017 
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- Bioinspire progress meetings, Fujifilm, Tilburg (x8) 
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2014-2016 
2014-2017 
2015-2017 
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- 4th Joint Meeting of European Calcified Tissue Society and 
International Bone and Mineral Society, Rotterdam 
“Synthetic collagen peptide (SCP) microspheres for tuned 
BMP-2 release in bone regeneration” 
- European Society of Biomaterials, Krakow, Poland 
“BMP-2 Release from Collagenous Particles” 
- World Biomaterials Congress, Montreal, Canada 
“BMP-2 release from synthetic collagen peptide particles” 
- Netherlands Society for Biomaterials and Tissue Engineering, 
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2015 
 
2016 
 
2016 
 
 
1 
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1 
 
1 
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“Development of Injectable BMP-2 Delivery Materials Using 
Collagen-I Based Recombinant Peptide Microspheres” 
- Tissue Engineering and Regenerative Medicine International 
Society, Davos, Switzerland 
“Development of Injectable BMP-2 Delivery Materials Using 
Collagen-I Based Recombinant Peptide Microspheres” 
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Supervising Master’s theses 
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Miranda Jekhmane, Department of Physical Chemistry and 
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Sciences, Fontys University of Applied Sciences 
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2016 
 
5 
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